<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews - Craig, SS - 2020 | Cochrane Library</title> <meta content="Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews - Craig, SS - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012977.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews - Craig, SS - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012977.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012977.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews" name="citation_title"/> <meta content="Simon S Craig" name="citation_author"/> <meta content="simon.craig@monash.edu" name="citation_author_email"/> <meta content="Stuart R Dalziel" name="citation_author"/> <meta content="Colin VE Powell" name="citation_author"/> <meta content="Andis Graudins" name="citation_author"/> <meta content="Franz E Babl" name="citation_author"/> <meta content="Carole Lunny" name="citation_author"/> <meta content="Faculty of Medicine, University of British Columbia" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD012977.pub2" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/08/05" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012977.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012977.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012977.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acute Disease; Administration, Inhalation; Adrenergic beta-2 Receptor Agonists [therapeutic use]; Aminophylline [administration &amp; dosage, adverse effects]; Anti-Asthmatic Agents [administration &amp; dosage, *therapeutic use]; Anti-Bacterial Agents [therapeutic use]; Asthma [drug therapy, *therapy]; Bias; Bronchodilator Agents [administration &amp; dosage, *therapeutic use]; Cholinergic Antagonists [therapeutic use]; *Disease Progression; Helium; Length of Stay; Leukotriene Antagonists [therapeutic use]; Magnesium Sulfate [administration &amp; dosage, adverse effects, therapeutic use]; Nausea [chemically induced, prevention &amp; control]; Oxygen [administration &amp; dosage]; Positive-Pressure Respiration; Randomized Controlled Trials as Topic; *Systematic Reviews as Topic; Vomiting [chemically induced]; Work of Breathing [drug effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012977.pub2&amp;doi=10.1002/14651858.CD012977.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012977.pub2&amp;doi=10.1002/14651858.CD012977.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012977.pub2&amp;doi=10.1002/14651858.CD012977.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012977.pub2&amp;doi=10.1002/14651858.CD012977.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012977.pub2&amp;doi=10.1002/14651858.CD012977.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012977.pub2&amp;doi=10.1002/14651858.CD012977.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012977.pub2&amp;doi=10.1002/14651858.CD012977.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012977.pub2&amp;doi=10.1002/14651858.CD012977.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012977.pub2&amp;doi=10.1002/14651858.CD012977.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012977.pub2&amp;doi=10.1002/14651858.CD012977.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012977.pub2&amp;doi=10.1002/14651858.CD012977.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012977.pub2&amp;doi=10.1002/14651858.CD012977.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012977.pub2&amp;doi=10.1002/14651858.CD012977.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012977.pub2&amp;doi=10.1002/14651858.CD012977.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012977.pub2&amp;doi=10.1002/14651858.CD012977.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012977.pub2&amp;doi=10.1002/14651858.CD012977.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012977.pub2&amp;doi=10.1002/14651858.CD012977.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012977.pub2&amp;doi=10.1002/14651858.CD012977.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012977.pub2&amp;doi=10.1002/14651858.CD012977.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012977.pub2&amp;doi=10.1002/14651858.CD012977.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012977.pub2&amp;doi=10.1002/14651858.CD012977.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012977.pub2&amp;doi=10.1002/14651858.CD012977.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012977.pub2&amp;doi=10.1002/14651858.CD012977.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="ytRBD0EW";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012977\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012977\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012977\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012977\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","ru","pt","ko","th","ms","ja","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012977.pub2",title:"Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews",firstPublishedDate:"Aug 5, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ytRBD0EW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012977.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012977.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012977.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012977.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012977.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012977.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012977.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012977.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012977.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012977.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>15118 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012977.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012977.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012977.pub2/full#CD012977-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012977.pub2/full#CD012977-sec-0153"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012977.pub2/full#CD012977-sec-0006"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012977.pub2/full#CD012977-sec-0015"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012977.pub2/full#CD012977-sec-0018"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012977.pub2/full#CD012977-sec-0038"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012977.pub2/full#CD012977-sec-0147"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012977.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012977.pub2/appendices#CD012977-sec-0157"> Search strategies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012977.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012977.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012977.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012977.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012977.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012977.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Overview</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012977.pub2/information#CD012977-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Simon S Craig</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012977.pub2/information#CD012977-cr-0005">Stuart R Dalziel</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012977.pub2/information#CD012977-cr-0006">Colin VE Powell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012977.pub2/information#CD012977-cr-0007">Andis Graudins</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012977.pub2/information#CD012977-cr-0008">Franz E Babl</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012977.pub2/information#CD012977-cr-0009">Carole Lunny</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/information/en#CD012977-sec-0178">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 05 August 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012977.pub2">https://doi.org/10.1002/14651858.CD012977.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012977-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012977-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012977-abs-0019">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012977-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012977-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012977-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD012977-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD012977-abs-0010">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012977-abs-0001" lang="en"> <section id="CD012977-sec-0001"> <h3 class="title" id="CD012977-sec-0001">Background</h3> <p>Asthma is an illness that commonly affects adults and children, and it serves as a common reason for children to attend emergency departments. An asthma exacerbation is characterised by acute or subacute worsening of shortness of breath, cough, wheezing, and chest tightness and may be triggered by viral respiratory infection, poor compliance with usual medication, a change in the weather, or exposure to allergens or irritants. </p> <p>Most children with asthma have mild or moderate exacerbations and respond well to first‐line therapy (inhaled short‐acting beta‐agonists and systemic corticosteroids). However, the best treatment for the small proportion of seriously ill children who do not respond to first‐line therapy is not well understood. Currently, a large number of treatment options are available and there is wide variation in management. </p> </section> <section id="CD012977-sec-0002"> <h3 class="title" id="CD012977-sec-0002">Objectives</h3> <p><b><i>Main objective</i> </b> </p> <p>‐ To summarise Cochrane Reviews with or without meta‐analyses of randomised controlled trials on the efficacy and safety of second‐line treatment for children with acute exacerbations of asthma (i.e. after first‐line treatments, titrated oxygen delivery, and administration of intermittent inhaled short‐acting beta<sub>2</sub>‐agonists and oral corticosteroids have been tried and have failed) </p> <p><b><i>Secondary objectives</i> </b> </p> <p>‐ To identify gaps in the current evidence base that will inform recommendations for future research and subsequent Cochrane Reviews </p> <p>‐ To categorise information on reported outcome measures used in trials of escalation of treatment for acute exacerbations of asthma in children, and to make recommendations for development and reporting of standard outcomes in future trials and reviews </p> <p>‐ To identify relevant randomised controlled trials that have been published since the date of publication of each included review </p> </section> <section id="CD012977-sec-0003"> <h3 class="title" id="CD012977-sec-0003">Methods</h3> <p>We included Cochrane Reviews assessing interventions for children with acute exacerbations of asthma. We searched the Cochrane Database of Systematic Reviews. The search is current to 28 December 2019. We also identified trials that were potentially eligible for, but were not currently included in, published reviews. We assessed the quality of included reviews using the ROBIS criteria (tool used to assess risk of bias in systematic reviews). We presented an evidence synthesis of data from reviews alongside an evidence map of clinical trials. Primary outcomes were length of stay, hospital admission, intensive care unit admission, and adverse effects. We summarised all findings in the text and reported data for each outcome in 'Additional tables'. </p> </section> <section id="CD012977-sec-0004"> <h3 class="title" id="CD012977-sec-0004">Main results</h3> <p>We identified 17 potentially eligible Cochrane Reviews but extracted data from, and rated the quality of, 13 reviews that reported results for children alone. We excluded four reviews as one did not include any randomised controlled trials (RCTs), one did not provide subgroup data for children, and the last two had been updated and replaced by subsequent reviews. </p> <p>The 13 reviews included 67 trials; the number of trials in each review ranged from a single trial up to 27 trials. The vast majority of comparisons included between one and three trials, involving fewer than 100 participants. The total number of participants included in reviews ranged from 40 to 2630. All studies included children; 16 (24%) included children younger than two years of age. Most of the reviews reported search dates older than four years. </p> <p>We have summarised the published evidence as outlined in Cochrane Reviews. Key findings, in terms of our primary outcomes, are that (1) intravenous magnesium sulfate was the only intervention shown to reduce hospital length of stay (high‐certainty evidence); (2) no evidence suggested that any intervention reduced the risk of intensive care admission (low‐ to very low‐certainty evidence); (3) the risk of hospital admission was reduced by the addition of inhaled anticholinergic agents to inhaled beta<sub>2</sub>‐agonists (moderate‐certainty evidence), the use of intravenous magnesium sulfate (high‐certainty evidence), and the use of inhaled heliox (low‐certainty evidence); (4) the addition of inhaled magnesium sulfate to usual bronchodilator therapy appears to reduce serious adverse events during hospital admission (moderate‐certainty evidence); (5) aminophylline increased vomiting compared to placebo (moderate‐certainty evidence) and increased nausea and nausea/vomiting compared to intravenous beta<sub>2</sub>‐agonists (low‐certainty evidence); and (6) the addition of anticholinergic therapy to short‐acting beta<sub>2</sub>‐agonists appeared to reduce the risk of nausea (high‐certainty evidence) and tremor (moderate‐certainty evidence) but not vomiting (low‐certainty evidence). </p> <p>We considered 4 of the 13 reviews to be at high risk of bias based on the ROBIS framework. In all cases, this was due to concerns regarding identification and selection of studies. The certainty of evidence varied widely (by review and also by outcome) and ranged from very low to high. </p> </section> <section id="CD012977-sec-0005"> <h3 class="title" id="CD012977-sec-0005">Authors' conclusions</h3> <p>This overview provides the most up‐to‐date evidence on interventions for escalation of therapy for acute exacerbations of asthma in children from Cochrane Reviews of randomised controlled trials. A vast majority of comparisons involved between one and three trials and fewer than 100 participants, making it difficult to assess the balance between benefits and potential harms. Due to the lack of comparative studies between various treatment options, we are unable to make firm practice recommendations. Intravenous magnesium sulfate appears to reduce both hospital length of stay and the risk of hospital admission. Hospital admission is also reduced with the addition of inhaled anticholinergic agents to inhaled beta<sub>2</sub>‐agonists. However, further research is required to determine which patients are most likely to benefit from these therapies. </p> <p>Due to the relatively rare incidence of acute severe paediatric asthma, multi‐centre research will be required to generate high‐quality evidence. A number of existing Cochrane Reviews should be updated, and we recommend that a new review be conducted on the use of high‐flow nasal oxygen therapy. Important priorities include development of an internationally agreed core outcome set for future trials in acute severe asthma exacerbations and determination of clinically important differences in these outcomes, which can then inform adequately powered future trials. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012977-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012977-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012977-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012977-abs-0020">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012977-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012977-abs-0017">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD012977-abs-0013">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012977-abs-0009">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012977-abs-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012977-abs-0018">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD012977-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012977-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD012977-abs-0011">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012977-abs-0004">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012977-abs-0002" lang="en"> <h3>Interventions for acute severe asthma attacks in children: an overview of Cochrane Reviews </h3> <p><i><b>Background</b> </i> </p> <p>Asthma is a common childhood illness that is caused by narrowing of the small air passages in the lungs. This narrowing is due to swelling and inflammation and to muscles around the air passages becoming tighter. An acute asthma attack results in shortness of breath, cough, wheeze, and chest tightness. </p> <p>When children have an asthma attack, the standard treatment is to give steroids to reduce inflammation and swelling (usually given by mouth) and inhaled medications to relax the muscles in the air passages (called "bronchodilators"). In this review, we call that standard treatment "first‐line" treatment. These medications are well understood to be the best treatments for use in the first instance. </p> <p>Some children's asthma attacks do not improve with first‐line treatment, and more treatment is necessary ‐ usually at the emergency department or hospital; in this review, we call this 'second‐line' treatment. However, the best second‐line treatment for children who do not respond to first‐line treatment is poorly understood. Many treatment options are available, and what is done for children varies from hospital to hospital. </p> <p>We wanted to look at existing Cochrane Reviews of second‐line treatments for children having asthma attacks. We hoped to be able to bring this information together in a useful document and to be able to present the evidence that would help the practitioner make the best treatment decision for each child having an asthma attack when inhaled bronchodilators and oral steroids have not helped with symptoms. </p> <p><i><b>Review question</b> </i> </p> <p>What is the effectiveness and safety of treatment options available for children with acute asthma who do not improve with standard first‐line treatment? </p> <p><i><b>Study characteristics</b> </i> </p> <p>We included 13 Cochrane Systematic Reviews on various treatment options, including inhaled medication, intravenous medications, and other therapies. This overview provides the most up‐to‐date evidence from systematic reviews with meta‐analyses of randomised controlled trials on acute severe asthma in children. This overview is current to December 2019. </p> <p><i><b>Quality of the evidence</b> </i> </p> <p>The quality of these reviews was assessed using a checklist, which helped us assess the risk of bias. Nine of the 13 reviews were considered to be high quality. Four reviews were considered at risk of bias due to concerns with the way studies were identified for inclusion in the reviews. Most of the reviews are out‐of‐date because they have not been updated since 2016. The quality of evidence for specific comparisons ranged from very low to high, with many results coming from small studies. It is difficult to be confident in making recommendations for clinical practice. </p> <p><i><b>Key results</b> </i> </p> <p>For children with acute severe asthma requiring additional treatment, we found that:</p> <p>‐ intravenous magnesium sulfate (a bronchodilator given through a vein) appears to reduce the length of time spent in hospital; </p> <p>‐ no evidence suggests that any treatment reduced the risk of being admitted to intensive care; </p> <p>‐ some treatments appeared to reduce the risk of hospital admission. These included adding a second type of inhaled bronchodilator treatment (anticholinergic medication such as ipratropium bromide) to standard inhaled treatment (beta‐agonist such as salbutamol), giving intravenous magnesium sulfate, and breathing a mixture of helium and oxygen; </p> <p>‐ serious adverse events may be reduced by inhaled magnesium sulfate;</p> <p>‐ nausea and/or vomiting is more common with aminophylline (another bronchodilator medication given through a vein); and </p> <p>‐ adding a second type of inhaled bronchodilator treatment (anticholinergic medication such as Ipratropium bromide) reduces the risk of nausea and tremor but not vomiting. </p> <p><i><b>Recommendations for future research</b> </i> </p> <p>One of the major problems with existing research is that a small number of patients is included in each study, likely because severe acute asthma in children is relatively uncommon. To work out whether or not a treatment is effective and/or to tell the difference between treatments, a research study must include enough patients receiving each treatment. Therefore, high‐quality research into severe acute asthma in children is likely to require studies that include a number of hospitals. </p> <p>It is also important to be able to compare results across studies. To do this, researchers across the world should agree on a standard way of measuring results in studies of acute severe asthma in children. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012977-sec-0153" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012977-sec-0153"></div> <h3 class="title" id="CD012977-sec-0154">Implications for practice</h3> <section id="CD012977-sec-0154"> <p>This overview provides the most up‐to‐date evidence on interventions for escalation of therapy for acute exacerbations of asthma in children from systematic reviews of RCTs. Four of the 13 included reviews were rated as being at high risk of bias. A vast majority of the 74 comparisons reported involved between one and three RCTs, with fewer than 100 participants. </p> <p>The key findings of this overview, in terms of our primary outcomes are that:</p> <p> <ul id="CD012977-list-0015"> <li> <p>intravenous magnesium sulfate was the only intervention shown to reduce hospital length of stay (high‐certainty evidence); </p> </li> <li> <p>no intervention was demonstrated to reduce the risk of intensive care admission (low‐ to very low‐certainty evidence); </p> </li> <li> <p>risk of hospital admission was reduced by the addition of inhaled anticholinergic agents to inhaled beta<sub>2</sub>‐agonists (moderate‐certainty evidence), the use of intravenous magnesium sulfate (high‐certainty evidence), and the use of inhaled heliox (low‐certainty evidence); </p> </li> <li> <p>the addition of inhaled magnesium sulfate to usual bronchodilator therapy appears to reduce serious adverse events during hospital admission (moderate‐certainty evidence); </p> </li> <li> <p>aminophylline increases vomiting compared to placebo (moderate‐certainty evidence) and increases nausea and nausea/vomiting compared to intravenous beta<sub>2</sub>‐agonists (low‐certainty evidence); and </p> </li> <li> <p>the addition of anticholinergic therapy to SABAs appears to reduce the risk of nausea (high‐certainty evidence) and tremor (moderate‐certainty evidence) but not vomiting (low‐certainty evidence). </p> </li> </ul> </p> <p>Comparative studies of the various treatment options are few; additional studies would enable us to draw firmer conclusions about which treatments are most effective. Further research is required to determine which patients are most likely to benefit from these therapies. </p> </section> <h3 class="title" id="CD012977-sec-0155">Implications for research</h3> <section id="CD012977-sec-0155"> <p>Due to the relatively rare incidence of acute severe paediatric asthma, multi‐centre research on a national or international scale will be required to ensure that high‐quality evidence is generated. </p> <p>Several of the included Cochrane Reviews need to be urgently updated. Further, we recommend that a new review into the use of high‐flow nasal oxygen therapy should be conducted. </p> <p>The GRADE assessment between reviews was heterogeneous. We recommend that consistent methods of applying this within the review group should be developed. </p> <p>More research should be conducted with preschool children separately, or results should be reported separately in studies with a combined population of younger and older children/adolescents. </p> <p>Clinical heterogeneity with regard to study setting (inpatient units, emergency departments, and intensive care units) should be addressed by using reliable and reproducible assessments of asthma severity at the point of study entry, enabling consistent inclusion criteria. Reproducible bedside assessment of asthma severity – particularly in young children who are unable to perform reliable spirometry ‐ will also prove useful in determining response to treatment. </p> <p>Currently, outcome measures are inconsistently used, and different measures are used at different times between studies and between reviews. The development of a core outcome set – with input from patients and families, clinicians, and researchers ‐ for future trials on acute severe asthma exacerbations in children is an international priority (<a href="./references#CD012977-bbs2-0037" title="CraigS , BablFE , DalzielSR , GrayC , PowellC , Al AnsariK , et al. Acute severe paediatric asthma: study protocol for the development of a core outcome set, a Pediatric Emergency Reserarch Networks (PERN) study. Trials2020;21(1):72.">Craig 2020</a>); we believe this will allow for better comparisons between treatments in the future. </p> <p>Once a set of core outcome measures is developed, agreement on clinically important differences will inform adequately powered studies able to determine which of the many available treatments is most effective for this group of children. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012977-sec-0006" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012977-sec-0006"></div> <section id="CD012977-sec-0007"> <h3 class="title" id="CD012977-sec-0007">Description of the condition</h3> <p>Asthma is defined as "a chronic inflammatory disorder associated with variable airflow obstruction and bronchial hyper‐responsiveness" (<a href="./references#CD012977-bbs2-0074" title="PapadopoulosNG , ArakawaH , CarlsenKH , CustovicA , GernJ , LemanskeR , et al. International consensus on (ICON) pediatric asthma. Allergy2012;67(8):976-97.">Papadopoulos 2012</a>). Clinical features include recurrent episodes of cough, shortness of breath, wheeze, and chest tightness (<a href="./references#CD012977-bbs2-0074" title="PapadopoulosNG , ArakawaH , CarlsenKH , CustovicA , GernJ , LemanskeR , et al. International consensus on (ICON) pediatric asthma. Allergy2012;67(8):976-97.">Papadopoulos 2012</a>), which may be triggered by viral respiratory infection, poor compliance with usual medication, exercise, a change in the weather, or exposure to allergens or irritants (<a href="./references#CD012977-bbs2-0041" title="Global Initiative for Asthma. 2019 GINA Report, Global Strategy for Asthma Management and Prevention 2019. https://ginasthma.org/gina-reports/ (accessed prior to 3 March 2020).">GINA 2019</a>). </p> <p>Airflow obstruction results primarily from episodic bronchoconstriction due to contraction of airway smooth muscle. However, other mechanisms also contribute, including mucosal oedema, inflammation, mucus hyper‐secretion, airway hyper‐responsiveness, and airway remodelling (<a href="./references#CD012977-bbs2-0071" title="National Heart, Lung, and Blood Institute (NHLBI). National Asthma Education and Prevention Program Expert Panel Report 3: guidelines for the diagnosis and management of asthma 2007. www.nhlbi.nih.gov/health-pro/guidelines/current/asthma-guidelines/full-report (accessed 3 August 2017).">NHLBI 2007</a>). </p> <p>The diagnosis and management of asthma are complicated in younger children, particularly those from birth to five years (<a href="./references#CD012977-bbs2-0033" title="CaveAJ , AtkinsonLL . Asthma in preschool children: a review of the diagnostic challenges. Journal of the American Board of Family Medicine2014;27(4):538-48.">Cave 2014</a>). In this age group, viral‐induced wheezing is very common and has clinical features overlapping those of asthma but does not necessarily have the same longer‐term implications (<a href="./references#CD012977-bbs2-0058" title="MartinezFD , WrightAL , TaussigLM , HolbergCJ , HalonenM , MorganWJ . Asthma and wheezing in the first six years of life. The Group Health Medical Associates. New England Journal of Medicine1995;332(3):133-8.">Martinez 1995</a>; <a href="./references#CD012977-bbs2-0032" title="CaudriD , WijgaA , SchipperCM , HoekstraM , PostmaDS , KoppelmanGH , et al. Predicting the long-term prognosis of children with symptoms suggestive of asthma at preschool age. Journal of Allergy and Clinical Immunology2009;124(5):903-10.e1-7.">Caudri 2009</a>; <a href="./references#CD012977-bbs2-0053" title="KonstantinouGN , XepapadakiP , ManousakisE , MakriniotiH , Kouloufakou-GratsiaK , Saxoni-PapageorgiouP , et al. Assessment of airflow limitation, airway inflammation, and symptoms during virus-induced wheezing episodes in 4- to 6-year-old children. Journal of Allergy and Clinical Immunology2013;131(1):87-93.e1-5.">Konstantinou 2013</a>). </p> <p>Care of a child with asthma requires long‐term management aimed at preventing recurrent exacerbations, as well as acute management of symptomatic exacerbations. Treatment for asthma addresses the underlying pathophysiological mechanisms of inflammation and bronchoconstriction. </p> <p>An asthma exacerbation is defined as an "acute or subacute episode of progressively worsening shortness of breath, cough, wheezing, and chest tightness ‐ or some combination of these symptoms" (<a href="./references#CD012977-bbs2-0071" title="National Heart, Lung, and Blood Institute (NHLBI). National Asthma Education and Prevention Program Expert Panel Report 3: guidelines for the diagnosis and management of asthma 2007. www.nhlbi.nih.gov/health-pro/guidelines/current/asthma-guidelines/full-report (accessed 3 August 2017).">NHLBI 2007</a>). First‐line therapy for management of acute exacerbations of asthma is well established and requires titrated oxygen delivery and administration of intermittent inhaled short‐acting beta<sub>2</sub>‐agonists (SABAs) and oral corticosteroids (OCSs) (<a href="./references#CD012977-bbs2-0071" title="National Heart, Lung, and Blood Institute (NHLBI). National Asthma Education and Prevention Program Expert Panel Report 3: guidelines for the diagnosis and management of asthma 2007. www.nhlbi.nih.gov/health-pro/guidelines/current/asthma-guidelines/full-report (accessed 3 August 2017).">NHLBI 2007</a>; <a href="./references#CD012977-bbs2-0041" title="Global Initiative for Asthma. 2019 GINA Report, Global Strategy for Asthma Management and Prevention 2019. https://ginasthma.org/gina-reports/ (accessed prior to 3 March 2020).">GINA 2019</a>; <a href="./references#CD012977-bbs2-0068" title="National Asthma Council Australia. Australian Asthma Handbook, Version 2.0. National Asthma Council Australia, Melbourne, 2019. https://www.asthmahandbook.org.au/about (accessed prior to 3 March 2020).">National Asthma Council Australia 2019</a>). </p> </section> <section id="CD012977-sec-0008"> <h3 class="title" id="CD012977-sec-0008">Description of the interventions</h3> <p>Most children with asthma have mild or moderate exacerbations and respond well to first‐line therapy (<a href="./references#CD012977-bbs2-0078" title="PowellCV , KellyAM , KerrD . Lack of agreement in classification of the severity of acute asthma between emergency physician assessment and classification using the National Asthma Council Australia guidelines (1998). Emergency Medicine2003;15(1):49-53.">Powell 2003</a>; <a href="./references#CD012977-bbs2-0051" title="KellyAM , KerrD , PowellC . Is severity assessment after one hour of treatment better for predicting the need for admission in acute asthma?Respiratory Medicine2004;98(8):777-81.">Kelly 2004</a>; <a href="./references#CD012977-bbs2-0042" title="GiordanoK , RodriguezE , GreenN , ArmaniM , RichardsJ , ShafferTH , et al. Pulmonary function tests in emergency department pediatric patients with acute wheezing/asthma exacerbation. Pulmonary Medicine2012;2012:724139. [DOI: 10.1155/2012/724139]">Giordano 2012</a>; <a href="./references#CD012977-bbs2-0072" title="O'ConnorMG , SavilleBR , HartertTV , ArnoldDH . Treatment variability of asthma exacerbations in a pediatric emergency department using a severity-based management protocol. Clinical Pediatrics2014;53(13):1288-90.">O'Connor 2014</a>). A minority of children with severe exacerbations are unresponsive to first‐line therapy and require escalation of (i.e. second‐line) treatment (<a href="./references#CD012977-bbs2-0072" title="O'ConnorMG , SavilleBR , HartertTV , ArnoldDH . Treatment variability of asthma exacerbations in a pediatric emergency department using a severity-based management protocol. Clinical Pediatrics2014;53(13):1288-90.">O'Connor 2014</a>; <a href="./references#CD012977-bbs2-0027" title="Biagini MyersJM , SimmonsJM , KercsmarCM , MartinLJ , PilipenkoVV , AustinSR , et al. Heterogeneity in asthma care in a statewide collaborative: the Ohio Pediatric Asthma Repository. Pediatrics2015;135(2):271-9.">Biagini Myers 2015</a>; <a href="./references#CD012977-bbs2-0062" title="MorrisI , LyttleMD , O'SullivanR , SargantN , DoullIJ , PowellCV . Which intravenous bronchodilators are being administered to children presenting with acute severe wheeze in the UK and Ireland?Thorax2015;70(1):88-91.">Morris 2015</a>). Many options are available for second‐line treatment, and available regimens show considerable variability amongst healthcare providers (<a href="./references#CD012977-bbs2-0023" title="BablFE , SheriffN , BorlandM , AcworthJ , NeutzeJ , KrieserD , et al. Paediatric acute asthma management in Australia and New Zealand: practice patterns in the context of clinical practice guidelines. Archives of Disease in Childhood2008;93(4):307-12.">Babl 2008</a>; <a href="./references#CD012977-bbs2-0054" title="LyttleMD , O'SullivanR , DoullI , HartshornS , MorrisI , PowellCV . Variation in treatment of acute childhood wheeze in emergency departments of the United Kingdom and Ireland: an international survey of clinician practice. Archives of Disease in Childhood2015;100(2):121-5.">Lyttle 2015</a>). </p> <p>Second‐line treatment can be grouped into the following broad categories.</p> <p> <ul id="CD012977-list-0001"> <li> <p>Additional inhaled bronchodilators, including continuous inhaled beta<sub>2</sub>‐agonists, anticholinergic medications such as ipratropium, and nebulised magnesium sulfate. </p> </li> <li> <p>Parenteral bronchodilators, including selective beta<sub>2</sub>‐agonists such as salbutamol or terbutaline; adrenaline (epinephrine), an agonist at both α‐ and β‐receptors; magnesium sulfate; methylxanthines such as theophylline or aminophylline; and ketamine. Subcutaneous, intramuscular, and intravenous routes may be utilised, and intravenous treatment may be delivered as a single loading dose or as a continuous infusion. </p> </li> <li> <p>Interventions to reduce the work of breathing, including inhalation of heliox (a mixture of helium and oxygen), administration of high‐flow humidified nasal oxygen therapy, or provision of non‐invasive ventilation with the use of continuous positive airway pressure (CPAP) or bi‐level positive airway pressure (BiPAP). </p> </li> </ul> </p> </section> <section id="CD012977-sec-0009"> <h3 class="title" id="CD012977-sec-0009">How the intervention might work</h3> <section id="CD012977-sec-0010"> <h4 class="title">Bronchodilators</h4> <p>Relief of bronchoconstriction, a major therapeutic target in an acute exacerbation of asthma, is achieved by several pharmacological agents acting by various mechanisms. Inhaled short‐acting beta<sub>2</sub>‐agonists (SABAs), such as salbutamol and terbutaline, are effective, provide rapid onset of action, and are accepted as first‐line therapy for acute asthma exacerbations (<a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>). In young children, administration using a spacer or a holding chamber is preferred over delivery via nebuliser (<a href="./references#CD012977-bbs2-0040" title="FergusonC , GidwaniS . Best evidence topic reports. Delivery of bronchodilators in acute asthma in children. Emergency Medicine Journal2006;23(6):471-2.">Ferguson 2006</a>). In patients with severe exacerbations unresponsive to first‐line administration of an intermittent inhaled SABA, healthcare providers may wish to administer continuous inhaled SABA (often by nebuliser) to saturate all available respiratory tract beta<sub>2</sub>‐receptors and achieve maximum bronchodilation from this pathway (<a href="./references#CD012977-bbs2-0052" title="KenyonCC , FieldstonES , LuanX , KerenR , ZorcJJ . Safety and effectiveness of continuous aerosolized albuterol in the non-intensive care setting. Pediatrics2014;134(4):e976-82.">Kenyon 2014</a>). If a patient requires oxygen, this can be provided via nasal prongs and SABA administered by spacer, or, alternatively, oxygen can be used to nebulise SABA. </p> <p>Inhaled anticholinergic agents such as ipratropium bromide are thought to cause bronchodilation by relieving cholinergic bronchoconstriction and reducing mucosal oedema and airway secretions (<a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>). Although not as effective as beta<sub>2</sub>‐agonists, it has been suggested that combining these medications may lead to greater bronchodilation than using either agent alone (<a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a>). </p> <p>Magnesium sulfate is an effective bronchodilator and is administered by nebuliser or by the intravenous route. The mode of action of magnesium sulfate is thought to be related to direct smooth muscle relaxation; however, additional mechanisms may be related to blocking calcium ion influx into smooth muscle cells, thus modulating mast cell histamine release, anti‐inflammatory properties, and cholinergic neural transmission (<a href="./references#CD012977-bbs2-0079" title="PowellC , DwanK , MilanSJ , BeasleyR , HughesR , Knopp-SihotaJA , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub5]">Powell 2012</a>). Some evidence suggests that simultaneous administration of magnesium sulfate and a beta<sub>2</sub>‐agonist has an additive bronchodilator effect, perhaps owing to magnesium sulfate augmenting the beta‐receptor agonist response (<a href="./references#CD012977-bbs2-0070" title="NeameM , AragonO , FernandesRM , SinhaI . Salbutamol or aminophylline for acute severe asthma: how to choose which one, when and why?Archives of Disease in Childhood. Education and Practice Edition2015;100(4):215-22.">Neame 2015</a>). </p> <p>In the setting of severe acute asthma, it has been suggested that inhaled beta<sub>2</sub>‐agonists may not reach their site of action through the airway owing to significant airflow obstruction, and that systemic (subcutaneous or intravenous) administration of bronchodilators may lead to a more rapid therapeutic response (<a href="./references#CD012977-bbs2-0010" title="TraversAH , MilanSJ , JonesAP , Camargo CA Jr, RoweBH . Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010179. [DOI: 10.1002/14651858.CD010179]">Travers 2012a</a>). </p> <p>Adrenaline (epinephrine) is a potent beta‐agonist with bronchodilating effects similar to the more selective beta<sub>2</sub>‐agonists. Historically, parenteral adrenaline was a standard therapy for acute asthma (<a href="./references#CD012977-bbs2-0080" title="ReesHA , MillarJS , DonaldKW . Adrenaline in bronchial asthma. Lancet1967;2(7527):1164-7.">Rees 1967</a>; <a href="./references#CD012977-bbs2-0087" title="ShimC . Adrenergic agonists and bronchodilator aerosol therapy in asthma. Clinics in Chest Medicine1984;5(4):659-68.">Shim 1984</a>); however, similar clinical efficacy and the less invasive nature of inhaled bronchodilators as reported by <a href="./references#CD012977-bbs2-0066" title="NaspitzCK , SoleD , WandalsenN . Treatment of acute attacks of bronchial asthma. A comparative study of epinephrine (subcutaneous) and fenoterol (inhalation). Annals of Allergy1987;59(1):21-4.">Naspitz 1987</a> have led clinicians to reserve this treatment as an option for severely ill patients who are unresponsive to inhaled therapy (<a href="./references#CD012977-bbs2-0047" title="HonKL , LeungAK . Management of status asthmaticus in children. Recent Patents on Inflammation and Allergy Drug Discovery2017;11(1):12-21.">Hon 2017</a>). </p> <p>Methylxanthines, such as theophylline and aminophylline, are used to treat patients with asthma. Bronchodilator effects may be due to inhibition of phosphodiesterase, leading to accumulation of cyclic adenosine monophosphate (cAMP) in smooth muscle cells, adenosine antagonism, and release of catecholamines (<a href="./references#CD012977-bbs2-0070" title="NeameM , AragonO , FernandesRM , SinhaI . Salbutamol or aminophylline for acute severe asthma: how to choose which one, when and why?Archives of Disease in Childhood. Education and Practice Edition2015;100(4):215-22.">Neame 2015</a>). Other actions are thought to include anti‐inflammatory and immunomodulatory effects (<a href="./references#CD012977-bbs2-0070" title="NeameM , AragonO , FernandesRM , SinhaI . Salbutamol or aminophylline for acute severe asthma: how to choose which one, when and why?Archives of Disease in Childhood. Education and Practice Edition2015;100(4):215-22.">Neame 2015</a>). </p> <p>Ketamine is commonly used in the emergency department (ED) for procedural sedation, analgesia, and intubation, and it has many effects, including dissociative anaesthesia, analgesia, amnesia, and anxiolysis. It can also induce bronchodilation, possibly as a sympathomimetic effect or as a direct effect on bronchial smooth muscle (<a href="./references#CD012977-bbs2-0004" title="JatKR , ChawlaD . Ketamine for management of acute exacerbations of asthma in children. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD009293. [DOI: 10.1002/14651858.CD009293.pub2]">Jat 2012</a>). Other potential effects include immunomodulation and inhibition of vagal outflow (<a href="./references#CD012977-bbs2-0043" title="GoyalS , AgrawalA . Ketamine in status asthmaticus: a review. Indian Journal of Critical Care Medicine2013;17(3):154-61.">Goyal 2013</a>). </p> </section> <section id="CD012977-sec-0011"> <h4 class="title">Interventions to reduce the work of breathing</h4> <p>Room air comprises nitrogen (79%) and oxygen (21%). Heliox (helium‐oxygen mixture) is produced when helium replaces nitrogen, leading to a less dense gas mixture. Theoretically, this may reduce turbulent airflow and airflow obstruction in patients with asthma. Heliox has also been used to deliver nebulised therapy, as it has been suggested that it may lead to improved transport of medication to the distal airways (<a href="./references#CD012977-bbs2-0081" title="RehderKJ . Adjunct therapies for refractory status asthmaticus in children. Respiratory Care2017;62(6):849-65.">Rehder 2017</a>). </p> <p>Non‐invasive respiratory support can be delivered via high‐flow nasal cannulae (HFNC), continuous positive airway pressure (CPAP), or bi‐level positive airway pressure (BiPAP). Patients with severe asthma often develop elevated intrinsic positive end‐expiratory pressure (PEEP). It is theorised that delivery of extrinsic positive pressure via face mask or nasal cannulae may overcome this intrinsic pressure, thereby reducing the work of breathing. </p> <p>HFNC provide warmed, humidified gas delivered via nasal prongs at a flow rate that exceeds the patient's peak inspiratory flow rate. This results in washout of anatomic dead space and also provides some PEEP, although the PEEP delivered is less consistent than that provided by CPAP or BiPAP (<a href="./references#CD012977-bbs2-0081" title="RehderKJ . Adjunct therapies for refractory status asthmaticus in children. Respiratory Care2017;62(6):849-65.">Rehder 2017</a>). High‐flow delivery is more comfortable and therefore is better tolerated with less requirement for sedation than other methods of non‐invasive respiratory support (<a href="./references#CD012977-bbs2-0025" title="BaudinF , BuissonA , VanelB , MassenavetteB , PouyauR , JavouheyE . Nasal high flow in management of children with status asthmaticus: a retrospective observational study. Annals of Intensive Care2017;7(1):55.">Baudin 2017</a>). </p> <p>CPAP provides constant pressure throughout the respiratory cycle, and BiPAP provides variable pressure according to phases of the respiratory cycle, with higher pressure delivered during inspiration. Positive effects of CPAP and BiPAP include a direct bronchodilating effect, improved alveolar recruitment, improved airflow, re‐expansion of areas of collapse, reduced hyperinflation, and reduced work of breathing (<a href="./references#CD012977-bbs2-0006" title="KorangSK , FeinbergJ , WetterslevJ , JakobsenJC . Non-invasive positive pressure ventilation for acute asthma in children. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012067. [DOI: 10.1002/14651858.CD012067.pub2]">Korang 2016</a>). </p> </section> </section> <section id="CD012977-sec-0012"> <h3 class="title" id="CD012977-sec-0012">Why it is important to do this overview</h3> <section id="CD012977-sec-0013"> <h4 class="title">Clinical rationale</h4> <p>Asthma is a common reason for paediatric visits to the ED (<a href="./references#CD012977-bbs2-0020" title="AlpernER , StanleyRM , GorelickMH , DonaldsonA , KnightS , TeachSJ , et al. Epidemiology of a pediatric emergency medicine research network: the PECARN core data project. Pediatric Emergency Care2006;22(10):689-99.">Alpern 2006</a>; <a href="./references#CD012977-bbs2-0018" title="AcworthJ , BablF , BorlandM , NgoP , KrieserD , SchutzJ , et al. Patterns of presentation to the Australian and New Zealand Paediatric Emergency Research Network. Emergency Medicine Australasia2009;21(1):59-66.">Acworth 2009</a>); it is one of the most common reasons for a child to be admitted to hospital after an ED visit (<a href="./references#CD012977-bbs2-0092" title="WeissAJ , WierLM , StocksC , BlanchardJ . Overview of emergency department visits in the United States, 2011. HCUP Statistical Brief #174. June 2014. Rockville, MD: Agency for Healthcare Research and Quality. www.hcup-us.ahrq.gov/reports/statbriefs/sb174-Emergency-Department-Visits-Overview.pdf (accessed 2 November 2017).">Weiss 2011</a>). In the USA, the rate of paediatric ED visits for asthma increased by 13.3% between 2001 and 2010 (<a href="./references#CD012977-bbs2-0067" title="NathJB , HsiaRY . Children's emergency department use for asthma, 2001-2010. Academic Pediatrics2015;15(2):225-30.">Nath 2015</a>), and in the UK, it is estimated that a child is admitted to hospital every 20 minutes owing to an asthma attack (<a href="./references#CD012977-bbs2-0021" title="AsthmaUK . Asthma facts and statistics. www.asthma.org.uk/about/media/facts-and-statistics/ (accessed 3 August 2017).">Asthma UK</a>). </p> <p>The care of children with asthma is based upon escalation of treatment in response to disease severity: mild disease receives less intensive treatment than severe disease. Broadly speaking, interventions take the form of inhaled bronchodilators, parenteral (intravenous or subcutaneous) pharmacotherapy, and mechanical efforts to reduce the work of breathing. With increasing 'level of treatment' come risks of increasing costs, patient discomfort, potential for complications, and requirement for monitoring and/or transfer to intensive care units. Some treatments ‐ particularly intravenous bronchodilators or assisted ventilation ‐ are given in higher‐acuity settings such as intensive care, and other treatments may be given in a standard ward environment. </p> <p>Variation in the management of acute severe asthma in children is considerable and may be due to considerations around efficacy, safety, cost, clinical experience, and individual practitioner preference. A recent survey of emergency physicians in the UK and Ireland found that over half preferred salbutamol as first‐line intravenous treatment, 28% preferred magnesium sulfate, and 15% preferred aminophylline (<a href="./references#CD012977-bbs2-0054" title="LyttleMD , O'SullivanR , DoullI , HartshornS , MorrisI , PowellCV . Variation in treatment of acute childhood wheeze in emergency departments of the United Kingdom and Ireland: an international survey of clinician practice. Archives of Disease in Childhood2015;100(2):121-5.">Lyttle 2015</a>). An earlier survey of paediatric emergency specialists in Australia and New Zealand found that aminophylline was used by 45%, intravenous magnesium sulfate by 55%, and intravenous salbutamol by 87% of respondents (<a href="./references#CD012977-bbs2-0023" title="BablFE , SheriffN , BorlandM , AcworthJ , NeutzeJ , KrieserD , et al. Paediatric acute asthma management in Australia and New Zealand: practice patterns in the context of clinical practice guidelines. Archives of Disease in Childhood2008;93(4):307-12.">Babl 2008</a>). A recent prospective study of 24 EDs in the UK and Ireland found wide variation in the prevalence of intravenous treatment for acute paediatric asthma, ranging from 0% to 19.4% (<a href="./references#CD012977-bbs2-0062" title="MorrisI , LyttleMD , O'SullivanR , SargantN , DoullIJ , PowellCV . Which intravenous bronchodilators are being administered to children presenting with acute severe wheeze in the UK and Ireland?Thorax2015;70(1):88-91.">Morris 2015</a>). </p> <p>With a large number of treatment options and wide variation in self‐reported and actual practice, it is important to have a single comprehensive and user‐friendly document that provides the best available evidence upon which to base clinical decisions. There is a need to present available evidence clearly to assist healthcare providers, patients, and other knowledge users. </p> <p>An overview of reviews of acute asthma treatment in children attending EDs was published in 2015 (<a href="./references#CD012977-bbs2-0031" title="Castro-RodriguezJA , RodrigoJG , Rodríguez-MartínezCE . Principal findings of systematic reviews of acute asthma treatment in childhood. Journal of Asthma2015;52(10):1038-45.">Castro‐Rodriguez 2015</a>). The review authors excluded reviews of treatment on the ward or in the intensive care unit. As treatment for a seriously ill child often involves transfer to higher levels of care, restricting inclusion to only reviews evaluating treatment within the ED may have led to exclusion of potentially important studies. </p> <p>The purpose of a Cochrane overview is to systematically summarise evidence from a range of Cochrane intervention reviews for a single health condition (<a href="./references#CD012977-bbs2-0077" title="PollockM , FernandesRM , BeckerLA , PieperD , HartlingL . Chapter V. Overviews of reviews. Draft version (8 October 2018) for inclusion. in: Higgins JPT, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, Welch V (editors). Cochrane Handbook for Systematic Reviews of Interventions. London: Cochrane. Available from www.training.cochrane.org/handbook.">Pollack 2018</a>). This overview will document the efficacy of second‐line interventions from systematic reviews and will provide information about toxicity and adverse effects. </p> <p>Potential additional benefits of this overview will include a clear foundation upon which further research can be based and an understanding of reported outcome measures, which may be used to assist in development of a set of core outcome measures for future clinical trials. </p> </section> <section id="CD012977-sec-0014"> <h4 class="title">Methodological rationale</h4> <p>Currently, the Cochrane Airways Group has prepared approximately 50 published reviews on the effectiveness of various interventions for acute asthma. These include 43 reviews on pharmacotherapy and another seven reviews on non‐pharmacotherapy interventions. Given the large number of potentially relevant reviews and the likely heterogeneity in eligibility criteria and study outcomes, we have chosen to utilise an overview design rather than a network meta‐analysis as the first step in assessing the literature. </p> </section> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012977-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012977-sec-0015"></div> <section id="CD012977-sec-0016"> <h3 class="title" id="CD012977-sec-0016">Main objective</h3> <p> <ul id="CD012977-list-0002"> <li> <p>To summarise Cochrane Reviews with or without meta‐analyses of randomised controlled trials on the efficacy and safety of second‐line treatment for children with acute exacerbations of asthma (i.e. after first‐line treatments, titrated oxygen delivery, and administration of intermittent inhaled short‐acting beta<sub>2</sub>‐agonists and oral corticosteroids have been tried and have failed) </p> </li> </ul> </p> </section> <section id="CD012977-sec-0017"> <h3 class="title" id="CD012977-sec-0017">Secondary objectives</h3> <p> <ul id="CD012977-list-0003"> <li> <p>To identify gaps in the current evidence base that will inform recommendations for future research and subsequent Cochrane Reviews </p> </li> <li> <p>To categorise information on reported outcome measures used in trials of escalation of treatment for acute exacerbations of asthma in children, and to make recommendations for development and reporting of standard outcomes in future trials and reviews </p> </li> <li> <p>To identify relevant randomised controlled trials that have been published since the date of publication of each included review </p> </li> </ul> </p> </section> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012977-sec-0018" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012977-sec-0018"></div> <section id="CD012977-sec-0019"> <h3 class="title">Criteria for considering reviews for inclusion</h3> <section id="CD012977-sec-0020"> <h4 class="title">Types of reviews</h4> <p>We included Cochrane systematic reviews on second‐line treatment of patients with acute asthma published in the <i>Cochrane Database of Systematic Reviews</i> (CDSR). We included Cochrane Reviews of randomised controlled trials (RCTs) and non‐randomised controlled clinical trials (CCTs). </p> </section> <section id="CD012977-sec-0021"> <h4 class="title">Types of participants</h4> <p>We included systematic reviews of children with a physician‐diagnosed acute exacerbation of asthma. We defined a child as any person younger than 18 years of age. However, as the definition of 'child' could vary between systematic reviews, we planned to include any systematic review in which a population was described as children, and we recorded the ages included within each review. We also included systematic reviews of adults and children in which the summary data for children could be separated from the summary data for adults. </p> </section> <section id="CD012977-sec-0022"> <h4 class="title">Types of interventions/comparisons</h4> <p>We included all treatments that may be considered second‐line therapy for acute exacerbations of asthma. We did not include Cochrane systematic reviews examining interventions including only corticosteroids or intermittent inhaled beta<sub>2</sub>‐agonists. </p> <p>We planned to divide treatments into the following categories, consistent with steps in the escalation of therapy (inhaled treatment, parenteral treatment, and other interventions to reduce the work of breathing). </p> <p> <ul id="CD012977-list-0004"> <li> <p>Inhaled bronchodilators.</p> <ul id="CD012977-list-0005"> <li> <p>Continuous nebulised inhaled beta<sub>2</sub>‐agonists. </p> </li> <li> <p>Anticholinergic medications.</p> </li> <li> <p>Magnesium sulfate.</p> </li> </ul> </li> <li> <p>Parenteral bronchodilators.</p> <ul id="CD012977-list-0006"> <li> <p>beta<sub>2</sub>‐agonists. </p> </li> <li> <p>Adrenaline/epinephrine.</p> </li> <li> <p>Magnesium sulfate.</p> </li> <li> <p>Methylxanthines.</p> </li> <li> <p>Ketamine.</p> </li> </ul> </li> <li> <p>Interventions to reduce the work of breathing.</p> <ul id="CD012977-list-0007"> <li> <p>Heliox.</p> </li> <li> <p>High‐flow nasal cannulae.</p> </li> <li> <p>Non‐invasive ventilation (CPAP or BiPAP).</p> </li> </ul> </li> </ul> </p> </section> <section id="CD012977-sec-0023"> <h4 class="title">Types of comparisons</h4> <p>We included systematic reviews with all possible comparisons, that is, versus placebo and/or versus another active comparator (ongoing first‐line treatment or an alternative intervention). </p> </section> <section id="CD012977-sec-0024"> <h4 class="title">Types of outcome measures</h4> <section id="CD012977-sec-0025"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012977-list-0008"> <li> <p>Length of stay (duration of ED stay and duration of inpatient stay)</p> </li> <li> <p>ED disposition (hospital admission/intensive care unit (ICU) admission/ED discharge)</p> </li> <li> <p>Number of adverse events in each treatment group</p> </li> </ul> </p> </section> <section id="CD012977-sec-0026"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012977-list-0009"> <li> <p>Symptom scores/clinical asthma scores (such as the Pulmonary Index (<a href="./references#CD012977-bbs2-0026" title="BeckerAB , NelsonNA , SimonsFE . The pulmonary index. Assessment of a clinical score for asthma. American Journal of Diseases of Children1984;138(6):574-6.">Becker 1984</a>), the Clinical Asthma Score (<a href="./references#CD012977-bbs2-0075" title="ParkinPC , MacarthurC , SaundersNR , DiamondSA , WindersPM . Development of a clinical asthma score for use in hospitalized children between 1 and 5 years of age. Journal of Clinical Epidemiology1996;49(8):821-5.">Parkin 1996</a>), the Pediatric Respiratory Assessment Measure (<a href="./references#CD012977-bbs2-0039" title="DucharmeFM , ChalutD , PlotnickL , SavdieC , KudirkaD , ZhangX , et al. The pediatric respiratory assessment measure: a valid clinical score for assessing acute asthma severity from toddlers to teenagers. Journal of Pediatrics2008;152(4):476-80, 480.e1.">Ducharme 2008</a>), and any other scores identified in the included systematic reviews) </p> </li> <li> <p>Lung function (peak expiratory flow rate (PEFR), forced expiratory volume in one second (FEV1), and other measures identified in included systematic reviews) </p> </li> <li> <p>Adverse events (vomiting, nausea, tremor, tachycardia, convulsions, and any other adverse events identified in included systematic reviews) </p> </li> <li> <p>Vital signs (pulse, blood pressure, respiratory rate, and pulse oximetry)</p> </li> <li> <p>Requirement for additional bronchodilator treatment</p> </li> <li> <p>Requirement for respiratory support (intubation, non‐invasive ventilation)</p> </li> <li> <p>Economic outcomes such as healthcare costs</p> </li> </ul> </p> <p>We planned to report on the primary and secondary outcomes outlined above. However, we tabulated all outcomes identified in the overview to present a taxonomy of outcomes for future reviews on this topic. </p> </section> </section> </section> <section id="CD012977-sec-0027"> <h3 class="title">Search methods for identification of reviews</h3> <p>We searched for systematic reviews in the Cochrane Library using the filter for reviews. We also searched for but did not identify any Cochrane Review protocols or titles for future inclusion. We used the search terms "asthma" and "respiratory sounds" (which included the medical subject heading (MeSH) term for "wheeze"). Our search strategy is detailed in <a href="./appendices#CD012977-sec-0158">Appendix 1</a>. The search is current to 28 December 2019. </p> <p>We included only the most recently published version of each systematic review. We did not include protocols and earlier versions of a review that have been superseded. We did not include systematic reviews from outside the Cochrane Library. If multiple reviews addressed the same question, we planned to examine them for unique content, and if none was found, we planned to include the most up‐to‐date review. If multiple systematic reviews addressed the same question and unique content was found in each, we planned to include them all and extract the unique data for each one. </p> <p>To identify possibly relevant research papers that have been published since the date of publication for each included systematic review, we utilised the search strategy of each included systematic review. We supplemented this by cross‐checking this against current British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN) guidelines (<a href="./references#CD012977-bbs2-0030" title="SIGN158 - British guideline on the management of asthma: a national clinical guideline. First published 2003. Revised edition published July 2019. www.brit-thoracic.org.uk/document-library/guidelines/asthma/btssign-guideline-for-the-management-of-asthma-2019/ (accessed prior to 3 March 2020).">BTS/SIGN 2019</a>), as well as the Global Initiative for Asthma (GINA) guidelines (<a href="./references#CD012977-bbs2-0041" title="Global Initiative for Asthma. 2019 GINA Report, Global Strategy for Asthma Management and Prevention 2019. https://ginasthma.org/gina-reports/ (accessed prior to 3 March 2020).">GINA 2019</a>), but we identified no additional reviews. </p> </section> <section id="CD012977-sec-0028"> <h3 class="title" id="CD012977-sec-0028">Data collection and analysis</h3> <section id="CD012977-sec-0029"> <h4 class="title">Selection of reviews</h4> <p>We assessed in two stages the eligibility of identified Cochrane Reviews. Two independent overview authors (SC and AG) screened each title and abstract. We planned to use a third overview author to resolve discrepancies when the two first authors could not reach consensus; however, no discrepancies occurred. Two independent overview authors (SC and AG) assessed in full text all titles/abstracts and then selected reviews by consensus. Again, no discrepancies occurred between the two overview authors. </p> </section> <section id="CD012977-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>A pilot data extraction form was designed and piloted by several authors (SC, CL, AG). Two overview authors (SC and one other of SRD, CVP, or AG) independently extracted data using the finalised data extraction form. We planned to involve an independent third overview author to resolve disagreements; however, there were none requiring their involvement. </p> <p>Data extracted (see <a href="./appendices#CD012977-sec-0159">Appendix 2</a>) include the following. </p> <p> <ul id="CD012977-list-0010"> <li> <p>Details of the included systematic reviews, including first author name, year of publication, number of included primary studies, eligibility criteria of included systematic reviews, numbers of included participants, and sample size of included RCTs. </p> </li> <li> <p>Details of trial populations, including age and severity of asthma (including inclusion criteria and definition of exacerbation of asthma for each review, treatment before enrolment, and severity of asthma at enrolment). </p> </li> <li> <p>Setting (ED, hospital ward, ICU).</p> </li> <li> <p>Types of interventions.</p> </li> <li> <p>Dose, duration, and frequency of intervention administration.</p> </li> <li> <p>Description of the comparison (placebo, regular doses of bronchodilators).</p> </li> <li> <p>Description of outcome measures used, including our predefined primary and secondary outcomes and all other reported outcomes. </p> </li> <li> <p>Timing of determination of outcome measures and duration of follow‐up.</p> </li> <li> <p>Risk of bias assessments of RCTs included in the reviews.</p> </li> <li> <p>For each predetermined primary and secondary outcome measure, and for all additional outcomes, numbers of participants in intervention and control groups; control event rate; effect estimates for the pooled risk ratio; odds ratio, hazard ratio, standardised mean difference, or absolute risk reduction and corresponding 95% confidence intervals (if not provided, we will calculate these, using the equations published in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012977-bbs2-0085" title="SchünemannHJ , VistGE , HigginsJPT , SantessoN , DeeksJJ , GlasziouP , et al. Chapter 15, Interpreting results and drawing conclusions. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Schüneman 2019</a>)). </p> </li> <li> <p>Quality assessment tools used (e.g. GRADE), along with the mean or median and the range of any reported quality scores. </p> </li> </ul> </p> <p>If the included systematic reviews included all RCTs relevant to a particular outcome, we extracted summary data alone. We extracted only data from RCTs conducted exclusively among children, or for which authors of the systematic review had been able to retrieve data for children. </p> <p>If we identified overlapping information across systematic reviews at the data extraction stage, we planned to extract data only from the most recently published review. We planned to acknowledge overlap among different reviews (overlapping trials), depict any potential overlap in tables, and discuss this limitation in the results. We identified no overlapping information. </p> <p>If we identified discrepant data across systematic reviews, we planned to extract data from all included reviews and reconcile the discrepancies by contacting the authors of included reviews, retrieving primary studies from the included reviews, and searching relevant trial registries. We planned to discuss potential discrepancies in data in the Results section. We identified no discrepant data. </p> <p>We planned to present the data in a series of summary tables.</p> </section> <section id="CD012977-sec-0031"> <h4 class="title">Assessment of methodological quality of included reviews</h4> <p>Two overview authors independently assessed the risk of bias of included systematic reviews using the Risk of Bias in Systematic Reviews (ROBIS) tool (<a href="./references#CD012977-bbs2-0093" title="WhitingP , SavovicJ , HigginsJP , CaldwellDM , ReevesBC , SheaB , et al. ROBIS: a new tool to assess risk of bias in systematic reviews was developed. Journal of Clinical Epidemiology2016;69:225-34.">Whiting 2016</a>). The ROBIS tool (see <a href="./appendices#CD012977-sec-0167">Appendix 3</a>) consists of three phases: assessment of relevance of the systematic review to the study question, identification of potential concerns regarding the review process, and a judgement of risk of bias. We planned to report in a table assessment for individual ROBIS items or domains (along with the rationale for judgements for each assessment). </p> <p>We defined a high‐quality systematic review with meta‐analysis as one that has low risk of bias judgements for the first three domains of the ROBIS tool, namely, specification of study eligibility (domain 1), methods used to identify and/or select studies (domain 2), and methods used to collect data and appraise studies (domain 3) (<a href="./references#CD012977-bbs2-0093" title="WhitingP , SavovicJ , HigginsJP , CaldwellDM , ReevesBC , SheaB , et al. ROBIS: a new tool to assess risk of bias in systematic reviews was developed. Journal of Clinical Epidemiology2016;69:225-34.">Whiting 2016</a>). If more than one review on a specific topic was included, we planned to choose the review judged as having low risk of bias in all three ROBIS domains, as well as the review that most closely matched our overview PICO criteria. However, we found no overlapping reviews. </p> <p>We planned to use the risk of bias assessment to conduct sensitivity analyses, but we did not exclude reviews on the basis of the risk of bias assessment. </p> <p>We planned to present a summary of this information according to guidelines provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012977-bbs2-0045" title="HigginsJPT , SavovićJ , PageMJ , ElbersRG , SterneJAC . Chapter 8. Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019</a>). </p> <section id="CD012977-sec-0032"> <h5 class="title">Quality of evidence in included reviews</h5> <p>Two overview authors independently evaluated the certainty of evidence on the basis of judgements made by the authors of the original Cochrane Reviews, if provided. </p> <p>We assessed the certainty of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (<a href="./references#CD012977-bbs2-0024" title="BalshemH , HelfandM , SchunemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401-6.">Balshem 2011</a>). </p> <p>First, we extracted the GRADE assessments for each systematic review for each independent outcome. We planned to first assess whether the domain judgements were consistent; if they were inconsistent, we planned to reconcile the inconsistency by comparing extracted data between reviews for missing or discrepant data, contacting the authors of the primary studies, or searching trial registries, if two or more systematic reviews reported GRADE assessments for the same outcome. We planned to choose the highest‐quality systematic review with meta‐analysis from which to extract effect estimates for our GRADE assessment of inconsistency and imprecision if we continued to note inconsistency in the reported GRADE domains (or none reported). </p> <p>We planned to independently conduct this assessment by constructing 'Summary of findings' tables using GRADEpro software if the original review published no GRADE assessment (<a href="./references#CD012977-bbs2-0044" title="GRADEpro GDT. Version accessed prior to 3 March 2020. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GradePro 2015</a>), or if outcome data in our overview had been re‐analysed from a subset of primary studies within a review. </p> <p>We based our assessment of the certainty of evidence in included reviews on data provided in the 'Characteristics of included studies', 'Risk of bias', and 'Summary of findings' tables provided in the included reviews, and we planned to present a summary of this information according to guidelines provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012977-bbs2-0045" title="HigginsJPT , SavovićJ , PageMJ , ElbersRG , SterneJAC . Chapter 8. Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019</a>) </p> </section> <section id="CD012977-sec-0033"> <h5 class="title">Dealing with missing data</h5> <p>We planned to address data missing from an included systematic review or variation in information reported across reviews by retrieving and examining the full reports of RCTs included in the systematic reviews; contacting systematic review authors for missing information or clarification; searching systematic review protocols; and/or searching registries of systematic reviews or clinical trials for further information. If this occurred, we planned to include discussion on potential discrepancies with information provided in the original reviews. </p> </section> </section> <section id="CD012977-sec-0034"> <h4 class="title">Data synthesis</h4> <p>We planned to tabulate PICO (population, intervention, control, and outcome) elements at the review level. Results tables include effect estimates, 95% confidence intervals (CIs), and measures of heterogeneity/risk of bias, as appropriate. </p> <p>We aimed to group data into the three broad groups described above: inhaled bronchodilators, parenteral bronchodilators, and interventions to reduce the work of breathing. We intended to compare all outcomes between inhaled bronchodilators (e.g. standard therapy/placebo versus continuous nebulised SABA versus inhaled magnesium), between parenteral bronchodilators (e.g. standard therapy/placebo versus aminophylline versus magnesium versus ketamine versus salbutamol versus terbutaline), and between interventions to reduce the work of breathing (standard therapy/placebo versus CPAP versus BiPAP versus heliox vs HFNC). We planned to extract effect estimates from the included systematic reviews, categorised by intervention and primary and secondary outcomes, and to present them in tables and figures. </p> <p>We planned to structure narrative descriptions of effect estimates of the included reviews according to risk of bias and GRADE assessments. </p> <p>We also planned to assess the impact of inclusion criteria (severity of asthma), treatment before enrolment (including type of first‐line intervention applied), and control treatment on the effects of interventions. </p> <p>The choice of effect estimate for summary and tabulation depended on the outcomes reported in various reviews. We intended to standardise the outcomes reported if an outcome was expressed differently between reviews. We standardised to risk ratios (RRs) or odds ratios (ORs) for dichotomous outcomes. We standardised to mean differences (MDs) or standardised mean differences (SMDs) by using equations published in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> for continuous outcomes (<a href="./references#CD012977-bbs2-0046" title="HigginsJPT , LiT , DeeksJJ . Chapter 6. Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019a</a>). </p> <p>We planned to discuss the limitations of currently available evidence with regards to heterogeneity of inclusion criteria for each review, consistency of effect size for each intervention, and consistent use of outcome measures. We planned to identify gaps in the current evidence base and to make recommendations for future research. </p> <section id="CD012977-sec-0035"> <h5 class="title">Assessment of non‐statistical heterogeneity</h5> <p>We planned to determine whether there is clinical heterogeneity between systematic reviews (i.e. differences in severity of asthma or differences in treatment administered before enrolment) by assessing the inclusion criteria of each systematic review. We also planned to assess clinical heterogeneity within each systematic review that will contribute to the certainty of evidence assessment of each review. </p> <p>We planned to identify commonly used outcomes and to categorise them in a taxonomy by creating a list of all outcomes and discussing their categorisation among the review author group until consensus was reached. This taxonomy will inform recommendations for a core set of outcome measures, which may be applicable in future RCTs. </p> </section> <section id="CD012977-sec-0036"> <h5 class="title">Subgroup analysis</h5> <p>Given the pathophysiological differences between preschoolers and older children, we intended to subgroup studies of children from birth to five years of age and children aged six to 18 years (or younger and older children as defined by review authors) and to provide separate summary tables within the overview. </p> <p>Finally, we planned to group studies occurring in the ED/outpatient setting separately from those occurring in the inpatient setting (ward or intensive care unit). </p> <p>We planned to extract summary event data for each treatment/placebo group from the included reviews for all subgroup analyses. </p> </section> <section id="CD012977-sec-0037"> <h5 class="title">Sensitivity analysis</h5> <p>We planned to conduct sensitivity analysis based on the ROBIS assessment of systematic reviews by comparing results of all reviews against data derived only from reviews in which the ROBIS tool identified domains with a "high" level of concern (i.e. by excluding studies that have one or more domains in the ROBIS tool rated as causing a "high" level of concern). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012977-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012977-sec-0038"></div> <section id="CD012977-sec-0039"> <h3 class="title" id="CD012977-sec-0039">Results of the search</h3> <p>The search of the <i>Cochrane Library</i> (issue 3, 2018) identified 293 records for Cochrane reviews. After review of titles and abstracts, 276 records were excluded. We excluded four reviews for the following reasons (<a href="#CD012977-fig-0001">Figure 1</a> and <a href="#CD012977-tbl-0001">Table 1</a>): one review because it did not include any trials (<a href="./references#CD012977-bbs2-0014" title="JonesA , RoweB , PetersJ , CamargoC , HammarquistC , RoweB . Inhaled beta-agonists for asthma in mechanically ventilated patients. Cochrane Database of Systematic Reviews2001, Issue 4. Art. No: CD001493. [DOI: 10.1002/14651858.CD001493]">Jones 2001</a>); one review because it did not have any trials where the results for children were able to be separated from the results for adults (<a href="./references#CD012977-bbs2-0015" title="ManserR , ReidD , AbramsonM . Corticosteroids for acute severe asthma in hospitalised patients. Cochrane Database of Systematic Reviews2001, Issue 1. Art. No: CD001740. [DOI: 10.1002/14651858.CD001740]">Manser 2001</a>); one because it had been updated and replaced by separate reviews on adults and children (<a href="./references#CD012977-bbs2-0016" title="RoweBH , BretzlaffJA , BourdonC , BotaGW , Camargo CAJr. Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. Cochrane Database of Systematic Reviews2000, Issue 1. Art. No: CD001490. [DOI: 10.1002/14651858.CD001490]">Rowe 2000</a>), and one because it had been replaced by two newer reviews, both of which were also included in this review (<a href="./references#CD012977-bbs2-0017" title="TraversA , JonesAP , KellyK , BarkerSJ , CamargoCA , RoweBH . Intravenous beta2-agonists for acute asthma in the emergency department. Cochrane Database of Systematic Reviews2001, Issue 2. Art. No: CD002988. [DOI: 10.1002/14651858.CD002988]">Travers 2001</a>). </p> <div class="figure" id="CD012977-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram." data-id="CD012977-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012977.pub2/media/CDSR/CD012977/image_n/nCD012977-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram.</p> </div> </div> </div> <div class="table" id="CD012977-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Excluded reviews</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Reference</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Title</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Reason for exclusion</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0016" title="RoweBH , BretzlaffJA , BourdonC , BotaGW , Camargo CAJr. Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. Cochrane Database of Systematic Reviews2000, Issue 1. Art. No: CD001490. [DOI: 10.1002/14651858.CD001490]">Rowe 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Magnesium sulfate for treating exacerbations of acute asthma in the emergency department</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Replaced by separate reviews in adults and children, <a href="./references#CD012977-bbs2-0003" title="GriffithsB , KewKM . Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD011050. [DOI: 10.1002/14651858.CD011050.pub2]">Griffiths 2016</a> contains all relevant paediatric trials </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0017" title="TraversA , JonesAP , KellyK , BarkerSJ , CamargoCA , RoweBH . Intravenous beta2-agonists for acute asthma in the emergency department. Cochrane Database of Systematic Reviews2001, Issue 2. Art. No: CD002988. [DOI: 10.1002/14651858.CD002988]">Travers 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intravenous beta2‐agonists for acute asthma in the emergency department</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Replaced by 2 new reviews: "Intravenous beta2‐agonists versus intravenous aminophylline for acute asthma" (<a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a>), and "Addition of intravenous beta2‐agonists for acute asthma" (<a href="./references#CD012977-bbs2-0010" title="TraversAH , MilanSJ , JonesAP , Camargo CA Jr, RoweBH . Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010179. [DOI: 10.1002/14651858.CD010179]">Travers 2012a</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0015" title="ManserR , ReidD , AbramsonM . Corticosteroids for acute severe asthma in hospitalised patients. Cochrane Database of Systematic Reviews2001, Issue 1. Art. No: CD001740. [DOI: 10.1002/14651858.CD001740]">Manser 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Corticosteroids for acute severe asthma in hospitalised patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies where the results for children could be separated from the results for adults </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0014" title="JonesA , RoweB , PetersJ , CamargoC , HammarquistC , RoweB . Inhaled beta-agonists for asthma in mechanically ventilated patients. Cochrane Database of Systematic Reviews2001, Issue 4. Art. No: CD001493. [DOI: 10.1002/14651858.CD001493]">Jones 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled beta2‐agonists for asthma in mechanically ventilated patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trials were included in the review</p> </td> </tr> </tbody> </table> </div> <p>We included and extracted data from 13 reviews (<a href="#CD012977-tbl-0002">Table 2</a>). No ongoing reviews were identified. An updated search of the library on 28 December 2019 did not identify any new or updated reviews. </p> <div class="table" id="CD012977-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Review characteristics</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Review ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Date of last search</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Total number of studies (total number of participants)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of studies involving children (number of children in review)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Population</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comparison interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes for which data were reported</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Review limitations</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="9" rowspan="1" scope="col" valign="top"> <p><b>Inhaled treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a> </p> <p>Continuous vs intermittent beta‐agonists for acute asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 March 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (644)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants presenting to an ED (or its equivalent) with acute asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous (defined as 1 nebulisation every 15 minutes or &gt; 4 nebulisations per hour) inhaled beta‐agonist therapy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermittent inhaled beta‐agonist therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ PEFR</p> <p>‐ Admission to hospital</p> <p>‐ ED treatment time</p> <p>‐ Respiratory therapist time</p> <p>‐ Symptom scores</p> <p>‐ Tremor</p> <p>‐ Nausea/vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited paediatric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a> </p> <p>Combined inhaled anticholinergics and short‐acting beta‐agonists for initial treatment of acute asthma in children </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 April 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (2632)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (2632)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 18 months to 18 years presenting to an ED with an acute exacerbation of asthma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single or repeated doses of nebulised or inhaled short‐acting anticholinergics plus SABAs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single or repeated doses of nebulised or inhaled placebo plus SABAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Hospital admission</p> <p>‐ FEV1</p> <p>‐ PEFR</p> <p>‐ Respiratory resistance</p> <p>‐ Clinical asthma score</p> <p>‐ Need for repeat bronchodilator treatment</p> <p>‐ Oxygen saturation measurements</p> <p>‐ Need for corticosteroids in the ED prior to disposition</p> <p>‐ Tremor</p> <p>‐ Vomiting</p> <p>‐ Nausea</p> <p>‐ Relapse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a> </p> <p>Inhaled anticholinergic and short‐acting beta2‐agonists vs short‐acting beta2‐agonists alone for children with acute asthma in hospital </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>November 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (472)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (472)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children 1 to 18 years of age who were hospitalised for an acute asthma exacerbation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nebulised or inhaled anticholinergics with SABA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nebulised or inhaled SABA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Duration of hospital stay</p> <p>‐ Admission to ICU</p> <p>‐ Need for supplemental asthma therapy</p> <p>‐ Time to SABA spaced at 4 hours or longer</p> <p>‐ Asthma clinical scores</p> <p>‐ Relapse within 72 hours of discharge from hospital</p> <p>‐ Predicted PEFR</p> <p>‐ Adverse health effects</p> <p>‐ Overall withdrawals</p> <p>‐ Withdrawals due to deterioration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a> </p> <p>Inhaled magnesium sulfate in the treatment of acute asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 September 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (3301)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (1247)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients with acute asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Inhaled MgSO4</p> <p>‐ Inhaled MgSO4 and inhaled beta2‐agonist</p> <p>‐ Inhaled MgSO4 and inhaled beta2‐agonist and ipratropium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Inhaled beta2‐agonist</p> <p>‐ Inhaled beta2‐agonist and placebo</p> <p>‐ Inhaled beta2‐agonist and ipratropium and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Clinical severity scores</p> <p>‐ Admission at first presentation</p> <p>‐ Admission to PICU/HDU or intubation</p> <p>‐ Serious adverse events</p> <p>‐ Any adverse event (during admission)</p> <p>‐ Hypotension</p> <p>‐ Flushing</p> <p>‐ Pulmonary function (% predicted FEV1)</p> <p>‐ PEF</p> <p>‐ Admission to hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="" class="headercell" colspan="9" rowspan="1" scope="col" valign="top"> <p><b>Parenteral treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a> </p> <p>Intravenous aminophylline for acute severe asthma in children over 2 years of age receiving inhaled bronchodilators </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>February 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (380)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (380)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged between 2 and 17 years with acute severe asthma or status asthmaticus (acute, severe, refractory exacerbations) attending EDs, or in hospital wards or ICUs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loading dose of IV aminophylline followed by maintenance infusion, intravenous aminophylline boluses, or oral theophylline </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ FEV1</p> <p>‐ Peak flow</p> <p>‐ Oxygenation (SaO2 or PaO2)</p> <p>‐ Supplemental oxygen reduction</p> <p>‐ Change in symptom scores</p> <p>‐ Number of nebulisers required in 24 hours</p> <p>‐ ICU admission rates</p> <p>‐ Rates of patients mechanically ventilated in ICU</p> <p>‐ Length of hospital stay</p> <p>‐ Vomiting</p> <p>‐ Headache</p> <p>‐ Tremor</p> <p>‐ Seizures</p> <p>‐ Hypokalaemia</p> <p>‐ Arrhythmias</p> <p>‐ Blood pressure</p> <p>‐ Magnitude of diuresis</p> <p>‐ Death</p> <p>‐ Withdrawal due to adverse health effects</p> <p>‐ Withdrawal due to poor asthma control</p> <p>‐ Withdrawal (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0010" title="TraversAH , MilanSJ , JonesAP , Camargo CA Jr, RoweBH . Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010179. [DOI: 10.1002/14651858.CD010179]">Travers 2012a</a> </p> <p>Addition of intravenous beta2‐agonists to inhaled beta2‐agonists for acute asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>September 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (102)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adult or paediatric patients with severe acute asthma presenting to an emergency department (or its equivalent) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV selective or non‐selective beta1‐ and beta2‐agonists in addition to inhaled beta2‐agonists and existing standards of care </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled beta2‐agonists and standard care alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Length of stay</p> <p>‐ Pulse rate</p> <p>‐ Clinical failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited paediatric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a> </p> <p>Intravenous beta2‐agonists vs intravenous aminophylline for acute asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>September 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (371)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (168)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults and children with severe acute asthma presenting to an ED (or its equivalent) and patients admitted to hospital with acute severe asthma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV beta2‐agonists and standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intravenous aminophylline and standard asthma care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Length of stay</p> <p>‐ Clinical failure</p> <p>‐ CPK elevation</p> <p>‐ CPK‐MB elevation</p> <p>‐ Dysrhythmia</p> <p>‐ Headache</p> <p>‐ Hyperglycaemia</p> <p>‐ Hypokalaemia</p> <p>‐ Palpitations</p> <p>‐ Tremor</p> <p>‐ Nausea/vomiting</p> <p>‐ Nausea</p> <p>‐ Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited paediatric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0003" title="GriffithsB , KewKM . Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD011050. [DOI: 10.1002/14651858.CD011050.pub2]">Griffiths 2016</a> </p> <p>Intravenous magnesium sulfate for treating children with acute asthma in the emergency department </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 February 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (182)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (182)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (18 months to 18 years) treated in the ED for acute asthma (all severities)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any dose of IV MgSO4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Hospital admissions</p> <p>‐ ED treatment time</p> <p>‐ Return to ED within 48 hours</p> <p>‐ Hospital length of stay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited paediatric data, small studies</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0004" title="JatKR , ChawlaD . Ketamine for management of acute exacerbations of asthma in children. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD009293. [DOI: 10.1002/14651858.CD009293.pub2]">Jat 2012</a> </p> <p>Ketamine for management of acute exacerbations of asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 September 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (&lt; 18 years) presenting with an acute asthma exacerbation who had not responded to standard therapy with aerosolised beta2‐agonist, with or without aerosolised anticholinergic drugs and oral or parenteral corticosteroid, for at least 1 hour </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketamine (IM or IV)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Reduction in pulmonary index score</p> <p>‐ Disposition for enrolled patients after study enrolment</p> <p>‐ Side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited paediatric data</p> </td> </tr> <tr> <th align="" class="headercell" colspan="9" rowspan="1" scope="col" valign="top"> <p><b>Interventions to reduce the work of breathing</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0009" title="RodrigoG , PollackC , RodrigoC , RoweBH . Heliox for nonintubated acute asthma patients. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD002884. [DOI: 10.1002/14651858.CD002884.pub2]">Rodrigo 2006</a> </p> <p>Heliox for non‐intubated acute asthma patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 August 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (529)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children or adult patients presenting to an ED or equivalent care settings for treatment of acute asthma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled heliox</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control (oxygen or air)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Pulmonary function</p> <p>‐ Heart rate</p> <p>‐ Oxygen saturations</p> <p>‐ Dyspnoea or pulmonary index</p> <p>‐ Hospital admissions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited paediatric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0006" title="KorangSK , FeinbergJ , WetterslevJ , JakobsenJC . Non-invasive positive pressure ventilation for acute asthma in children. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012067. [DOI: 10.1002/14651858.CD012067.pub2]">Korang 2016</a> </p> <p>Non‐invasive positive‐pressure ventilation for acute asthma in children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>February 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (aged &lt; 18 years) hospitalised for an asthma attack (as defined by the trialists)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any type of NPPV (including CPAP and BiPAP) as add‐on therapy to usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Mortality</p> <p>‐ Serious adverse events</p> <p>‐ Asthma symptom score</p> <p>‐ Pneumonia</p> <p>‐ Non‐serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited paediatric data</p> </td> </tr> <tr> <th align="" class="headercell" colspan="9" rowspan="1" scope="col" valign="top"> <p><b>Other interventions</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0008" title="NormansellR , SayerB , WatersonS , DennettEJ , Del FornoM , DunleavyA . Antibiotics for exacerbations of asthma. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD002741. [DOI: 10.1002/14651858.CD002741.pub2]">Normansell 2018</a> </p> <p>Antibiotics for exacerbations of asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 October 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (670)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (133)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children and adults who presented to an ED, primary care, outpatient clinics, or inpatient wards with an asthma exacerbation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intravenous or oral antibiotics, given at any dose and for any duration of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo or standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Adverse events</p> <p>‐ Serious adverse events</p> <p>‐ Length of hospital stay</p> <p>‐ Peak expiratory flow</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited paediatric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a> </p> <p>Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>February 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (1940)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (470)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children and adults with acute asthma presenting for acute medical care to an ED or equivalent setting </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTRA (oral or IV) and standard care (inhaled beta2‐agonists, systemic corticosteroids ± oxygen, ipratropium bromide) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo and standard care (inhaled beta2‐agonists, systemic corticosteroids ± oxygen, ipratropium bromide) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Hospital admission</p> <p>‐ Requirement for additional care at end of study</p> <p>‐ Change in FEV1</p> <p>‐ Change in pulmonary index score</p> <p>‐ Change in respiratory rate</p> <p>‐ Withdrawals</p> <p>‐ Relapse (within 7 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> </table> <div class="table-footnote"> <p>ED: emergency department; PEFR: peak expiratory flow rate; FEV1: forced expiratory volume in one second; SABA: short‐acting beta‐agonist; ICU: intensive care unit; LTRA: leukotriene receptor antagonist; MgSO4: magnesium sulfate; PICU: paediatric intensive care unit; HDU: high‐dependency unit; PEF: peak expiratory flow; IV: intravenous; SaO2: saturation of oxygen; PaO2: arterial pressure of oxygen; CPK: creatine phosphokinase; CPK‐MB: creatine phosphokinase myocardial band; IM: intramuscular; NPPV: non‐invasive positive‐pressure ventilation; CPAP: continuous positive airway pressure; BiPAP: bilevel positive airway pressure. </p> </div> </div> <p>We utilised the search strategy (in August 2019) of each included review to update the searches for new randomised controlled trials (RCTs). We identified 1,885 records, and after screening of titles and abstracts, we identified 31 new RCTs which may be eligible for inclusion in updated reviews (<a href="#CD012977-tbl-0003">Table 3</a>). </p> <div class="table" id="CD012977-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Evidence map</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Cochrane Review</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of included studies involving children (number of participants)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Potential new studies based on review search strategy</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Overview team recommendations for new Cochrane Reviews, or changes to existing reviews</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Overview team suggested research priorities based on evidence presented in this evidence map</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>Inhaled treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous vs intermittent beta‐agonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0082" title="RoseJ , CancelliereS , MatyeP , O'RiordanM . Comparing a breath-actuated vs a conventional continuous-output nebulizer in treating acute asthma in a pediatric emergency department: an ongoing randomized controlled trial. Academic Emergency Medicine2011;18(5):S83-4.">Rose 2011</a>; <a href="./references#CD012977-bbs2-0083" title="SabatoK , WardP , HawkW , GildengorinV , AsselinJM . Randomized controlled trial of a breath-actuated nebulizer in pediatric asthma patients in the emergency department. Respiratory Care2011;56(6):761-70.">Sabato 2011</a>; <a href="./references#CD012977-bbs2-0094" title="WilkinsonM , KingB , IyerS , HigginbothamE , WallaceA , HovingaC , et al. Comparison of a rapid albuterol pathway with a standard pathway for the treatment of children with a moderate to severe asthma exacerbation in the emergency department. Journal of Asthma2018;55(3):244-51.">Wilkinson 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Update review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compare effectiveness in preschool and older children</p> <p>Develop and use core outcome measures, consistent assessment of asthma severity at study entry, and consistent inclusion criteria in future trials </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Combined inhaled anticholinergics and short‐acting beta‐agonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Emergency department setting</p> <p><a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (2632)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0089" title="SupriyatnoB , HarumdiniM , IndawatiW . The efficacy of adding ipratropium bromide to salbutamol nebulization for mild acute asthma attack in children. Paediatric Respiratory Reviews2012;13:S78.">Supriyatno 2012</a>; <a href="./references#CD012977-bbs2-0086" title="Sengul GokalpA , BicerS , SiraneciR . Efficiacy of nebulized ipratropium bromide in the treatment of acute asthma in children: randomised, double blind, placebo-controlled trial. Nobel Medicus2013;9(1):67-75.">Sengul Gokalp 2013</a>; <a href="./references#CD012977-bbs2-0060" title="MemonBN , ParkashAT , AhmedKKM , Gowa MurtazaA , BaiC . Response to nebulized salbutamol versus combination with ipratropium bromide in children with acute severe asthma. Journal of Pakiston Medical Association2016;66(3):243-6.">Memon 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Update review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compare effectiveness in preschool and older children</p> <p>Develop and use core outcome measures, consistent assessment of asthma severity at study entry, and consistent inclusion criteria in future trials </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient setting</p> <p><a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (472)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0095" title="WyattEL , BorlandML , DoyleSK , GeelhoedGC . Metered-dose inhaler ipratropium bromide in moderate acute asthma in children: a single-blinded randomised controlled trial. Journal of Paediatrics and Child Health2015;51(2):192-8.">Wyatt 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Update review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compare effectiveness in preschool and older children</p> <p>Develop and use core outcome measures, consistent assessment of asthma severity at study entry, and consistent inclusion criteria in future trials </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled magnesium sulfate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (1247)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0063" title="MotamedH , VerkiMM , PooladzadeM , MajidiA . Efficacy evaluation of nebulized magnesium, as an additional complementary treatment, in clinical and peak flow metric improvements of acute asthma attack: a randomized double-blinded clinical trial. Jundishapur Journal of Natural Pharmaceutical Products2017;12:4.">Motamed 2017</a>; <a href="./references#CD012977-bbs2-0064" title="MustafaJ , IqbalSMJ , AzharIA , SultanMA . Nebulized magnesium sulphate as an adjunct therapy in the management of children presenting with acute exacerbation of asthma. Pakistan Journal of Medical and Health Sciences2018;12(2):554‐5.">Mustafa 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Update review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compare effectiveness in preschool and older children</p> <p>Develop and use core outcome measures, consistent assessment of asthma severity at study entry, and consistent inclusion criteria in future trials </p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>Parenteral bronchodilators</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intravenous aminophylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (380)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0065" title="NaaoM , KatsunumaT , KimKC , FujisawaT . Efficacy and safety of intravenous aminophylline in children with acute exacerbation of asthma: a multicenter randomized trial. Journal of Allergy and Clinical Immunology2007;119(1 Suppl 2):8.">Naao 2007</a>; <a href="./references#CD012977-bbs2-0035" title="Chen Z-G, LiM , ChenH , Chen Y-F, Chen F-H, Ji J-Zhi. Efficacy of pulmicort suspension plus salbutamol and ipratropium bromide for management of acute asthma exacerbation in children: a comparative study. Journal of Southern Medical University2008;28(3):470-2.">Chen 2008</a>; <a href="./references#CD012977-bbs2-0038" title="D'AvilaRS , PivaJP , MarosticaPJ , AmanteaSL . Early administration of two intravenous bolus of aminophylline added to the standard treatment of children with acute asthma. Respiratory Medicine2008;102(1):156-61.">D'Avila 2008</a>; <a href="./references#CD012977-bbs2-0088" title="SinghiS , GroverS , BansalA , ChopraK . Randomised comparison of intravenous magnesium sulphate, terbutaline and aminophylline for children with acute severe asthma. Acta Paediatrica2014;103(12):1301-6.">Singhi 2014</a>; <a href="./references#CD012977-bbs2-0090" title="TiwariA , GuglaniV , JatKR . Ketamine versus aminophylline for acute asthma in children: a randomized, controlled trial. Annals of Thoracic Medicine2016;11(4):283-8.">Tiwari 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Update review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compare effectiveness in preschool and older children</p> <p>Develop and use core outcome measures, consistent assessment of asthma severity at study entry, and consistent inclusion criteria in future trials </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Addition of intravenous beta2‐agonists to inhaled beta2‐agonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0010" title="TraversAH , MilanSJ , JonesAP , Camargo CA Jr, RoweBH . Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010179. [DOI: 10.1002/14651858.CD010179]">Travers 2012a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0022" title="AubuchonK , MatsudaK , HouseL , FergusonI , SchneiderJ , LewisL . Increased serum albuterol concentrations may be associated with elevations of serum lactate in subjects with acute asthma exacerbations. Academic Emergency Medicine2012;19:S312‐3.">Aubuchon 2012</a>; <a href="./references#CD012977-bbs2-0084" title="SchneiderJ , MatsudaK , HouseSL , FergusonI , AubuchonK , LewisL . Dyspnea scores may be a better predictor of hospital admissions than FEV1 for patients with acute asthma exacerbations. Academic Emergency Medicine2012;19(s1):S312.">Schneider 2012</a>; <a href="./references#CD012977-bbs2-0048" title="HouseSL , MatsudaK , O'BrienG , MakhayM , IwakiY , FergusonI , et al. Efficacy of a new intravenous β2-adrenergic agonist (bedoradrine, MN-221) for patients with an acute exacerbation of asthma. Respiratory Medicine2015;109(10):1268-73.">House 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Update review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compare effectiveness in preschool and older children</p> <p>Develop and use core outcome measures, consistent assessment of asthma severity at study entry, and consistent inclusion criteria in future trials </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intravenous beta2‐agonists vs intravenous aminophylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (168)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0088" title="SinghiS , GroverS , BansalA , ChopraK . Randomised comparison of intravenous magnesium sulphate, terbutaline and aminophylline for children with acute severe asthma. Acta Paediatrica2014;103(12):1301-6.">Singhi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Update review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compare effectiveness in preschool and older children</p> <p>Develop and use core outcome measures, consistent assessment of asthma severity at study entry, and consistent inclusion criteria in future trials </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intravenous magnesium sulfate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0003" title="GriffithsB , KewKM . Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD011050. [DOI: 10.1002/14651858.CD011050.pub2]">Griffiths 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (182)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compare effectiveness in preschool and older children</p> <p>Develop and use core outcome measures, consistent assessment of asthma severity at study entry, and consistent inclusion criteria in future trials </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0004" title="JatKR , ChawlaD . Ketamine for management of acute exacerbations of asthma in children. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD009293. [DOI: 10.1002/14651858.CD009293.pub2]">Jat 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compare effectiveness in preschool and older children</p> <p>Develop and use core outcome measures, consistent assessment of asthma severity at study entry, and consistent inclusion criteria in future trials </p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>Interventions to reduce the work of breathing</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heliox</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0009" title="RodrigoG , PollackC , RodrigoC , RoweBH . Heliox for nonintubated acute asthma patients. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD002884. [DOI: 10.1002/14651858.CD002884.pub2]">Rodrigo 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0028" title="BighamMT , JacobsBR , MonacoMA , BrilliRJ , WellsD , ConwayEM , et al. Helium/oxygen-driven albuterol nebulization in the management of children with status asthmaticus: a randomized, placebo-controlled trial. Pediatric Critical Care Medicine2010;11(3):356-61.">Bigham 2010</a>; <a href="./references#CD012977-bbs2-0029" title="BrandãoDC , BrittoMC , PessoaMF , deSá RafaelaB , AlcoforadoL , MatosLO , et al. Heliox and forward-leaning posture improve the efficacy of nebulized bronchodilator in acute asthma: a randomized trial. Respiratory Care2011;56(7):947-52.">Brandão 2011</a>; <a href="./references#CD012977-bbs2-0073" title="OrtizJA , FonsecaJS , Salas-SeguraDA . Use of heliox in moderate and severe asthma attacks in the emergency service Rafael Angel Calderon Guardia Hospital. A prospective study. Revista del Instituto Nacional de Enfermedades Respiratorias2012;71(1):21-8.">Ortiz 2012</a>; <a href="./references#CD012977-bbs2-0061" title="MorimotoK , ShimizuN , SaitoO , KodaniT , IkiY , NagaiY , et al. The impact of heliox on obstructive airway diseases with mechanical ventilation. A pilot study. Pediatric Critical Care Medicine2018;19(6 Suppl 1):46.">Morimoto 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Update review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compare effectiveness in preschool and older children</p> <p>Develop and use core outcome measures, consistent assessment of asthma severity at study entry, and consistent inclusion criteria in future trials </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐invasive positive‐pressure ventilation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0006" title="KorangSK , FeinbergJ , WetterslevJ , JakobsenJC . Non-invasive positive pressure ventilation for acute asthma in children. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012067. [DOI: 10.1002/14651858.CD012067.pub2]">Korang 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0069" title="Navanandan Ni, FedericoM , MistryRD . Positive expiratory pressure for the treatment of acute asthma exacerbations: a randomized controlled trial. Journal of Pediatrics2017;185:149-54.e2.">Navanandan 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Update review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compare effectiveness in preschool and older children</p> <p>Develop and use core outcome measures, consistent assessment of asthma severity at study entry, and consistent inclusion criteria in future trials </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐flow nasal oxygen therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>New review needed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compare effectiveness in preschool and older children</p> <p>Develop and use core outcome measures, consistent assessment of asthma severity at study entry, and consistent inclusion criteria in future trials </p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>Other interventions</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0008" title="NormansellR , SayerB , WatersonS , DennettEJ , Del FornoM , DunleavyA . Antibiotics for exacerbations of asthma. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD002741. [DOI: 10.1002/14651858.CD002741.pub2]">Normansell 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (133)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0057" title="MandhanePJ , Paredes Zambrano de SilbernagelP , AungYN , WilliamsonJ , Lee BonitaE , SpierS , et al. Treatment of preschool children presenting to the emergency department with wheeze with azithromycin: a placebo-controlled randomized trial. PloS One2017;12(8):e0182411.">Mandhane 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Update review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compare effectiveness in preschool and older children</p> <p>Develop and use core outcome measures, consistent assessment of asthma severity at study entry, and consistent inclusion criteria in future trials </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Leukotriene receptor antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (470)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0019" title="AdachiM , TaniguchiH , TohdaY , SanoY , IshineT , SmugarSS , et al. The efficacy and tolerability of intravenous montelukast in acute asthma exacerbations in Japanese patients. Journal of Asthma2012;49(6):649-56.">Adachi 2012</a>; <a href="./references#CD012977-bbs2-0059" title="MatsuseH , FukahoriS , TsuchidaT , KawanoT , TomariS , MatsuoN , et al. Effects of a short course of pranlukast combined with systemic corticosteroid on acute asthma exacerbation induced by upper respiratory tract infection. Journal of Asthma2012;49(6):637-41.">Matsuse 2012</a>; <a href="./references#CD012977-bbs2-0096" title="Zubairi AB, SalahuddinN , KhawajaA , AwanS , ShahAA , HaqueAS , et al. A randomized, double-blind, placebo-controlled trial of oral montelukast in acute asthma exacerbation. BMC Pulmonary Medicine2013;13:20.">Zubairi 2013</a>; <a href="./references#CD012977-bbs2-0050" title="KanchanateeraphongS , PhongsamartG , DangsuwanT , VangveeravongM . Study of montelukast for the treatment of acute and post viral-induced wheezing. Journal of Allergy and Clinical Immunology2014;133(2 Suppl 1):AB190.">Kanchanateeraphong 2014</a>; <a href="./references#CD012977-bbs2-0055" title="MagazineR , ShahulHA , ChogtuB , KamathA . Comparison of oral montelukast with oral zileuton in acute asthma: a randomized, double-blind, placebo-controlled study. Lung India2016;33(3):281-6.">Magazine 2016</a>; <a href="./references#CD012977-bbs2-0034" title="ChaudhuryA , GaudeGS , HattiholiJ . Effects of oral montelukast on airway function in acute asthma: a randomized trial. Lung India2017;34(4):349-54.">Chaudhury 2017</a>; <a href="./references#CD012977-bbs2-0056" title="MagazineR , SurendraVU , ChogtuB . Comparison of oral montelukast with oral ozagrel in acute asthma: a randomized, double-blind, placebo-controlled study. Lung India2018;35(1):16-20.">Magazine 2018</a>; <a href="./references#CD012977-bbs2-0091" title="WangX , ZhouJ , ZhaoX , YiX . Montelukast treatment of acute asthma exacerbations in children aged 2 to 5 years: a randomized, double-blind, placebo-controlled trial. Pediatric Emergency Care2018;34(3):160-4.">Wang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Update review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compare effectiveness in preschool and older children</p> <p>Develop and use core outcome measures, consistent assessment of asthma severity at study entry, and consistent inclusion criteria in future trials </p> </td> </tr> </tbody> </table> </div> </section> <section id="CD012977-sec-0040"> <h3 class="title" id="CD012977-sec-0040">Description of included reviews</h3> <p>A table of the main characteristics of the included reviews is presented in <a href="#CD012977-tbl-0002">Table 2</a>. </p> <section id="CD012977-sec-0041"> <h4 class="title">Study design</h4> <p>All 13 reviews included RCTs, with 74 comparisons conducted from 67 individual trials. A majority of trials were of parallel‐group design, and three were cross‐over studies. Each review included from 1 to 27 trials. Thirty‐eight per cent (n = 28) of the comparisons included 40 or fewer participants. The total number of participants included in reviews ranged from 40 in <a href="./references#CD012977-bbs2-0006" title="KorangSK , FeinbergJ , WetterslevJ , JakobsenJC . Non-invasive positive pressure ventilation for acute asthma in children. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012067. [DOI: 10.1002/14651858.CD012067.pub2]">Korang 2016</a> to 2630 in <a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a>; five reviews included more than 300 participants. </p> </section> <section id="CD012977-sec-0042"> <h4 class="title">Included participants</h4> <p>Of the 67 RCTs included across the reviews, all included children. Twenty‐four per cent (n = 16) of the studies included children younger than two years of age, and three studies (4%) included children younger than one year of age. </p> </section> <section id="CD012977-sec-0043"> <h4 class="title">Diagnosis of asthma in included reviews</h4> <p><a href="#CD012977-tbl-0004">Table 4</a> outlines details of asthma diagnosis and asthma severity in the included reviews. Inclusion criteria were varied and comprised acute asthma (six reviews), acute exacerbation of asthma (three reviews), asthma exacerbation (two reviews), and asthma attack (one review). One review did not provide a clear statement on inclusion criteria with regards to how diagnosis of asthma was defined (<a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a>). Three studies provided information regarding exclusion of other respiratory illnesses such as bronchiectasis and chronic obstructive pulmonary disease. </p> <div class="table" id="CD012977-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Details of asthma diagnosis and asthma severity in included reviews</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Review</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Asthma diagnosis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Asthma severity</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Inhaled treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients presenting to an ED or its equivalent</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute exacerbation of asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients presenting to an ED</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute asthma exacerbation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalised for an acute asthma exacerbation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute asthma (excluded chronic or “stable” asthma). “We accepted any reasonable diagnosis of asthma, namely clinical and guideline‐based criteria” </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided</p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Parenteral treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute severe asthma or status asthmaticus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No definition provided for severe</p> <p>Status asthmaticus defined as “acute, severe, refractory exacerbations”</p> <p>Patients were attending ED, hospital wards, or intensive care</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0010" title="TraversAH , MilanSJ , JonesAP , Camargo CA Jr, RoweBH . Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010179. [DOI: 10.1002/14651858.CD010179]">Travers 2012a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe acute asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No definition provided for “severe”. Included patients presenting to an ED (or its equivalent) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe acute asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No definition provided for “severe”. Included patients presenting to an ED or admitted to hospital </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0003" title="GriffithsB , KewKM . Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD011050. [DOI: 10.1002/14651858.CD011050.pub2]">Griffiths 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients treated in the ED with acute asthma (all severities)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0004" title="JatKR , ChawlaD . Ketamine for management of acute exacerbations of asthma in children. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD009293. [DOI: 10.1002/14651858.CD009293.pub2]">Jat 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute asthma exacerbation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not responded to standard therapy with aerosolised beta2‐agonist, with or without aerosolised anticholinergic drugs and oral or parenteral corticosteroid, for at least 1 hour </p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Other interventions to reduce the work of breathing</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0009" title="RodrigoG , PollackC , RodrigoC , RoweBH . Heliox for nonintubated acute asthma patients. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD002884. [DOI: 10.1002/14651858.CD002884.pub2]">Rodrigo 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical diagnosis asthma exacerbation (according to accepted criteria such as those published by the American Thoracic Society). Excluded patients with COPD </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presenting to an ED or equivalent care setting. Excluded patients requiring mechanical ventilation at presentation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0006" title="KorangSK , FeinbergJ , WetterslevJ , JakobsenJC . Non-invasive positive pressure ventilation for acute asthma in children. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012067. [DOI: 10.1002/14651858.CD012067.pub2]">Korang 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asthma attack (as defined by the trialists). Excluded children with pneumonia, aspiration, bronchiolitis, cystic fibrosis, or any ciliary dyskinetic syndrome </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children hospitalised for an asthma attack</p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Other interventions</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0008" title="NormansellR , SayerB , WatersonS , DennettEJ , Del FornoM , DunleavyA . Antibiotics for exacerbations of asthma. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD002741. [DOI: 10.1002/14651858.CD002741.pub2]">Normansell 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asthma exacerbation. Excluded pneumonia, COPD, and bronchiectasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presented to the ED, primary care, outpatient clinics, or inpatient wards. Included both inpatients and outpatients </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presenting for acute medical care to an ED or equivalent setting</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>COPD: chronic obstructive pulmonary disease; ED: emergency department.</p> </div> </div> </section> <section id="CD012977-sec-0044"> <h4 class="title">Severity of asthma in included reviews</h4> <p>Of the 13 reviews, three referred to "severe" asthma exacerbations, but none provided information regarding how this was defined. One review described treatment duration and medication use prior to inclusion (<a href="./references#CD012977-bbs2-0004" title="JatKR , ChawlaD . Ketamine for management of acute exacerbations of asthma in children. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD009293. [DOI: 10.1002/14651858.CD009293.pub2]">Jat 2012</a>). Another review excluded patients who required mechanical ventilation at presentation (<a href="./references#CD012977-bbs2-0009" title="RodrigoG , PollackC , RodrigoC , RoweBH . Heliox for nonintubated acute asthma patients. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD002884. [DOI: 10.1002/14651858.CD002884.pub2]">Rodrigo 2006</a>). </p> </section> <section id="CD012977-sec-0045"> <h4 class="title">Interventions in included reviews</h4> <p>We mapped the Cochrane Reviews onto the framework of interventions specified in our protocol in <a href="#CD012977-tbl-0002">Table 2</a>, covering three broad classes of therapy: inhaled treatment, parenteral treatment, and other interventions to reduce the work of breathing (<a href="./references#CD012977-bbs2-0036" title="CraigSS , DalzielSR , PowellCVE , GraudinsA , BablFE , LunnyC . Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews. Cochrane Database of Systematic Reviews2018, Issue 3. Art. No: CD012977. [DOI: 10.1002/14651858.CD012977]">Craig 2018</a>). Two reviews were not able to be classified within our prespecified subgroups. </p> <section id="CD012977-sec-0046"> <h5 class="title">Inhaled treatment</h5> <p>We identified four reviews on inhaled treatment.</p> <p> <ul id="CD012977-list-0011"> <li> <p>One compared continuous nebulised versus intermittent nebulised beta‐agonists (<a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a>). </p> </li> <li> <p>Two compared inhaled beta<sub>2</sub>‐agonists versus a combination of inhaled beta<sub>2</sub>‐agonists and inhaled anticholinergic agents. One of these was restricted to children hospitalised with asthma (<a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>), and the other examined initial treatment in the ED (<a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a>). </p> </li> <li> <p>One assessed the use of inhaled magnesium sulfate (<a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>). </p> </li> </ul> </p> </section> <section id="CD012977-sec-0047"> <h5 class="title">Parenteral treatment</h5> <p>We identified five reviews on parenteral treatment, of which:</p> <p> <ul id="CD012977-list-0012"> <li> <p>one assessed the use of intravenous aminophylline for children older than two years of age who were administered inhaled bronchodilators (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>); </p> </li> <li> <p>one assessed the addition of intravenous beta<sub>2</sub>‐agonists to inhaled beta<sub>2</sub>‐agonists (<a href="./references#CD012977-bbs2-0010" title="TraversAH , MilanSJ , JonesAP , Camargo CA Jr, RoweBH . Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010179. [DOI: 10.1002/14651858.CD010179]">Travers 2012a</a>); </p> </li> <li> <p>one compared the use of intravenous beta<sub>2</sub>‐agonists to intravenous aminophylline (<a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a>); </p> </li> <li> <p>one assessed the use of intravenous magnesium (<a href="./references#CD012977-bbs2-0003" title="GriffithsB , KewKM . Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD011050. [DOI: 10.1002/14651858.CD011050.pub2]">Griffiths 2016</a>); and </p> </li> <li> <p>one assessed the use of intramuscular or intravenous ketamine (<a href="./references#CD012977-bbs2-0004" title="JatKR , ChawlaD . Ketamine for management of acute exacerbations of asthma in children. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD009293. [DOI: 10.1002/14651858.CD009293.pub2]">Jat 2012</a>). </p> </li> </ul> </p> </section> <section id="CD012977-sec-0048"> <h5 class="title">Interventions to reduce the work of breathing</h5> <p>We identified two reviews on interventions to reduce the work of breathing, of which:</p> <p> <ul id="CD012977-list-0013"> <li> <p>one assessed the use of heliox for non‐intubated asthma patients (<a href="./references#CD012977-bbs2-0009" title="RodrigoG , PollackC , RodrigoC , RoweBH . Heliox for nonintubated acute asthma patients. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD002884. [DOI: 10.1002/14651858.CD002884.pub2]">Rodrigo 2006</a>); and </p> </li> <li> <p>one assessed the use of non‐invasive positive‐pressure ventilation (<a href="./references#CD012977-bbs2-0006" title="KorangSK , FeinbergJ , WetterslevJ , JakobsenJC . Non-invasive positive pressure ventilation for acute asthma in children. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012067. [DOI: 10.1002/14651858.CD012067.pub2]">Korang 2016</a>). </p> </li> </ul> </p> </section> <section id="CD012977-sec-0049"> <h5 class="title">Other interventions</h5> <p>We identified two additional reviews that did not fit into our prespecified classifications.</p> <p> <ul id="CD012977-list-0014"> <li> <p>One compared the use of antibiotics (oral or parenteral) to no antibiotics for asthma (<a href="./references#CD012977-bbs2-0008" title="NormansellR , SayerB , WatersonS , DennettEJ , Del FornoM , DunleavyA . Antibiotics for exacerbations of asthma. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD002741. [DOI: 10.1002/14651858.CD002741.pub2]">Normansell 2018</a>). </p> </li> <li> <p>One assessed the use of leukotriene receptor antagonists in addition to usual care for acute asthma (<a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a>). </p> </li> </ul> </p> </section> </section> </section> <section id="CD012977-sec-0050"> <h3 class="title" id="CD012977-sec-0050">Methodological quality of included reviews</h3> <section id="CD012977-sec-0051"> <h4 class="title">Risk of bias assessment of systematic reviews</h4> <p>We assessed the risk of bias of included reviews by using the ROBIS tool (<a href="#CD012977-tbl-0004">Table 4</a>; ROBIS assessment available in <a href="./appendices#CD012977-sec-0158">Appendix 1</a>). All of the included reviews were at low risk of bias with regard to study eligibility criteria. Four reviews had high risk of bias with regard to identification and selection of studies. In all cases, this was due to a single author selecting studies (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>; <a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a>; <a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>; <a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>). One review had an unclear risk of bias for data collection and study appraisal, as no information was provided regarding who extracted the data or whether a data collection form was used (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>). All reviews were rated as having low risk of bias regarding synthesis and findings. </p> <p>Overall, we considered four of the thirteen included reviews (31%) to be at high risk of bias. In all cases, this was due to concerns regarding identification and selection of studies. </p> <p>Only five of the thirteen reviews (38%) had conducted a literature search later than 1 January 2016. </p> </section> <section id="CD012977-sec-0052"> <h4 class="title">Risk of bias assessment in included RCTs</h4> <p>The reviews used various tools to assess risk of bias of included RCTs (<a href="#CD012977-tbl-0005">Table 5</a>). Three reviews assessed the quality of trials using the Jadad Scale (an old quality scale with a maximum score of 5 points, in which a higher score suggests lower risk of bias) (<a href="./references#CD012977-bbs2-0049" title="JadadAR , MooreRA , CarrollD , JenkinsonC , ReynoldsDJ , GavaghanDJ , et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?Controlled Clinical Trials1996;17(1):1-12.">Jadad 1996</a>). Of these, one review included a single study with a score of 2/5 (<a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a>); another review included three RCTs, with two trials scored 3/5 and one 4/5 (<a href="./references#CD012977-bbs2-0009" title="RodrigoG , PollackC , RodrigoC , RoweBH . Heliox for nonintubated acute asthma patients. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD002884. [DOI: 10.1002/14651858.CD002884.pub2]">Rodrigo 2006</a>); and one review included seven RCTs, with three scored as 4/5 and four as 5/5 (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>). </p> <div class="table" id="CD012977-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">ROBIS assessment of included reviews</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Review</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Domain 1: study eligibility criteria</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Domain 2: identification and selection of studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Domain 3: data collection and study appraisal</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Domain 4: synthesis and findings</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk of bias in the review</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>Inhaled treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>Parenteral treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0010" title="TraversAH , MilanSJ , JonesAP , Camargo CA Jr, RoweBH . Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010179. [DOI: 10.1002/14651858.CD010179]">Travers 2012a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0003" title="GriffithsB , KewKM . Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD011050. [DOI: 10.1002/14651858.CD011050.pub2]">Griffiths 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0004" title="JatKR , ChawlaD . Ketamine for management of acute exacerbations of asthma in children. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD009293. [DOI: 10.1002/14651858.CD009293.pub2]">Jat 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>Other interventions to reduce the work of breathing</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0009" title="RodrigoG , PollackC , RodrigoC , RoweBH . Heliox for nonintubated acute asthma patients. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD002884. [DOI: 10.1002/14651858.CD002884.pub2]">Rodrigo 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0006" title="KorangSK , FeinbergJ , WetterslevJ , JakobsenJC . Non-invasive positive pressure ventilation for acute asthma in children. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012067. [DOI: 10.1002/14651858.CD012067.pub2]">Korang 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>Other interventions</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0008" title="NormansellR , SayerB , WatersonS , DennettEJ , Del FornoM , DunleavyA . Antibiotics for exacerbations of asthma. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD002741. [DOI: 10.1002/14651858.CD002741.pub2]">Normansell 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Complete details of all components of the ROBIS assessment are presented in <a href="./appendices#CD012977-sec-0171">Appendix 4</a>. </p> </div> </div> <p>The other ten reviews used the Cochrane risk of bias tool for methodological quality assessments. Most assessments included a combination of low and unclear risk of bias. The review on antibiotics included three RCTs; each of these studies was rated as having high risk for two of the seven risk of bias domains: one RCT for performance bias and detection bias, and two RCTs for attrition bias and reporting bias (<a href="./references#CD012977-bbs2-0008" title="NormansellR , SayerB , WatersonS , DennettEJ , Del FornoM , DunleavyA . Antibiotics for exacerbations of asthma. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD002741. [DOI: 10.1002/14651858.CD002741.pub2]">Normansell 2018</a>). Four other reviews included at least one RCT with high risk of bias on at least one item, including selective reporting (2/8 RCTs in <a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>), allocation concealment (2/7 RCTs in <a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>), incomplete outcome data (1/2 RCTs in <a href="./references#CD012977-bbs2-0006" title="KorangSK , FeinbergJ , WetterslevJ , JakobsenJC . Non-invasive positive pressure ventilation for acute asthma in children. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012067. [DOI: 10.1002/14651858.CD012067.pub2]">Korang 2016</a>), and other bias (1/5 RCTs in <a href="./references#CD012977-bbs2-0003" title="GriffithsB , KewKM . Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD011050. [DOI: 10.1002/14651858.CD011050.pub2]">Griffiths 2016</a>). </p> </section> <section id="CD012977-sec-0053"> <h4 class="title">Certainty of evidence assessments in included reviews</h4> <p>Eight reviews contained a Grading of Recommendations, Assessment, Development and Evaluation (GRADE) 'Summary of findings' table, which we have summarised in <a href="#CD012977-tbl-0006">Table 6</a>. One review judged the outcomes reported in the 'Summary of findings' table to be high certainty (<a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a>), another moderate certainty (<a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>), one low certainty (<a href="./references#CD012977-bbs2-0003" title="GriffithsB , KewKM . Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD011050. [DOI: 10.1002/14651858.CD011050.pub2]">Griffiths 2016</a>), and one very low certainty (<a href="./references#CD012977-bbs2-0006" title="KorangSK , FeinbergJ , WetterslevJ , JakobsenJC . Non-invasive positive pressure ventilation for acute asthma in children. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012067. [DOI: 10.1002/14651858.CD012067.pub2]">Korang 2016</a>). The other four reviews contained a mixture of ratings of certainty, including two reviews with a combination of moderate and low certainty (<a href="./references#CD012977-bbs2-0010" title="TraversAH , MilanSJ , JonesAP , Camargo CA Jr, RoweBH . Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010179. [DOI: 10.1002/14651858.CD010179]">Travers 2012a</a>; <a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a>); one review ranging from very low to moderate certainty (<a href="./references#CD012977-bbs2-0008" title="NormansellR , SayerB , WatersonS , DennettEJ , Del FornoM , DunleavyA . Antibiotics for exacerbations of asthma. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD002741. [DOI: 10.1002/14651858.CD002741.pub2]">Normansell 2018</a>); and one review ranging from very low to high certainty (<a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>). </p> <div class="table" id="CD012977-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Certainty of evidence in the included reviews</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Review</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of studies where results for children are available and included in this overview</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Summary of findings</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Methodological quality assessment tool</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk of bias assessment (from review authors)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Inhaled treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jadad score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jadad score: 2/5</p> <p>Unclear sequence generation; no allocation concealment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes. High‐certainty evidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assessed according to recommendations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random sequence generation: low risk in 17/27</p> <p>Allocation concealment: low risk in 21/27</p> <p>Blinding: low risk in 23/27</p> <p>Incomplete outcome data: low risk in 23/27</p> <p>Selective reporting: low risk in 20/27</p> <p>Other bias: low risk in 23/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes. Moderate‐certainty evidence for all comparisons</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cochrane ‘Risk of bias’ tool</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random sequence generation: low risk in 2/4</p> <p>Allocation concealment: low risk in 2/4</p> <p>Blinding of participants and personnel: Low risk in 4/4</p> <p>Blinding of outcome assessment: low risk in 4/4</p> <p>Incomplete outcome data: low risk in 4/4</p> <p>Selective reporting: low risk in 2/4</p> <p>Other bias: low risk in 4/4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes. Certainty ranges from very low to low to moderate to high</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cochrane ‘Risk of bias’ tool</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random sequence generation: low risk in 4/8</p> <p>Allocation concealment: low risk in 4/8</p> <p>Blinding of participants and personnel: low risk in 5/8</p> <p>Blinding of outcome assessment: low risk in 5/8</p> <p>Incomplete outcome data: low risk in 5/8</p> <p>Selective reporting: low risk in 5/8; high risk in 2/8</p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Parenteral treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jadad score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jadad score: 4/5 (3 studies); 5/5 (4 studies)</p> <p>Adequate sequence generation: low risk in 2/7</p> <p>Allocation concealment: low risk in 3/7; high risk in 2/7</p> <p>Blinding: low risk in 7/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0010" title="TraversAH , MilanSJ , JonesAP , Camargo CA Jr, RoweBH . Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010179. [DOI: 10.1002/14651858.CD010179]">Travers 2012a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes. Moderate‐ and low‐certainty evidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assessed according to recommendations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random sequence generation: low risk in 2/2</p> <p>Allocation concealment: low risk in 2/2</p> <p>Blinding of participants and personnel: low risk in 2/2</p> <p>Blinding of outcome assessment: low risk in 2/2</p> <p>Incomplete outcome data: low risk in 2/2</p> <p>Selective reporting: unclear risk in 2/2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes. Most scores of moderate certainty. Low certainty for heart rate at 60 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cochrane ‘Risk of bias’ tool</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random sequence generation: low risk in 2/4</p> <p>Allocation concealment: low risk in 2/4</p> <p>Blinding of participants and personnel: low risk in 3/4</p> <p>Blinding of outcome assessment: low risk in 3/4</p> <p>Incomplete outcome data: unclear risk in 4/4</p> <p>Selective reporting: unclear risk in 4/4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0003" title="GriffithsB , KewKM . Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD011050. [DOI: 10.1002/14651858.CD011050.pub2]">Griffiths 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes. Low certainty for all outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cochrane ‘Risk of bias’ tool</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random sequence generation: low risk in 2/5</p> <p>Allocation concealment: low risk in 2/5</p> <p>Blinding of participants and personnel: low risk in 5/5</p> <p>Blinding of outcome assessment: low risk in 4/5</p> <p>Incomplete outcome data: low risk in 2/5</p> <p>Selective reporting: low risk in 3/5</p> <p>Other bias: low risk in 4/5; high risk in 1/5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0004" title="JatKR , ChawlaD . Ketamine for management of acute exacerbations of asthma in children. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD009293. [DOI: 10.1002/14651858.CD009293.pub2]">Jat 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cochrane ‘Risk of bias’ tool</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random sequence generation: low risk</p> <p>Allocation concealment: low risk</p> <p>Blinding of participants and personnel: unclear risk</p> <p>Blinding of outcome assessment: low risk</p> <p>Incomplete outcome data: low risk</p> <p>Selective reporting: unclear risk</p> <p>Other bias: unclear risk</p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Other interventions to reduce the work of breathing</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0009" title="RodrigoG , PollackC , RodrigoC , RoweBH . Heliox for nonintubated acute asthma patients. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD002884. [DOI: 10.1002/14651858.CD002884.pub2]">Rodrigo 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jadad score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jadad score: 4/5 (1 study); 3/5 (2 studies)</p> <p>Allocation concealment: unclear risk in 3/3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0006" title="KorangSK , FeinbergJ , WetterslevJ , JakobsenJC . Non-invasive positive pressure ventilation for acute asthma in children. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012067. [DOI: 10.1002/14651858.CD012067.pub2]">Korang 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes. Very low certainty for all outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cochrane ‘Risk of bias’ tool</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random sequence generation: unclear risk in 2/2</p> <p>Allocation concealment: unclear risk in 2/2</p> <p>Blinding of participants and personnel: low risk in 2/2</p> <p>Blinding of outcome assessment: unclear risk in 2/2</p> <p>Incomplete outcome data: high risk in 1/21/2; low risk in 1/2</p> <p>Selective reporting: low risk in 1/2</p> <p>Other bias: low risk in 2/2</p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Other interventions</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0008" title="NormansellR , SayerB , WatersonS , DennettEJ , Del FornoM , DunleavyA . Antibiotics for exacerbations of asthma. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD002741. [DOI: 10.1002/14651858.CD002741.pub2]">Normansell 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes. Moderate, low, and very low certainty.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assessed according to recommendations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random sequence generation: low risk in 1/3</p> <p>Allocation concealment: low risk in 1/3</p> <p>Blinding of participants and personnel: high risk in 1/3; low risk in 2/3</p> <p>Blinding of outcome assessment: high risk in 1/3</p> <p>Incomplete outcome data: high risk in 2/3; low risk in 1/3</p> <p>Selective reporting: high risk in 2/3</p> <p>Other bias: low risk in 2/3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assessed according to recommendations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random sequence generation: low risk in 3/4</p> <p>Allocation concealment: low risk in 3/4</p> <p>Blinding of participants and personnel: low risk in 3/4</p> <p>Blinding of outcome assessment: low risk in 1/4</p> <p>Incomplete outcome data: low risk in 4/4</p> </td> </tr> </tbody> </table> </div> <p>We rated the certainty of evidence from the included systematic reviews with meta‐analysis using GRADE methods. The certainty of evidence varied widely (by review and also by outcome) and ranged from very low to high (<a href="#CD012977-tbl-0007">Table 7</a>; <a href="#CD012977-tbl-0008">Table 8</a>; <a href="#CD012977-tbl-0009">Table 9</a>; <a href="#CD012977-tbl-0010">Table 10</a>; <a href="#CD012977-tbl-0011">Table 11</a>; <a href="#CD012977-tbl-0012">Table 12</a>; <a href="#CD012977-tbl-0013">Table 13</a>; <a href="#CD012977-tbl-0014">Table 14</a>; <a href="#CD012977-tbl-0015">Table 15</a>; <a href="#CD012977-tbl-0016">Table 16</a>; <a href="#CD012977-tbl-0017">Table 17</a>; <a href="#CD012977-tbl-0018">Table 18</a>; <a href="#CD012977-tbl-0019">Table 19</a>; <a href="#CD012977-tbl-0020">Table 20</a>). </p> <div class="table" id="CD012977-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Length of stay measures</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention/Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Results: treatment effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments: overview authors' assessment of the certainty of evidence</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>ED treatment time</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous vs intermittent nebulisation: moderate to severe (<a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ED treatment time (units not specified)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐1.00 (‐13.50 to 11.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and serious risk of bias of the single study: unclear sequence generation, no allocation concealment (single‐blind study) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV magnesium sulfate (<a href="./references#CD012977-bbs2-0003" title="GriffithsB , KewKM . Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD011050. [DOI: 10.1002/14651858.CD011050.pub2]">Griffiths 2016</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ED treatment time (minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 5.00 (‐24.40 to 34.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision</p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>Hospital length of stay</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotics vs placebo (<a href="./references#CD012977-bbs2-0008" title="NormansellR , SayerB , WatersonS , DennettEJ , Del FornoM , DunleavyA . Antibiotics for exacerbations of asthma. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD002741. [DOI: 10.1002/14651858.CD002741.pub2]">Normansell 2018</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay (days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.10 (‐0.53 to 0.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision, risk of bias in single study (before good reporting standards introduced: 6 participants excluded but unclear from which arm they were excluded), indirectness (all children with status asthmaticus and study conducted before current asthma management had been introduced (e.g. they all received IV adrenaline) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Addition of IV SABA to inhaled SABA (<a href="./references#CD012977-bbs2-0010" title="TraversAH , MilanSJ , JonesAP , Camargo CA Jr, RoweBH . Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010179. [DOI: 10.1002/14651858.CD010179]">Travers 2012a</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PICU length of stay (hours)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐12.95 (‐38.74 to 12.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled anticholinergics + SABA vs SABA alone for children hospitalised with asthma (<a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of hospital stay (hours)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.28 (‐5.07 to 4.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>327 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>IV aminophylline + SABA + systemic steroids vs placebo + SABA + systemic steroids (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay (hours): all patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐2.1 (‐9.45 to 5.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay (hours): submaximal inhaled beta2‐agonists <br/>(&lt; 45 mg/kg/h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 6.00 (‐20.49 to 32.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract) and very serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay (hours): maximised inhaled beta2‐agonists (≥ 45 mg/kg/h)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 4.10 (‐13.73 to 21.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay (hours): maximised inhaled beta2‐agonists (≥ 45 mg/kg/h) and anticholinergics </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐4.32 (‐12.79 to 4.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>IV SABA vs intravenous aminophylline for acute asthma (<a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of stay (hours): all patients <i>(positive values favour aminophylline)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 23.19 (‐2.40 to 48.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of stay (hours): paediatric (non‐PICU) patients <i>(positive values favour aminophylline)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 28.10 (‐2.60 to 58.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of stay (hours): PICU patients</p> <p><i>(positive values favour aminophylline)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 12.00 (‐34.31 to 58.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV magnesium sulfate (<a href="./references#CD012977-bbs2-0003" title="GriffithsB , KewKM . Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD011050. [DOI: 10.1002/14651858.CD011050.pub2]">Griffiths 2016</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital length of stay (hours)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐5.30 (‐9.46 to ‐1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; ED: emergency department; IV: intravenous; MD: mean difference; PICU: paediatric intensive care unit: SABA: short‐acting beta2‐agonist; SMD: standardised mean difference. </p> </div> </div> <div class="table" id="CD012977-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Hospital admission</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Intervention/Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Population</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect: risk ratio (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments: overview authors' assessment of the certainty of evidence</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With intervention</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Inhaled treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Continuous vs intermittent nebulisation: moderate to severe (<a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>667 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>460 per 1000 (220 to 974)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.69 (0.33 to 1.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision; serious risk of bias of single study; unclear sequence generation; no allocation concealment (single‐blind study) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Less severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 per 1000 (11 to 322)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67 (0.12 to 3.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision; serious risk of bias of single study; unclear sequence generation; no allocation concealment (single‐blind study) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="16" valign="top"> <p>Anticholinergic and SABA vs SABA alone (<a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169 per 1000 (146 to 197)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73 (0.63 to 0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2497 (19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐dose protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>176 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148 per 1000 (98 to 222)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.84 (0.56 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>419 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple fixed‐dose protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>252 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>181 per 1000 (154 to 212)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (0.61 – 0.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1998 (15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple flexible‐dose protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (not estimable)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and single study with high risk of bias (consecutive assignment rather than randomised) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>298 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217 per 1000 (182 to 259)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73 (0.61 to 0.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1188 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>269 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>161 per 1000 (110 to 239)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.60 (0.41 to 0.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>371 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112 per 1000 (71 to 177)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.77 (0.49 to 1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>463 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122 per 1000 (73 to 206)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.87 (0.52 to 1.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>358 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 per 1000 (29 to 336)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.43 (0.42 to 4.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and very serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Highest tertile control group event rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>487 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>331 per 1000 (273 to 399)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.68 (0.56 to 0.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>669 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle tertile control group event rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>241 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>181 per 1000 (137 to 239)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 (0.57 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>780 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lowest tertile control group event rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 per 1000 (47 to 114)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91 (0.59 to 1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>968 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Background corticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>317 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225 per 1000 (187 to 273)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71 (0.59 to 0.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1043 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No background corticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>297 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>199 per 1000 (140 to 279)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67 (0.47 to 0.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>353 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Corticosteroids administered variably (at physician discretion)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>214 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>165 per 1000 (116 to 235)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.77 (0.54 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>511 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Background corticosteroids not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77 per 1000 (44 to 139)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.85 (0.48 to 1.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and very serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Inhaled magnesium sulfate</p> <p>(<a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MgSO4 + SABA + Ipratropium/Placebo + SABA + Ipratropium (Admission at first presentation)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>957 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>919 per 1000 (880 to 967)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96 (0.92 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>508 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author decided on trial inclusion) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MgSO4 + SABA vs Placebo + SABA</p> <p>(<a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98 per 1000 (38 to 257)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.14 (0.44 to 2.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author decided on trial inclusion), and because a majority of patients were from a study judged to be at risk of reporting bias </p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Parenteral treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intravenous magnesium sulfate (<a href="./references#CD012977-bbs2-0003" title="GriffithsB , KewKM . Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD011050. [DOI: 10.1002/14651858.CD011050.pub2]">Griffiths 2016</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intravenous MgSO4/Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>767 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>537 per 1000 (414 to 698)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70 (0.54 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intravenous ketamine vs placebo (<a href="./references#CD012977-bbs2-0004" title="JatKR , ChawlaD . Ketamine for management of acute exacerbations of asthma in children. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD009293. [DOI: 10.1002/14651858.CD009293.pub2]">Jat 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketamine/Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>829 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>788 per 1000 (622 to 995)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95 (0.75 to 1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to single small study – risk of serious imprecision</p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Other interventions to reduce the work of breathing</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heliox vs placebo for non‐intubated asthma patients (<a href="./references#CD012977-bbs2-0009" title="RodrigoG , PollackC , RodrigoC , RoweBH . Heliox for nonintubated acute asthma patients. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD002884. [DOI: 10.1002/14651858.CD002884.pub2]">Rodrigo 2006</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heliox vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>750 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>517 per 1000 (360 to 742)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.69 (0.48 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of serious imprecision. SR shows asymmetrical funnel plot, suggesting publication bias </p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Other interventions</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Leukotriene receptor antagonists in addition to usual care (<a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral LTRA/Control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 per 1000 (13 to 218)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.86 (0.12 to 3.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intravenous LTRA/Control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>252 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>199 per 1000 (129 to 310)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 (0.51 to 1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>276 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; LTRA: leukotriene receptor antagonist; MgSO4: magnesium sulfate; SABA: short‐acting beta2‐agonist. </p> </div> </div> <div class="table" id="CD012977-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Intensive care unit admission</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Intervention/Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect: risk ratio (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments: overview authors' assessment of the certainty of evidence</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With intervention</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled anticholinergics + SABA vs SABA alone for children hospitalised with asthma (<a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Admission to the ICU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (not estimable)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MgSO4 + SABA + Ipratropium/Placebo + SABA + Ipratropium (<a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HDU/ICU admission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87 per 1000 (47 to 165)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.48 (0.79 to 2.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>505 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author decided on trial inclusion) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intravenous aminophylline + beta2‐agonists + systemic steroids vs placebo + beta2‐agonists + systemic steroids (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU admission rates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>370 per 1000 (260 to 530)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.74 (0.52 to 1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; HDU: high‐dependency unit; ICU: intensive care unit; LTRA: leukotriene receptor antagonist; MgSO4: magnesium sulfate; SABA: short‐acting beta2‐agonist. </p> </div> </div> <div class="table" id="CD012977-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Adverse effects</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Intervention/Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect: risk ratio (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments: overview authors' assessment of the certainty of evidence</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With intervention</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>All adverse events</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotics vs placebo (<a href="./references#CD012977-bbs2-0008" title="NormansellR , SayerB , WatersonS , DennettEJ , Del FornoM , DunleavyA . Antibiotics for exacerbations of asthma. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD002741. [DOI: 10.1002/14651858.CD002741.pub2]">Normansell 2018</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 per 1000 (19 to 541)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80 (0.15 to 4.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in single study (possible attrition bias and reporting bias) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled anticholinergics + SABA vs SABA alone for children hospitalised with asthma (<a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse health effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (not estimable)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>290 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and very serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MgSO4 + SABA + Ipratropium vs Placebo + SABA + Ipratropium (<a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse event (during admission)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>204 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>186 per 1000 (131 to 265)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91 (0.64 to 1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>507 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and risk of bias in review (single author decided on trial inclusion) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MgSO4 + SABA vs Placebo + SABA (<a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 per 1000 (0 to 57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.46 (0.04 to 4.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>365 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author decided on trial inclusion) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Serious adverse events</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotics vs placebo (<a href="./references#CD012977-bbs2-0008" title="NormansellR , SayerB , WatersonS , DennettEJ , Del FornoM , DunleavyA . Antibiotics for exacerbations of asthma. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD002741. [DOI: 10.1002/14651858.CD002741.pub2]">Normansell 2018</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (not estimable)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in single study (possible performance bias and detection bias) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MgSO4 + SABA + Ipratropium vs Placebo + SABA + Ipratropium (<a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events (during admission)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 per 1000 (3 to 42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25 (0.07 to 0.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>507 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author decided on trial inclusion) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MgSO4 + SABA vs Placebo + SABA (<a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (not estimable)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author decided on trial inclusion) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐invasive positive‐pressure ventilation (<a href="./references#CD012977-bbs2-0006" title="KorangSK , FeinbergJ , WetterslevJ , JakobsenJC . Non-invasive positive pressure ventilation for acute asthma in children. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012067. [DOI: 10.1002/14651858.CD012067.pub2]">Korang 2016</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (not estimable)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias and very serious imprecision</p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Death</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV aminophylline + SABA + systemic steroids vs placebo + SABA + systemic steroids (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (not estimable)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>326 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐invasive positive‐pressure ventilation (<a href="./references#CD012977-bbs2-0006" title="KorangSK , FeinbergJ , WetterslevJ , JakobsenJC . Non-invasive positive pressure ventilation for acute asthma in children. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012067. [DOI: 10.1002/14651858.CD012067.pub2]">Korang 2016</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (not estimable)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in included study and very serious imprecision</p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Tremor</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous vs intermittent nebulisation: moderate to severe (<a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>257 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144 per 1000 (54 to 383)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.56 (0.21 to 1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and serious risk of bias of the single study; unclear sequence generation; no allocation concealment (single‐blind study) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergic and SABA vs SABA alone (<a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139 per 1000 (103 to 188)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.69 (0.51 to 0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>524 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>IV aminophylline + SABA + systemic steroids vs placebo + SABA + systemic steroids (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tremor: all patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>263 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>355 per 1000 (231 to 545)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.35 (0.88 to 2.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tremor: mean theophylline levels &lt; 15 mg/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>385 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 per 1000 (216 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.30 (0.56 to 3.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tremor: mean theophylline levels ≥ 15 mg/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>244 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>334 per 1000 (205 to 544)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.37 (0.84 to 2.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV SABA vs IV aminophylline for acute asthma (<a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>375 per 1000 w<i>ith SABA</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>694 (334 to 1000) <i>with aminophylline</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.85 (0.89 to 3.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Nausea and/or vomiting</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous vs intermittent nebulisation: moderate to severe (<a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea/Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 per 1000 (0 to 230)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.20 (0.01 to 4.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and serious risk of bias of the single study; unclear sequence generation; no allocation concealment (single‐blind study) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Anticholinergic and SABA vs SABA alone (<a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 per 1000 (18 to 56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.88 (0.49 to 1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1230 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 per 1000 (41 to 102)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.60 (0.38 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>757 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>IV aminophylline + SABA + systemic steroids vs placebo + SABA + systemic steroids (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vomiting: all patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>311 per 1000 (181 to 534)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.69 (2.15 to 6.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>305 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vomiting: mean theophylline levels &lt; 15 mg/L (mcg/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189 per 1000 (81 to 443)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.73 (1.17 to 6.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vomiting: mean theophylline levels ≥ 15 mg/L (mcg/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>433 per 1000 (214 to 874)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.43 (2.19 to 8.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>IV SABA vs IV aminophylline for acute asthma (<a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea/Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000 <i>with</i> <br/><i>SABA</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable due to rate of 0 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.00 (1.15 to 313.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>313 per 1000 w<i>ith SABA</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>694 per 1000 (307 to 1000) <i>with aminophylline</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.22 (0.98 to 4.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>438 per 1000 w<i>ith SABA</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>692 (359 to 1000) <i>with aminophylline</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.58 (0.82 to 3.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Cardiovascular adverse effects</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MgSO4 + SABA + Ipratropium /[SD2] Placebo + SABA + Ipratropium (<a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000 (1 to 44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.51 (0.05 to 5.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>507 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and risk of bias in review (single author decided on trial inclusion) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 per 1000 (2 to 27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67 (0.11 to 4.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>507 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and risk of bias in review (single author decided on trial inclusion) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV aminophylline + SABA + systemic steroids vs placebo + SABA + systemic steroids (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arrhythmias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 per 1000 (1 to 234)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.40 (0.02 to 9.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>IV SABA vs IV aminophylline for acute asthma (<a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dysrhythmia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188 per 1000 w<i>ith SABA</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 per 1000 (2 to 578) wi<i>th aminophylline</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.17 (0.01 to 3.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Palpitations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (not estimable)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Neurological adverse effects</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>IV aminophylline + SABA + systemic steroids vs placebo + SABA + systemic steroids (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache: all patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159 per 1000 (87 to 289)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.28 (0.70 to 2.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>238 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache: mean theophylline levels &lt; 15 mg/L (mcg/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable due to rate of 0 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.48 (0.67 to 44.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache: mean theophylline levels ≥ 15 mg/L (mcg/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>185 per 1000 (97 to 353)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.01 (0.53 to 1.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV SABA vs IV aminophylline for acute asthma (<a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188 per 1000 <i>with SABA</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231 per 1000 (57 to 959) <i>with aminophylline</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.23 (0.30 to 5.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>IV aminophylline + SABA + systemic steroids vs placebo + SABA + systemic steroids (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seizures: all patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 per 1000 (0 to 116)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.01 (0.06 to 15.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>274 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seizures: mean theophylline levels &lt; 15 mg/L (mcg/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (not estimable)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seizures: mean theophylline levels ≥ 15 mg/L (mcg/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 per 1000 (1 to 171)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.01 (0.06 to 15.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>186 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Pneumonia</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐invasive positive‐pressure ventilation (<a href="./references#CD012977-bbs2-0006" title="KorangSK , FeinbergJ , WetterslevJ , JakobsenJC . Non-invasive positive pressure ventilation for acute asthma in children. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012067. [DOI: 10.1002/14651858.CD012067.pub2]">Korang 2016</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pneumonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (not estimable)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Laboratory results</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>IV SABA vs IV aminophylline for acute asthma (<a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CPK elevation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250 per 1000 w<i>ith SABA</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>385 (130 to 1000) <i>with aminophylline</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.54 (0.52 to 4.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CPK‐MB elevation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 per 1000 w<i>ith SABA</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>154 per 1000 (110 to 1000) <i>with aminophylline</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.46 (0.25 to 24.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyperglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000 <i>with SABA</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>920 per 1000 (750 to 1000) <i>with aminophylline</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92 (0.75 to 1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypokalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163 per 1000 w<i>ith SABA</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169 per 1000 (90 to 353) <i>with aminophylline</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.04 (0.48 to 2.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; CPK: creatine phosphokinase; CPK‐MB: creatine phosphokinase myocardial band; GRADE: Grading of Recommendations Assessment, Development and Evaluation; MgSO4: magnesium sulfate; SABA: short acting beta2‐agonist. </p> </div> </div> <div class="table" id="CD012977-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Symptom scores</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention/Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Results: treatment effect (95% CI) unless otherwise stated</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments: overview authors' assessment of the certainty of evidence</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous vs intermittent nebulisation (<a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.66 (0.18 to 1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and serious risk of bias of the single study; unclear sequence generation; no allocation concealment (single‐blind study) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergic and SABA vs SABA alone (<a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in clinical score at 120 minutes (± 30 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.23 (‐0.42 to ‐0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>934 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral LTRA vs control (<a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in pulmonary index score (final assessment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐1.20 (‐1.37 to ‐1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heliox vs placebo for non‐intubated asthma patients (<a href="./references#CD012977-bbs2-0009" title="RodrigoG , PollackC , RodrigoC , RoweBH . Heliox for nonintubated acute asthma patients. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD002884. [DOI: 10.1002/14651858.CD002884.pub2]">Rodrigo 2006</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dyspnoea or pulmonary index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.51 (‐1.14 to 0.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of serious imprecision. SR shows asymmetrical funnel plot, suggesting publication bias </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled anticholinergics + SABA vs SABA alone for children hospitalised with asthma (<a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asthma clinical scores 8 to 36 hours after initial treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.02 (‐0.34 to 0.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled magnesium sulfate (<a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yung asthma severity score at 60 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.23 (‐0.48 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>472 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author decided on trial inclusion) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign="top"> <p>IV aminophylline + SABA + systemic steroids vs placebo + SABA + systemic steroids</p> <p>(<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in symptom scores 6 to 8 hours after enrolment (all patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.42 (‐0.70 to ‐0.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in symptom scores 6 to 8 hours after enrolment: submaximal inhaled beta‐2 agonists (&lt; 45 mg/kg/h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.31 (‐0.94 to 0.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in symptom scores 6 to 8 hours after enrolment: maximised inhaled beta‐2 agonists (≥ 45 mg/kg/h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in symptom scores 6 to 8 hours after enrolment: maximised inhaled beta‐2 agonists (≥ 45 mg/kg/h) and anticholinergics </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.45 (‐0.77 to ‐0.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in symptom scores 12 to 18 hours after enrolment: submaximal inhaled beta‐2 agonists (&lt; 45 mg/kg/h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.45 (‐1.09 to 0.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in symptom scores 12 to 18 hours after enrolment: maximised inhaled beta‐2 agonists (≥ 45 mg/kg/h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in symptom scores 24 hours after enrolment (all patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.13 (‐0.52 to 0.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in symptom scores 24 hours after enrolment: submaximal inhaled beta‐2 agonists (&lt; 45 mg/kg/h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in symptom scores 24 hours after enrolment: maximised inhaled beta‐2 agonists (≥ 45 mg/kg/h) and anticholinergics </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.13 (‐0.52 to 0.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV ketamine vs placebo (<a href="./references#CD012977-bbs2-0004" title="JatKR , ChawlaD . Ketamine for management of acute exacerbations of asthma in children. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD009293. [DOI: 10.1002/14651858.CD009293.pub2]">Jat 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary Index Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.40 (‐1.21 to 0.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐invasive positive‐pressure ventilation (<a href="./references#CD012977-bbs2-0006" title="KorangSK , FeinbergJ , WetterslevJ , JakobsenJC . Non-invasive positive pressure ventilation for acute asthma in children. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012067. [DOI: 10.1002/14651858.CD012067.pub2]">Korang 2016</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asthma symptom score in the acute phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐2.50 (‐4.70 to ‐0.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in included study</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; LTRA: leukotriene receptor antagonist; MD: mean difference; mg/kg: milligram per kilogram; SABA: short‐acting beta2‐agonist; SMD: standardised mean difference; SR: systematic review. </p> </div> </div> <div class="table" id="CD012977-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Lung function</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention/Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Results: treatment effect (95% CI) unless otherwise stated</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments: overview authors' assessment of the certainty of evidence</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous vs intermittent nebulisation: moderate to severe (<a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PEFR values (end of study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.25 (‐0.22 to 0.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and serious risk of bias of the single study; unclear sequence generation; no allocation concealment (single‐blind study) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="10" valign="top"> <p>Anticholinergic and SABA vs SABA alone: variable corticosteroids (at physicians’ discretion) (<a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change from baseline in %predicted FEV1, 60 minutes after last dose of inhaled bronchodilator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 10.08 (6.24 to 13.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>402 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change from baseline in %predicted FEV1, 120 minutes after last dose of inhaled bronchodilator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 6.87 (1.17 to 12.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% Change in FEV1 or PEFR at 60 minutes after last inhaled bronchodilator (± 15 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.57 (0.25 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% Change in FEV1 or PEFR at 120 minutes after last inhaled bronchodilator (± 30 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.12 (‐0.15 to 0.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% Change in respiratory resistance at 60 minutes after inhaled bronchodilator (± 15 minutes) – all studies </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.02 (‐0.02 to 0.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>294 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% Change in respiratory resistance at 60 minutes after inhaled bronchodilator (± 15 minutes) – with corticosteroids given within previous 60 minutes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.02 (‐0.13 to 0.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% Change in respiratory resistance at 60 minutes after inhaled bronchodilator (± 15 minutes) – no corticosteroids </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.03 (‐0.02 to 0.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>224 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% Change in respiratory resistance at 120 minutes after inhaled bronchodilator (± 30 minutes) – all studies </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.01 (‐0.09 to 0.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% Change in respiratory resistance at 120 minutes after inhaled bronchodilator (± 30 minutes) – with corticosteroids given within previous 120 minutes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.02 (‐0.12 to 0.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% Change in respiratory resistance at 120 minutes after inhaled bronchodilator (± 30 minutes) – no corticosteroids </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.02 (‐0.12 to 0.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotics vs placebo (<a href="./references#CD012977-bbs2-0008" title="NormansellR , SayerB , WatersonS , DennettEJ , Del FornoM , DunleavyA . Antibiotics for exacerbations of asthma. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD002741. [DOI: 10.1002/14651858.CD002741.pub2]">Normansell 2018</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PEFR (L/min)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 38.80 (‐11.19 to 88.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and risk of bias in single study (possible performance bias and detection bias) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral LTRA vs control (<a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in FEV1 (predicted)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐3.10 (‐12.70 to 6.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV LTRA vs control (<a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in FEV1 (litres)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.01 (‐0.06 to 0.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>276 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heliox vs placebo for non‐intubated asthma patients (<a href="./references#CD012977-bbs2-0009" title="RodrigoG , PollackC , RodrigoC , RoweBH . Heliox for nonintubated acute asthma patients. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD002884. [DOI: 10.1002/14651858.CD002884.pub2]">Rodrigo 2006</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.32 (‐0.52 to 1.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of serious imprecision. SR shows asymmetrical funnel plot, suggesting publication bias </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled anticholinergics + SABA vs SABA alone for children hospitalised with asthma (<a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percentages of predicted PEFR at 8 to 36 hours after initial treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐1.60 (‐17.20 to 14.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MgSO4 + SABA vs Placebo + SABA</p> <p>(<a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary function %predicted FEV1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 8.10 (‐3.03 to 19.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision (single small study) and risk of bias in review (single author decided on trial inclusion) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary function PEF L/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 11.90 (‐6.86 to 30.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision (single small study) and risk of bias in review (single author decided on trial inclusion) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="23" valign="top"> <p>IV aminophylline + SABA + systemic steroids vs placebo + SABA + systemic steroids (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in % predicted FEV1 within 4 hours of enrolment: submaximal inhaled SABA (&lt; 45 mg/kg/h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in % predicted FEV1 within 4 hours of enrolment: maximised inhaled SABA (≥ 45 mg/kg/h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.08 (‐9.04 to 13.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision (single small study) and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in % predicted FEV1 6 to 8 hours after enrolment (all patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 8.37 (0.82 to 15.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in % predicted FEV1 6 to 8 hours after enrolment: submaximal inhaled SABA (&lt; 45 mg/kg/h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision (single small study) and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in % predicted FEV1 6 to 8 hours after enrolment: maximised inhaled SABA (≥ 45 mg/kg/h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 5.45 (‐6.33 to 17.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in % predicted FEV1 6 to 8 hours after enrolment: maximised inhaled SABA (≥ 45 mg/kg/h) and anticholinergics </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 10.4 (0.57 to 20.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in % predicted FEV1 12 to 18 hours after enrolment (all patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 8.15 (1.04 to 15.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in % predicted FEV1 12 to 18 hours after enrolment: submaximal inhaled SABA (&lt; 45 mg/kg/h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in % predicted FEV1 12 to 18 hours after enrolment: maximised inhaled SABA (≥ 45 mg/kg/h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 5.74 (‐6.14 to 17.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in % predicted FEV1 12 to 18 hours after enrolment: maximised inhaled SABA (≥ 45 mg/kg/h) and anticholinergics </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 9.50 (0.62 to 18.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in % predicted FEV1 24 hours after enrolment (all patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 8.87 (1.25 to 16.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in % predicted FEV1 24 hours after enrolment: submaximal inhaled SABA (&lt; 45 mg/kg/h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in % predicted FEV1 24 hours after enrolment: maximised inhaled SABA (≥ 45 mg/kg/h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 7.36 (‐7.61 to 22.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in % predicted FEV1 24 hours after enrolment: maximised inhaled SABA (≥ 45 mg/kg/h) and anticholinergics </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 9.40 (0.54 to 18.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in PEF at 6 to 8 hours after enrolment (all patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.92 (0.32 to 1.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in PEF at 6 to 8 hours after enrolment: submaximal inhaled SABA (&lt; 45 mg/kg/h)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.51 (‐0.96 to 1.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract) and very serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in PEF at 6 to 8 hours after enrolment: maximised inhaled SABA (≥ 45 mg/kg/h) and anticholinergics </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 1.00 (0.35 to 1.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in PEF at 12 to 18 hours after enrolment (all patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.75 (0.25 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in PEF at 12 to 18 hours after enrolment: submaximal inhaled SABA (&lt; 45 mg/kg/h)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.71 (‐0.01 to 1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in PEF at 12 to 18 hours after enrolment: maximised inhaled SABA (≥ 45 mg/kg/h) and anticholinergics </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.77 (0.08 to 1.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in PEF at 24 hours after enrolment (all patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.39 (‐0.51 to 1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in PEF at 24 hours after enrolment: submaximal inhaled SABA (&lt; 45 mg/kg/h)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.33 (‐1.39 to 2.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in PEF at 24 hours after enrolment: maximised inhaled SABA (≥ 45 mg/kg/h) and anticholinergics </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.66 (0.01 to 1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract) and serious imprecision </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; FEV1: forced expiratory volume in one second; LTRA: leukotriene receptor antagonist; MD: mean difference; mg/kg: milligram per kilogram; PEF: peak expiratory flow; PEFR: peak expiratory flow rate; SABA: short‐acting beta2<sub>-</sub>agonist; SMD: standardised mean difference. </p> </div> </div> <div class="table" id="CD012977-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Vital signs: dichotomous outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Intervention/Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect: risk ratio (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments: overview authors' assessment of the certainty of evidence</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With intervention</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Anticholinergic and SABA vs SABA alone (<a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxygen saturations &lt; 95% at 60 minutes (± 15 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>365 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>267 per 1000 (210 to 354)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73 (0.55 to 0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>416 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxygen saturations &lt; 95% at 120 minutes (± 30 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>367 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>404 per 1000 (279 to 583)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.10 (0.76 to 1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>185 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious inconsistency, serious imprecision, and serious risk of bias in review (single author selected possible citations) </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; SABA: short‐acting beta2‐agonist. </p> </div> </div> <div class="table" id="CD012977-tbl-0014"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Vital signs: continuous outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention/Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Results: treatment effect (95% CI) unless otherwise stated</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments: overview authors' assessment of the certainty of evidence</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Addition of IV SABA to inhaled SABA (<a href="./references#CD012977-bbs2-0010" title="TraversAH , MilanSJ , JonesAP , Camargo CA Jr, RoweBH . Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010179. [DOI: 10.1002/14651858.CD010179]">Travers 2012a</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulse rate (beats/min) at 2 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 10.00 (‐1.07 to 21.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral LTRA vs control (<a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in respiratory rate (breaths/min) (final assessment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐4.60 (‐6.84 to ‐2.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Heliox vs placebo for non‐intubated asthma patients (<a href="./references#CD012977-bbs2-0009" title="RodrigoG , PollackC , RodrigoC , RoweBH . Heliox for nonintubated acute asthma patients. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD002884. [DOI: 10.1002/14651858.CD002884.pub2]">Rodrigo 2006</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heart rate (beats/min)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.0 (‐13.80 to 13.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious imprecision. SR shows asymmetrical funnel plot, suggesting publication bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SaO2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.0 (‐2.51 to 2.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious imprecision. SR shows asymmetrical funnel plot, suggesting publication bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV aminophylline + SABA + systemic steroids vs. placebo + SABA + systemic steroids</p> <p>(<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; LTRA: leukotriene receptor antagonist; MD: mean difference; SABA: short‐acting beta2‐agonist; SaO2: oxygen saturation. </p> </div> </div> <div class="table" id="CD012977-tbl-0015"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Rates of mechanical ventilation in the intensive care unit</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Intervention/Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect: risk ratio (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments: overview authors' assessment of the certainty of evidence</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With intervention</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV aminophylline + SABA + systemic steroids vs Placebo + SABA + systemic steroids (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rates of patients mechanically ventilated in ICU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 per 1000 (1 to 100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.09 (0.01 to 1.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; ICU: intensive care unit; SABA: short‐acting beta2‐agonist. </p> </div> </div> <div class="table" id="CD012977-tbl-0016"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 16.</span> <span class="table-title">Clinical failure</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Intervention/Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect: risk ratio (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments: overview authors' assessment of the certainty of evidence</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With intervention</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Addition of IV SABA to inhaled SABA (<a href="./references#CD012977-bbs2-0010" title="TraversAH , MilanSJ , JonesAP , Camargo CA Jr, RoweBH . Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010179. [DOI: 10.1002/14651858.CD010179]">Travers 2012a</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>933 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>354 per 1000 (177 to 728)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.38 (0.19 to 0.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One point deducted as data contributed by only 1 study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV SABA vs IV aminophylline for acute asthma (<a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>303 per 1000 <i>with SABA</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>303 per 1000 (145 to 630) <i>with aminophylline</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 (0.48 to 2.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; IV: Intravenous; SABA: short‐acting beta2‐agonist. </p> </div> </div> <div class="table" id="CD012977-tbl-0017"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 17.</span> <span class="table-title">Relapse/Return to the emergency department</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Intervention/Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect: risk ratio (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certaintyof the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments: overview authors' assessment of the certainty of evidence</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With intervention</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergic and SABA vs SABA alone (<a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 per 1000 (31 to 76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.07 (0.68 to 1.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1389 (10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral LTRA vs control (<a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse within 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 per 1000 (1 to 727)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.39 (0.02 to 8.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled anticholinergics + SABA vs SABA alone for children hospitalised with asthma (<a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse within 72 hours of discharge from hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (not estimable)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV magnesium sulfate (<a href="./references#CD012977-bbs2-0003" title="GriffithsB , KewKM . Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD011050. [DOI: 10.1002/14651858.CD011050.pub2]">Griffiths 2016</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Return to ED within 48 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 per 1000 (1 to 211)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.41 (0.02 to 9.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; ED: emergency department; GRADE: Grading of Recommendations Assessment, Development and Evaluation; LTRA: leukotriene receptor antagonist; SABA: short acting beta2‐agonist. </p> </div> </div> <div class="table" id="CD012977-tbl-0018"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 18.</span> <span class="table-title">Withdrawals</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Intervention/Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect: risk ratio (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments: overview authors' assessment of the certainty of evidence</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With intervention</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral LTRA vs control (<a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 per 1000 (4 to 178)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 (0.16 to 6.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded due to very serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV LTRA vs control (<a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 per 1000 (10 to 126)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.13 (0.31 to 4.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>276 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded due to very serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Inhaled anticholinergics + SABA vs SABA alone for children hospitalised with asthma (<a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall withdrawals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 per 1000 (38 to 154)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.62 (0.31 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>294 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to deterioration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 per 1000 (7 to 206)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.04 (0.38 to 10.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and very serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>IV aminophylline + SABA + systemic steroids vs placebo + SABA + systemic steroids (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse health effects: all patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 per 1000 (9 to 75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.48 (0.32 to 6.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>370 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and very serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse health effects: mean theophylline levels &lt; 15 mg/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 per 1000 (7 to 148)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.48 (0.32 to 6.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>186 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and very serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse health effects: mean theophylline levels ≥ 15 mg/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (not estimable)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>184 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and very serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to poor asthma control: all patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 per 1000 (2 to 63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70 (0.13 to 3.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>370 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and very serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to poor asthma control: mean theophylline levels &lt; 15 mg/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 per 1000 (4 to 126)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70 (0.13 to 3.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>186 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and very serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to poor asthma control: mean theophylline levels ≥ 15 mg/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (not estimable)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>184 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and very serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to any cause</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 per 1000 (26 to 154)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.65 (0.67 to 4.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>371 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; LTRA: leukotriene receptor antagonist; mg/L: milligrams per litre; SABA: short acting beta2‐agonist. </p> </div> </div> <div class="table" id="CD012977-tbl-0019"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 19.</span> <span class="table-title">Other measures: continuous outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention/Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Results: treatment effect (95% CI) unless otherwise stated</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments: overview authors' assessment of the certainty of evidence</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous vs intermittent nebulisation: moderate to severe (<a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Respiratory therapist time</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐22.00 (‐26.82 to ‐17.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious risk of bias of the single study; unclear sequence generation; no allocation concealment (single‐blind study) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled anticholinergics + SABA vs SABA alone for children hospitalised with asthma (<a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to SABA spaced at 4 hours or longer (hours)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐2.17 (‐7.01 to 2.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>290 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV aminophylline + SABA + systemic steroids vs Placebo + SABA + systemic steroids (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of nebulisers required in 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.15 (‐0.52 to 0.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; MD: mean difference; SABA: short‐acting beta2‐agonist. </p> </div> </div> <div class="table" id="CD012977-tbl-0020"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 20.</span> <span class="table-title">Other measures: dichotomous outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Intervention/Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect: risk ratio (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments: overview authors' assessment of the certainty of evidence</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With intervention</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Anticholinergic and SABA vs SABA alone (<a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Need for repeat bronchodilator treatment after standard protocol prior to disposition</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>539 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>469 per 1000 (426 to 523)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.87 (0.79 to 0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1074 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Need for corticosteroids in<br/>ED prior to disposition </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>516 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>459 per 1000 (377 to 557)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.89 (0.73 to 1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>378 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral LTRA vs control (<a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Requirement for additional care at end of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 per 1000 (4 to 431)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.54 (0.05 to 5.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled anticholinergics + SABA vs SABA alone for children hospitalised with asthma (<a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Need for supplemental asthma therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 per 1000 (35 to 122)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.77 (0.41 to 1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>465 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV ketamine vs placebo (<a href="./references#CD012977-bbs2-0004" title="JatKR , ChawlaD . Ketamine for management of acute exacerbations of asthma in children. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD009293. [DOI: 10.1002/14651858.CD009293.pub2]">Jat 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worsened and required other adjuvant therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 per 1000 (6 to 638)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.12 (0.2 to 22.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; ED: emergency department; LTRA: leukotriene receptor antagonist; SABA: short‐acting beta2‐agonist. </p> </div> </div> </section> </section> <section id="CD012977-sec-0054"> <h3 class="title" id="CD012977-sec-0054">Effect of interventions</h3> <p>Outcomes varied considerably between systematic reviews, and similar outcomes were measured via different methods at different points in time. A categorised list of all outcomes is presented in <a href="./appendices#CD012977-sec-0171">Appendix 4</a>. A series of tables is presented, including data for each outcome from the included systematic reviews (<a href="#CD012977-tbl-0007">Table 7</a>; <a href="#CD012977-tbl-0008">Table 8</a>; <a href="#CD012977-tbl-0009">Table 9</a>; <a href="#CD012977-tbl-0010">Table 10</a>; <a href="#CD012977-tbl-0011">Table 11</a>; <a href="#CD012977-tbl-0012">Table 12</a>; <a href="#CD012977-tbl-0013">Table 13</a>; <a href="#CD012977-tbl-0014">Table 14</a>; <a href="#CD012977-tbl-0015">Table 15</a>; <a href="#CD012977-tbl-0016">Table 16</a>; <a href="#CD012977-tbl-0017">Table 17</a>; <a href="#CD012977-tbl-0018">Table 18</a>; <a href="#CD012977-tbl-0019">Table 19</a>; <a href="#CD012977-tbl-0020">Table 20</a>). These tables present odds or risk ratios and also absolute event rates per thousand in each group. We summarise below information from reviews that contribute data to each outcome, including the certainty of evidence assessment we performed on each included systematic review with meta‐analysis. Comparisons are between treatment and placebo unless otherwise stated. </p> <p>Common themes in recommendations for future research (<a href="./appendices#CD012977-sec-0173">Appendix 5</a>) from the included reviews were the need for adequately powered and methodologically sound RCTs, an agreed core outcome set for acute asthma in children, reliable assessment of baseline severity and response to treatment, and the need to perform subgroup analyses in preschool and school‐aged children, and for varying degrees of asthma severity. </p> <p>There was no overlap between reviews. We contacted no review authors for further information. We obtained data only from the included Cochrane Reviews; we did not obtain data from individual trial reports. </p> <section id="CD012977-sec-0055"> <h4 class="title">Primary outcome: length of stay</h4> <p>Two reviews included ED treatment time as an outcome measure, and six reviews included hospital length of stay (<a href="#CD012977-tbl-0007">Table 7</a>). Comparisons ranged from single RCTs with as few as 29 participants to three RCTs with a total of 327 participants. </p> <section id="CD012977-sec-0056"> <h5 class="title">Inhaled treatment</h5> <p>Two reviews reported low‐certainty evidence for the effects of inhaled treatment on length of stay. The review comparing continuous versus intermittent nebulisation showed an unclear difference in ED treatment time between the two groups (mean difference (MD) ‐1.00 hours; 95% confidence interval (CI) ‐13.50 to 11.50 hours; 70 participants; 1 trial) (<a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a>). </p> <p>A review examining the effects of adding inhaled anticholinergics to short acting beta<sub>2</sub>‐agonists (SABAs) found an unclear difference in hospital length of stay (MD ‐0.28 hours; 95% CI ‐5.07 to 4.52 hours; 327 participants; 3 trials) (<a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>). </p> </section> <section id="CD012977-sec-0057"> <h5 class="title">Parenteral treatment</h5> <p>Four reviews examined the effects of intravenous medications on hospital length of stay. No clear difference was demonstrated when intravenous beta<sub>2</sub>‐agonists were added to inhaled beta<sub>2</sub>‐agonists (moderate‐certainty evidence; MD ‐12.95 hours; 95% CI ‐38.74 to 12.84; 46 participants; 1 trial) (<a href="./references#CD012977-bbs2-0010" title="TraversAH , MilanSJ , JonesAP , Camargo CA Jr, RoweBH . Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010179. [DOI: 10.1002/14651858.CD010179]">Travers 2012a</a>); when intravenous aminophylline was used (low‐certainty evidence; MD ‐2.1 hours, 95% CI ‐9.45 to 5.25; 231 participants; 3 trials) (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>); or when intravenous beta<sub>2</sub>‐agonists were compared to intravenous aminophylline (low‐certainty evidence; MD 23.19 hours; 95% CI ‐2.40 to 48.77; 44 participants; 1 trial) (<a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a>). </p> <p>The review on intravenous magnesium sulfate showed high‐certainty evidence of a reduction in hospital length of stay (MD ‐5.3 hours, 95% CI ‐9.46 to ‐1.14 hours; 47 participants; 1 trial) and moderate‐certainty evidence of an unclear effect on ED treatment time compared to placebo (MD 5.00 minutes, 95% CI ‐24.40 to 34.40; 27 participants; 1 trial) (<a href="./references#CD012977-bbs2-0003" title="GriffithsB , KewKM . Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD011050. [DOI: 10.1002/14651858.CD011050.pub2]">Griffiths 2016</a>). </p> </section> <section id="CD012977-sec-0058"> <h5 class="title">Interventions to reduce the work of breathing</h5> <p>Neither review on interventions to reduce the work of breathing included length of stay as an outcome measure. </p> </section> <section id="CD012977-sec-0059"> <h5 class="title">Other interventions</h5> <p>One review reported very low‐certainty evidence for the effects of antibiotics versus placebo on hospital length of stay and found an unclear difference (MD ‐0.10, 95% CI ‐0.53 to 0.33; 43 participants; 1 trial) (<a href="./references#CD012977-bbs2-0008" title="NormansellR , SayerB , WatersonS , DennettEJ , Del FornoM , DunleavyA . Antibiotics for exacerbations of asthma. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD002741. [DOI: 10.1002/14651858.CD002741.pub2]">Normansell 2018</a>). </p> </section> </section> <section id="CD012977-sec-0060"> <h4 class="title">Primary outcome: hospital admission</h4> <p>Seven reviews included hospital admission as an outcome measure (<a href="#CD012977-tbl-0008">Table 8</a>). Comparisons ranged from planned subgroup analyses of a single RCT with 22 participants to a review including 19 RCTs and 2497 participants. </p> <section id="CD012977-sec-0061"> <h5 class="title">Inhaled treatment</h5> <p>Very low‐certainty evidence suggested an unclear difference in the rate of hospital admissions for continuous nebulised versus intermittent nebulised beta<sub>2</sub>‐agonists for both moderate to severe asthma (RR 0.69, 95% CI 0.33 to 1.46; 22 participants; 1 trial) and less severe asthma (RR 0.67, 95% CI 0.12 to 3.75; 70 participants; 1 trial) (<a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a>). </p> <p>This review conducted a number of subgroup analyses for this outcome and identified a reduction in the risk of hospital admission for those with more severe asthma, along with an unclear effect in children with milder asthma (<a href="#CD012977-tbl-0008">Table 8</a>). A multiple fixed‐dose protocol of inhaled anticholinergic agents resulted in reduced risk of hospital admission compared with SABA alone (RR 0.72, 95% CI 0.61 to 0.84; 1998 participants; 15 trials), but a single‐dose regimen did not have a clear effect on the risk of hospital admission (RR 0.84, 95% CI 0.56 to 1.26; 419 participants; 3 trials). </p> <p>When RCTs were grouped by co‐intervention with corticosteroids, a reduction in risk was noted when corticosteroids were given (RR 0.71, 95% CI 0.59 to 0.86; 1043 participants; 8 trials), and in RCTs in which corticosteroids were not administered (RR 0.67, 95% CI 0.47 to 0.94; 353 participants; 6 trials). However, in RCTs in which corticosteroids were administered at physician discretion, the reduction in risk was non‐significant (RR 0.77, 95% CI 0.54 to 1.10; 511 participants; 3 trials). </p> <p>Inhaled magnesium sulfate had an unclear effect on hospital admission when administered with SABAs (very low‐certainty evidence; RR 1.14, 95% CI 0.44 to 2.98; 162 participants; 2 trials) or with a combination of inhaled anticholinergics and SABAs (moderate‐certainty evidence; RR 0.96, 95% CI 0.92 to 1.01; 508 participants; 1 trial) (<a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>). </p> </section> <section id="CD012977-sec-0062"> <h5 class="title">Parenteral treatment</h5> <p>The review on intravenous magnesium sulfate yielded high‐certainty evidence of a reduction in the risk of hospital admission compared to placebo (RR 0.70, 95% CI 0.54 to 0.91; 115 participants; 3 trials) (<a href="./references#CD012977-bbs2-0003" title="GriffithsB , KewKM . Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD011050. [DOI: 10.1002/14651858.CD011050.pub2]">Griffiths 2016</a>). </p> <p>The review on intravenous ketamine showed moderate‐certainty evidence of an unclear effect (RR 0.95, 95% CI 0.75 to 1.20; 68 participants; 1 trial) (<a href="./references#CD012977-bbs2-0004" title="JatKR , ChawlaD . Ketamine for management of acute exacerbations of asthma in children. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD009293. [DOI: 10.1002/14651858.CD009293.pub2]">Jat 2012</a>). </p> </section> <section id="CD012977-sec-0063"> <h5 class="title">Interventions to reduce the work of breathing</h5> <p>Low‐certainty evidence suggests that the use of heliox led to a small reduction in hospital admission compared to placebo (RR 0.69, 95% CI 0.48 to 0.99; 71 participants; 2 trials) (<a href="./references#CD012977-bbs2-0009" title="RodrigoG , PollackC , RodrigoC , RoweBH . Heliox for nonintubated acute asthma patients. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD002884. [DOI: 10.1002/14651858.CD002884.pub2]">Rodrigo 2006</a>). </p> </section> <section id="CD012977-sec-0064"> <h5 class="title">Other interventions</h5> <p>The use of leukotriene receptor antagonists (LTRA) in addition to usual care had an unclear effect on hospital admission for either oral LTRA (RR 0.86, 95% CI 0.12 to 3.52; 194 participants; 3 trials) or intravenous LTRA (RR 0.79, 95% CI 0.51 to 1.23; 276 participants; 1 trial) (<a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a>). </p> </section> </section> <section id="CD012977-sec-0065"> <h4 class="title">Primary outcome: intensive care unit admission</h4> <p>Three reviews included intensive care admission as an outcome measure (<a href="#CD012977-tbl-0009">Table 9</a>). Each review included a single trial. Comparisons ranged from a trial with 163 participants to a trial with 508 participants. </p> <section id="CD012977-sec-0066"> <h5 class="title">Inhaled treatment</h5> <p>Results show no intensive care unit admissions for treatment or control participants in the review on inhaled anticholinergics added to SABA versus SABA alone (<a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>). </p> <p>Very low‐certainty evidence suggests that the addition of inhaled magnesium sulfate to a combination of ipratropium and a SABA had an unclear effect on the rate of high dependency/intensive care unit admission (RR 1.48, 95% CI 0.79 to 2.79; 505 participants; 1 trial) (<a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>). </p> </section> <section id="CD012977-sec-0067"> <h5 class="title">Parenteral treatment</h5> <p>The addition of intravenous aminophylline to inhaled SABA and systemic corticosteroids had an unclear effect on intensive care unit admission (RR 0.74, 95% CI 0.52 to 1.06; 163 participants; 1 trial) (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>). </p> </section> <section id="CD012977-sec-0068"> <h5 class="title">Interventions to reduce the work of breathing</h5> <p>No reviews reported intensive care unit admission as an outcome.</p> </section> <section id="CD012977-sec-0069"> <h5 class="title">Other intervention</h5> <p>No reviews reported intensive care unit admission as an outcome.</p> </section> </section> <section id="CD012977-sec-0070"> <h4 class="title">Primary outcome: adverse events</h4> <p><a href="#CD012977-tbl-0010">Table 10</a> presents our findings related to adverse events (a primary outcome for this overview) and secondary outcomes related to specific adverse events (tremor, nausea and vomiting, and other adverse events). </p> <p>Four reviews presented a total of eight comparisons related to adverse events. Of these comparisons, half were related to any adverse event, and the other half examined serious adverse events. Comparisons ranged from a review including 35 participants within two RCTs to a single RCT of 507 participants. </p> <section id="CD012977-sec-0071"> <h5 class="title">Inhaled treatment</h5> <p>Risk for adverse events was not estimable, as none occurred in the review on inhaled anticholinergics combined with SABA versus SABA alone (290 participants; 2 trials) (<a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>). </p> <p>Very low‐certainty evidence suggests an unclear difference in the risk for either any adverse events or serious adverse events when inhaled magnesium sulfate and SABA were compared to inhaled SABA alone (<a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>). When inhaled magnesium sulfate was added to a combination of SABA and inhaled anticholinergic, a single trial of 507 participants provided low‐certainty evidence for an unclear effect on the risk of any adverse event (RR 0.91, 95% CI 0.64 to 1.30), and moderate‐certainty evidence for reduced risk of serious adverse events (RR 0.25, 95% CI 0.07 to 0.89). </p> </section> <section id="CD012977-sec-0072"> <h5 class="title">Parenteral treatment</h5> <p>No reviews of parenteral treatment provided overall estimates of adverse events or serious adverse events. Information related to specific adverse events is provided under secondary outcomes (below). </p> </section> <section id="CD012977-sec-0073"> <h5 class="title">Interventions to reduce the work of breathing</h5> <p>Risk for adverse events was not estimable, as none occurred in the review on non‐invasive positive‐pressure ventilation (35 participants; 2 trials) (<a href="./references#CD012977-bbs2-0006" title="KorangSK , FeinbergJ , WetterslevJ , JakobsenJC . Non-invasive positive pressure ventilation for acute asthma in children. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012067. [DOI: 10.1002/14651858.CD012067.pub2]">Korang 2016</a>). </p> </section> <section id="CD012977-sec-0074"> <h5 class="title">Other intervention</h5> <p>Very low‐certainty evidence from the review on antibiotics versus placebo suggests an unclear difference in the risk for all adverse events (RR 0.80, 95% CI 0.15 to 4.33; 44 participants; 1 trial) (<a href="./references#CD012977-bbs2-0008" title="NormansellR , SayerB , WatersonS , DennettEJ , Del FornoM , DunleavyA . Antibiotics for exacerbations of asthma. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD002741. [DOI: 10.1002/14651858.CD002741.pub2]">Normansell 2018</a>). Review authors were unable to estimate a risk for serious adverse events, as no such events occurred in the 40 included participants. </p> </section> </section> <section id="CD012977-sec-0075"> <h4 class="title">Secondary outcome: death/mortality</h4> <p>Two reviews, one on intravenous aminophylline ‐ <a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a> ‐ and another on non‐invasive positive‐pressure ventilation ‐ <a href="./references#CD012977-bbs2-0006" title="KorangSK , FeinbergJ , WetterslevJ , JakobsenJC . Non-invasive positive pressure ventilation for acute asthma in children. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012067. [DOI: 10.1002/14651858.CD012067.pub2]">Korang 2016</a>, presented comparisons related to death or mortality (<a href="#CD012977-tbl-0010">Table 10</a>). No events were reported in either review, both of which were rated as providing very low‐certainty evidence, and we were unable to estimate a relative risk for death/mortality. </p> </section> <section id="CD012977-sec-0076"> <h4 class="title">Secondary outcome: adverse events (tremor)</h4> <p>Four reviews presented a total of six comparisons related to tremor (<a href="#CD012977-tbl-0010">Table 10</a>). Comparisons ranged from 29 participants in a single RCT to a total of 524 participants in nine RCTs. </p> <section id="CD012977-sec-0077"> <h5 class="title">Inhaled treatment</h5> <p>The review on continuous nebulised versus intermittent nebulised beta<sub>2</sub>‐agonists identified a single RCT showing low‐certainty evidence suggesting an unclear effect on tremor (RR 0.56, 95% CI 0.21 to 1.49; 70 participants) (<a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a>). </p> <p>The review on anticholinergic agents added to SABAs for initial treatment of asthma showed moderate‐certainty evidence for a reduction in the risk of tremor when use of anticholinergic medication was compared to use of SABAs alone (RR 0.69, 95% CI 0.51 to 0.93; 524 participants; 9 trials). </p> </section> <section id="CD012977-sec-0078"> <h5 class="title">Parenteral treatment</h5> <p>A review assessing the effectiveness of intravenous aminophylline presented very low‐certainty evidence of an unclear effect on tremor between treatment groups (RR 1.35, RR 0.88 to 2.07; 192 participants; 2 trials) (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>). Subgroup analysis by mean theophylline levels demonstrated similar results. </p> <p>The review comparing intravenous aminophylline to intravenous beta<sub>2</sub>‐agonists presented low‐certainty evidence suggesting an unclear difference between treatment groups (RR 1.85, 95% CI 0.89 to 3.83; 29 participants; 1 trial) (<a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a>). </p> </section> <section id="CD012977-sec-0079"> <h5 class="title">Interventions to reduce the work of breathing</h5> <p>No reviews reported tremor as an outcome.</p> </section> <section id="CD012977-sec-0080"> <h5 class="title">Other intervention</h5> <p>No reviews reported tremor as an outcome.</p> </section> </section> <section id="CD012977-sec-0081"> <h4 class="title">Secondary outcome: adverse events (nausea and/or vomiting)</h4> <p>Four reviews presented a total of nine comparisons related to nausea and/or vomiting (<a href="#CD012977-tbl-0010">Table 10</a>). Comparisons ranged from 29 participants within a single RCT to a total of 1330 participants in eight RCTs. </p> <section id="CD012977-sec-0082"> <h5 class="title">Inhaled treatment</h5> <p>The review on continuous nebulised versus intermittent nebulised beta<sub>2</sub>‐agonists identified a single RCT showing very low‐certainty evidence for an unclear effect on nausea/vomiting (RR 0.20, 95% CI 0.01 to 4.02; 70 participants) (<a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a>). </p> <p>The review on anticholinergic agents added to SABAs for initial treatment of asthma presented separate results for nausea and vomiting (<a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a>). The addition of anticholinergic treatment did not affect the incidence of vomiting (RR 0.88, 95% CI 0.49 to 1.56; 1230 participants; 8 trials; low‐certainty evidence), although the risk of nausea was reduced (RR 0.60, 95% CI 0.38 to 0.95; 757 participants; 7 trials; high‐certainty evidence). </p> </section> <section id="CD012977-sec-0083"> <h5 class="title">Parenteral treatment</h5> <p>The review assessing effectiveness of intravenous aminophylline presented data on vomiting for all patients, as well as subgroup analysis according to mean theophylline levels (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>). All comparisons yielded moderate‐certainty evidence of increased risk of vomiting for participants randomised to theophylline (RR 3.69, 95% CI 2.15 to 6.33; 305 participants; 5 trials), regardless of whether the mean theophylline level was &lt; 15 mg/L (RR 2.73, 95% CI 1.17 to 6.39) or ≥ 15 mg/L (RR 4.43, 95% CI 2.19 to 8.95; 163 participants; 1 trial). </p> <p>The review comparing intravenous aminophylline to intravenous beta<sub>2</sub>‐agonists presented low‐certainty evidence suggesting that aminophylline administration led to increased risk for nausea (RR 2.22, 95% CI 0.98 to 4.99; 29 participants; 1 trial) and nausea/vomiting (RR 19.00, 95% CI 1.15 to 313.64; 66 participants; 1 trial) (<a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a>). The risk for vomiting alone was not significantly different (RR 1.58, 95% CI 0.82 to 3.07; 29 participants; 1 trial). </p> </section> <section id="CD012977-sec-0084"> <h5 class="title">Interventions to reduce the work of breathing</h5> <p>No reviews reported nausea/vomiting as an outcome.</p> </section> <section id="CD012977-sec-0085"> <h5 class="title">Other intervention</h5> <p>No reviews reported nausea/vomiting as an outcome.</p> </section> </section> <section id="CD012977-sec-0086"> <h4 class="title">Secondary outcome: cardiovascular adverse events (hypotension, flushing, palpitations, arrhythmia) </h4> <p>Three reviews presented a total of five comparisons related to cardiovascular adverse events, including hypotension, flushing, palpitations, dysrhythmia, and arrhythmia (<a href="#CD012977-tbl-0010">Table 10</a>). Comparisons ranged from 29 participants from a single RCT to 507 participants from a single RCT. </p> <section id="CD012977-sec-0087"> <h5 class="title">Inhaled treatment</h5> <p>The review comparing inhaled magnesium sulfate and SABA to inhaled SABA alone (507 participants; 1 trial) provided low‐certainty evidence suggesting an unclear effect on hypotension (RR 0.51, 95% CI 0.05 to 5.54; 507 participants; 1 trial) or flushing (RR 0.67, 95% CI 0.11 to 4.00) (<a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>). </p> </section> <section id="CD012977-sec-0088"> <h5 class="title">Parenteral treatment</h5> <p>The review assessing the effectiveness of aminophylline in addition to SABA and systemic steroids presented very low‐certainty evidence suggesting an unclear effect on arrhythmia compared to SABA and systemic steroids alone (RR 0.40, 95% CI 0.02 to 9.12; 75 participants; 2 trials) (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>). </p> <p>The review comparing intravenous beta<sub>2</sub>‐agonists to intravenous aminophylline presented low‐certainty evidence suggesting an unclear effect on dysrhythmia (RR 0.17, 95% CI 0.01 to 3.08; 29 participants; 1 trial) (<a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a>). This review was unable to provide an estimate for the risk of palpitations, as none were identified in either treatment group in the single trial (29 participants) included. </p> </section> <section id="CD012977-sec-0089"> <h5 class="title">Interventions to reduce the work of breathing</h5> <p>No reviews reported cardiovascular adverse events as an outcome.</p> </section> <section id="CD012977-sec-0090"> <h5 class="title">Other intervention</h5> <p>No reviews reported cardiovascular adverse events as an outcome.</p> </section> </section> <section id="CD012977-sec-0091"> <h4 class="title">Secondary outcome: neurological adverse events (headache and seizures)</h4> <p>Two reviews presented data on seizures and/or headaches (<a href="#CD012977-tbl-0010">Table 10</a>). Comparisons ranged from 29 participants from a single RCT to 274 participants from four RCTs. </p> <section id="CD012977-sec-0092"> <h5 class="title">Inhaled treatment</h5> <p>No reviews reported neurological adverse events as an outcome.</p> </section> <section id="CD012977-sec-0093"> <h5 class="title">Parenteral treatment: headache</h5> <p>The review assessing the effectiveness of aminophylline in addition to SABA and systemic steroids presented very low‐certainty evidence suggesting an unclear effect on headache compared to SABA and systemic steroids alone (RR 1.28, 95% CI 0.70 to 2.33; 238 participants; 3 trials) (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>). Subgroup analysis according to mean theophylline levels provided similar results. </p> <p>The review comparing intravenous beta<sub>2</sub>‐agonists to intravenous aminophylline presented low‐certainty evidence suggesting an unclear effect on headache (RR 1.23, 95% CI 0.30 to 5.11; 29 participants; 1 trial) (<a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a>). </p> </section> <section id="CD012977-sec-0094"> <h5 class="title">Parenteral treatment: seizures</h5> <p>The review assessing the effectiveness of aminophylline in addition to SABA and systemic steroids presented very low‐certainty evidence suggesting an unclear effect on seizures compared to SABA and systemic steroids alone (RR 1.01, 95% CI 0.06 to 15.91; 274 participants; 4 trials) (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>). Subgroup analysis according to mean theophylline levels was not estimable in those with a mean theophylline level &lt; 15 mg/L due to no events in either treatment group, and the analysis of those with mean theophylline levels ≥ 15 mg/L provided similar results to the overall comparison. </p> </section> <section id="CD012977-sec-0095"> <h5 class="title">Interventions to reduce the work of breathing</h5> <p>No reviews reported neurological adverse events as an outcome.</p> </section> <section id="CD012977-sec-0096"> <h5 class="title">Other intervention</h5> <p>No reviews reported neurological adverse events as an outcome.</p> </section> </section> <section id="CD012977-sec-0097"> <h4 class="title">Secondary outcome: adverse events (pneumonia)</h4> <p>A single review on the use of non‐invasive positive‐pressure ventilation presented information on the risk for pneumonia (<a href="#CD012977-tbl-0010">Table 10</a>). </p> <section id="CD012977-sec-0098"> <h5 class="title">Inhaled treatment</h5> <p>No reviews reported pneumonia as an outcome.</p> </section> <section id="CD012977-sec-0099"> <h5 class="title">Parenteral treatment</h5> <p>No reviews reported pneumonia as an outcome.</p> </section> <section id="CD012977-sec-0100"> <h5 class="title">Interventions to reduce the work of breathing</h5> <p>A review on the addition of non‐invasive positive‐pressure ventilation was unable to estimate the risk of pneumonia because no events occurred in either treatment group (19 participants; 1 trial) (<a href="./references#CD012977-bbs2-0006" title="KorangSK , FeinbergJ , WetterslevJ , JakobsenJC . Non-invasive positive pressure ventilation for acute asthma in children. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012067. [DOI: 10.1002/14651858.CD012067.pub2]">Korang 2016</a>). </p> </section> <section id="CD012977-sec-0101"> <h5 class="title">Other intervention</h5> <p>No reviews reported pneumonia as an outcome.</p> </section> </section> <section id="CD012977-sec-0102"> <h4 class="title">Secondary outcome: changes in laboratory results</h4> <p>One review comparing intravenous beta<sub>2</sub>‐agonists versus intravenous aminophylline presented four comparisons related to laboratory results (<a href="#CD012977-tbl-0010">Table 10</a>) (<a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a>). Three comparisons were from a single RCT involving 29 participants, and the other comparison involved 95 participants from two RCTs. </p> <section id="CD012977-sec-0103"> <h5 class="title">Inhaled treatment</h5> <p>No reviews reported changes in laboratory results as an outcome.</p> </section> <section id="CD012977-sec-0104"> <h5 class="title">Parenteral treatment</h5> <p>The review comparing intravenous beta<sub>2</sub>‐agonists to intravenous aminophylline presented low‐certainty evidence suggesting an unclear effect on creatine phosphokinase (CPK) elevation (RR 1.54, 95% CI 0.52 to 4.59; 29 participants; 1 trial), CPK‐myocardial band (CPK‐MB) elevation (RR 2.46, 95% CI 0.25 to 24.21; 29 participants; 1 trial), and hypokalaemia (RR 1.04, 95% CI 0.48 to 2.25; 95 participants; 2 trials) (<a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a>). This review presented high‐certainty evidence showing an unclear difference in hyperglycaemia (RR 0.92, 95% CI 0.75 to 1.12; 29 participants; 1 trial). </p> </section> <section id="CD012977-sec-0105"> <h5 class="title">Interventions to reduce the work of breathing</h5> <p>No reviews reported changes in laboratory results as an outcome.</p> </section> <section id="CD012977-sec-0106"> <h5 class="title">Other intervention</h5> <p>No reviews reported changes in laboratory results as an outcome.</p> </section> </section> <section id="CD012977-sec-0107"> <h4 class="title">Secondary outcome: symptom scores/clinical asthma scores</h4> <p>Nine reviews presented a total of 17 comparisons related to symptom scores/clinical asthma scores (<a href="#CD012977-tbl-0011">Table 11</a>). Comparisons ranged from 19 participants within a single RCT to 934 participants in three RCTs. </p> <section id="CD012977-sec-0108"> <h5 class="title">Inhaled treatment</h5> <p>The review on continuous nebulised versus intermittent nebulised beta<sub>2</sub>‐agonists identified a single RCT showing low‐certainty evidence suggesting the benefit of continuous therapy (standardised mean difference (SMD) 0.66, 95% CI 0.18 to 1.14; 70 participants; 1 trial) (<a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a>). </p> <p>The review on anticholinergic agents added to SABAs for initial treatment of asthma identified three RCTs showing moderate‐certainty evidence for a small benefit when anticholinergic agents were added compared to SABAs alone (SMD ‐0.23, 95% CI ‐0.42 to ‐0.04; 934 participants; 3 trials) (<a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a>). However anticholinergic agents added to SABAs in children admitted to hospital with asthma showed low‐certainty evidence of no change in asthma scores compared to SABA treatment alone (SMD 0.02, 95% CI ‐0.34 to 0.38; 117 participants; 2 trials) (<a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>). </p> <p>The addition of inhaled magnesium to SABA and ipratropium yielded moderate‐certainty evidence of an unclear effect on the Yung asthma severity score at 60 minutes compared to SABA and ipratropium alone (MD ‐0.23, 95% CI ‐0.48 to 0.02; 472 participants; 1 trial) (<a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>). </p> </section> <section id="CD012977-sec-0109"> <h5 class="title">Parenteral treatment</h5> <p>The review assessing the effectiveness of intravenous aminophylline presented data on asthma scores at 6 to 8 hours, at 12 to 18 hours, and at 24 hours after study enrolment (very low‐ to low‐certainty evidence) (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>). Subgroup analysis was also performed according to the dosing of inhaled beta<sub>2</sub>‐agonists (submaximal and maximal doses), and whether or not anticholinergic medications were also administered. Addition of aminophylline reduced symptom scores overall at 6 to 8 hours after enrolment (SMD ‐0.42, 95% CI ‐0.70 to ‐0.13; 215 participants; 3 trials); all subgroups suggested a similar direction of effect, although this was statistically significant only in the subgroup that included combined maximised inhaled beta<sub>2</sub>‐agonist and anticholinergic treatment (SMD ‐0.45, 95% CI ‐0.77 to ‐0.13; 155 participants; 1 trial). Very low‐ and low‐certainty evidence suggests no effect of aminophylline at 12 to 18 hours after enrolment (SMD ‐0.45, 95% CI ‐1.09 to 0.19; 39 participants; 1 trial) nor at 24 hours after enrolment (SMD ‐0.13, 95% CI ‐0.52 to 0.25; 127 participants; 1 trial). </p> <p>The review assessing use of intravenous ketamine provided moderate‐certainty evidence that ketamine had an unclear effect on the Pulmonary Index score (MD 0.40, 95% CI ‐1.21 to 0.41; 68 participants; 1 trial) (<a href="./references#CD012977-bbs2-0004" title="JatKR , ChawlaD . Ketamine for management of acute exacerbations of asthma in children. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD009293. [DOI: 10.1002/14651858.CD009293.pub2]">Jat 2012</a>). </p> </section> <section id="CD012977-sec-0110"> <h5 class="title">Interventions to reduce the work of breathing</h5> <p>Low‐certainty evidence suggests that the use of heliox had no clear effect on asthma symptom scores (MD ‐0.51, 95% CI ‐1.14 to 0.11; 93 participants; 3 trials) (<a href="./references#CD012977-bbs2-0009" title="RodrigoG , PollackC , RodrigoC , RoweBH . Heliox for nonintubated acute asthma patients. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD002884. [DOI: 10.1002/14651858.CD002884.pub2]">Rodrigo 2006</a>). </p> <p>The use of non‐invasive positive‐pressure ventilation resulted in moderate‐certainty evidence of a reduction in asthma symptom score in the acute phase (MD ‐2.50, 95% CI ‐4.70 to ‐0.30; 19 participants; 1 trial) (<a href="./references#CD012977-bbs2-0006" title="KorangSK , FeinbergJ , WetterslevJ , JakobsenJC . Non-invasive positive pressure ventilation for acute asthma in children. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012067. [DOI: 10.1002/14651858.CD012067.pub2]">Korang 2016</a>). </p> </section> <section id="CD012977-sec-0111"> <h5 class="title">Other interventions</h5> <p>The review on the use of leukotriene receptor antagonists (LTRAs) provided high‐certainty evidence of a change in the Pulmonary Index score at final assessment (MD ‐1.20, 95% CI ‐1.37 to ‐1.03; 50 participants; 1 trial) for those administered an oral LTRA (<a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a>). </p> </section> </section> <section id="CD012977-sec-0112"> <h4 class="title">Secondary outcome: lung function</h4> <p>Eight reviews presented a total of 41 comparisons related to a variety of lung function tests including peak expiratory flow rate (PEFR), change from baseline in forced expiratory volume in 1 second (FEV1), change in respiratory resistance, and pulmonary function at various time points after enrolment (<a href="#CD012977-tbl-0012">Table 12</a>). Comparisons ranged from two participants within a single RCT to 402 participants in five RCTs. </p> <section id="CD012977-sec-0113"> <h5 class="title">Inhaled treatment</h5> <p>The review on continuous nebulised versus intermittent nebulised beta<sub>2</sub>‐agonists identified a single RCT showing low‐certainty evidence of an unclear effect on PEFR values at the end of the RCT (SMD 0.25, 95% CI ‐0.22 to 0.72; 70 participants; 1 trial) (<a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a>). </p> <p>The review on anticholinergic agents added to SABAs for initial treatment of asthma presented a number of subgroup comparisons (<a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a>). Moderate‐certainty evidence showed a change from baseline in percentage of predicted FEV1 at 60 minutes (MD 10.08, 95% CI 6.24 to 13.92; 402 participants; 5 trials) and at 120 minutes (MD 6.87, 95% CI 1.17 to 12.56; 117 participants; 2 trials) after the last dose of inhaled bronchodilator. The review also presented low‐certainty evidence suggesting a difference in percentage change in FEV1 or PEFR at 60 minutes after the last dose of inhaled bronchodilator (SMD 0.57, 95% CI 0.25 to 0.88; 166 participants; 4 trials). An unclear effect on the percentage change in respiratory resistance from baseline measured at 60 minutes or 120 minutes after the last inhaled bronchodilator was noted, regardless of the relative timing of corticosteroids. </p> <p>When anticholinergic agents were tested in children admitted to hospital with asthma (<a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>), low‐certainty evidence suggested an unclear effect on percentages of predicted PEFR at 8 to 36 hours after identification of initial treatment (MD ‐1.60, 95% CI ‐17.20 to 14.00; 20 participants; 1 trial). </p> <p>Inhaled magnesium did not appear to significantly alter the percentage of predicted FEV1 (MD 8.10, 95% CI ‐3.03 to 19.23; 62 participants; 1 trial; low‐certainty evidence) or peak expiratory flow rates (MD 11.90, 95% CI ‐6.86 to 30.66; 80 participants; 1 trial; low‐certainty evidence) (<a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>). </p> </section> <section id="CD012977-sec-0114"> <h5 class="title">Parenteral treatment</h5> <p>The review assessing the effectiveness of intravenous aminophylline presented 23 comparisons relating to lung function tests: 14 relating to FEV1 and 9 to PEFR (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>). </p> <p>At 6 to 8 hours after enrolment, moderate‐certainty evidence showed improvement in the percentage of predicted FEV1 for all patients (MD 8.37, 95% CI 0.82 to 15.92; 65 participants; 3 trials). Similar findings were seen at 12 to 18 hours and at 24 hours after enrolment. </p> <p>Changes in PEF were also assessed at 6 to 8 hours after enrolment, at 12 to 18 hours after enrolment, and at 24 hours after enrolment. At 6 to 8 hours after enrolment, low‐certainty evidence suggested a change in PEFR for all patients (SMD 0.92, 95% CI 0.32 to 1.52; 50 participants; 2 trials). Similar findings were seen at 12 to 18 hours. At 24 hours, low‐certainty evidence suggested a change when SABAs were combined with inhaled anticholinergic medication (SMD 0.66, 95% CI 0.01 to 1.31; 39 participants; 1 trial). </p> </section> <section id="CD012977-sec-0115"> <h5 class="title">Interventions to reduce the work of breathing</h5> <p>Low‐certainty evidence suggests that use of heliox had an unclear effect on pulmonary function (SMD 0.32, 95% CI ‐0.52 to 1.16; 22 patients; 1 trial) (<a href="./references#CD012977-bbs2-0009" title="RodrigoG , PollackC , RodrigoC , RoweBH . Heliox for nonintubated acute asthma patients. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD002884. [DOI: 10.1002/14651858.CD002884.pub2]">Rodrigo 2006</a>). </p> </section> <section id="CD012977-sec-0116"> <h5 class="title">Other intervention</h5> <p>A review on the use of LTRAs resulted in high‐certainty evidence of no significant change in FEV1 for intravenous LTRA therapy (MD 0.01, 95% CI ‐0.06 to 0.08; 276 participants; 1 trial) and moderate‐certainty evidence showing an unclear effect on FEV1 for oral LTRA therapy (MD ‐3.10, 95% CI ‐12.70 to 6.50; 26 participants; 1 trial) (<a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a>). </p> <p>Low‐certainty evidence from the review on antibiotics versus placebo suggested an unclear effect on PEFR (MD 38.80, 95% CI ‐11.19 to 88.79; 40 participants; 1 trial) (<a href="./references#CD012977-bbs2-0008" title="NormansellR , SayerB , WatersonS , DennettEJ , Del FornoM , DunleavyA . Antibiotics for exacerbations of asthma. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD002741. [DOI: 10.1002/14651858.CD002741.pub2]">Normansell 2018</a>). </p> </section> </section> <section id="CD012977-sec-0117"> <h4 class="title">Secondary outcome: vital signs</h4> <p>Five reviews presented seven comparisons related to vital signs (<a href="#CD012977-tbl-0013">Table 13</a>; <a href="#CD012977-tbl-0014">Table 14</a>). Comparisons ranged from two participants in a single RCT to 416 participants in two RCTs. </p> <section id="CD012977-sec-0118"> <h5 class="title">Inhaled treatment</h5> <p>The review on anticholinergic agents added to SABAs for initial treatment of asthma presented moderate‐certainty evidence showing lower risk of oxygen saturation &lt; 95% at 60 minutes (± 15 minutes) after study commencement (RR 0.73, 95% CI 0.55 to 0.97; 416 participants; 2 trials) and very low‐certainty evidence suggesting an unclear effect on the proportion of participants with oxygen saturation &lt; 95% at 120 minutes (± 15 minutes) after study commencement (RR 1.10, 95% CI 0.76 to 1.59; 185 participants; 2 trials) (<a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a>). </p> </section> <section id="CD012977-sec-0119"> <h5 class="title">Parenteral treatment</h5> <p>The review comparing the addition of intravenous beta<sub>2</sub>‐agonists to inhaled beta<sub>2</sub>‐agonists presented moderate‐certainty evidence showing an unclear effect on pulse rate at two hours (MD 10.00, 95% CI ‐1.07 to 21.07; 29 participants; 1 trial) (<a href="./references#CD012977-bbs2-0010" title="TraversAH , MilanSJ , JonesAP , Camargo CA Jr, RoweBH . Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010179. [DOI: 10.1002/14651858.CD010179]">Travers 2012a</a>). </p> </section> <section id="CD012977-sec-0120"> <h5 class="title">Interventions to reduce the work of breathing</h5> <p>Low‐certainty evidence suggests that the use of heliox had no effect on heart rate (MD 0.0, 95% CI ‐13.80 to 13.80) nor on oxygen saturation (MD 0.0, 95% CI ‐2.51 to 2.51) compared to placebo (22 participants; 1 trial) (<a href="./references#CD012977-bbs2-0009" title="RodrigoG , PollackC , RodrigoC , RoweBH . Heliox for nonintubated acute asthma patients. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD002884. [DOI: 10.1002/14651858.CD002884.pub2]">Rodrigo 2006</a>). </p> </section> <section id="CD012977-sec-0121"> <h5 class="title">Other intervention</h5> <p>The review on the use of LTRAs yielded high‐certainty evidence showing a reduction in the respiratory rate at final assessment (MD ‐4.60, 95% CI ‐6.84 to ‐2.36; 50 participants; 1 trial) for those administered an oral LTRA (<a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a>). </p> </section> </section> <section id="CD012977-sec-0122"> <h4 class="title">Secondary outcome: mechanical ventilation in the intensive care unit</h4> <p>A single review assessed the rates of patients receiving mechanical ventilation in the intensive care unit (<a href="#CD012977-tbl-0015">Table 15</a>). </p> <section id="CD012977-sec-0123"> <h5 class="title">Inhaled treatment</h5> <p>No reviews reported mechanical ventilation in the intensive care unit as an outcome.</p> </section> <section id="CD012977-sec-0124"> <h5 class="title">Parenteral treatment</h5> <p>The review assessing the effectiveness of aminophylline presented very low‐certainty evidence suggesting an unclear effect on rates of patients mechanically ventilated in the intensive care unit (RR 0.09, 95% CI 0.01 to 1.64; 163 participants; 1 trial) (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>). </p> </section> <section id="CD012977-sec-0125"> <h5 class="title">Interventions to reduce the work of breathing</h5> <p>No reviews reported mechanical ventilation in the intensive care unit as an outcome.</p> </section> <section id="CD012977-sec-0126"> <h5 class="title">Other intervention</h5> <p>No reviews reported mechanical ventilation in the intensive care unit as an outcome.</p> </section> </section> <section id="CD012977-sec-0127"> <h4 class="title">Secondary outcome: clinical failure</h4> <p>Clinical failure was presented for two reviews, both for parenteral treatment (<a href="#CD012977-tbl-0016">Table 16</a>). There were no comparisons for inhaled treatment, interventions to reduce the work of breathing, or other interventions. </p> <section id="CD012977-sec-0128"> <h5 class="title">Inhaled treatment</h5> <p>No reviews reported clinical failure as an outcome.</p> </section> <section id="CD012977-sec-0129"> <h5 class="title">Parenteral treatment</h5> <p>The review comparing intravenous beta<sub>2</sub>‐agonists to intravenous aminophylline presented low‐certainty evidence suggesting an unclear effect on clinical failure (RR 1.00, 95% CI 0.48 to 2.08; 66 participants; 1 trial) (<a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a>). </p> <p>The review comparing the addition of intravenous beta<sub>2</sub>‐agonists to inhaled beta<sub>2</sub>‐agonists presented moderate‐certainty evidence of a reduction in clinical failure with the addition of intravenous beta<sub>2</sub>‐agonists (RR 0.38, 95% CI 0.19 to 0.78; 29 participants; 1 trial) (<a href="./references#CD012977-bbs2-0010" title="TraversAH , MilanSJ , JonesAP , Camargo CA Jr, RoweBH . Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010179. [DOI: 10.1002/14651858.CD010179]">Travers 2012a</a>). </p> </section> <section id="CD012977-sec-0130"> <h5 class="title">Interventions to reduce the work of breathing</h5> <p>No reviews reported clinical failure as an outcome.</p> </section> <section id="CD012977-sec-0131"> <h5 class="title">Other intervention</h5> <p>No reviews reported clinical failure as an outcome.</p> </section> </section> <section id="CD012977-sec-0132"> <h4 class="title">Secondary outcome: relapse/return to ED</h4> <p>Four reviews each presented a single comparison related to relapse/return to the ED, although this was defined differently for each review (<a href="#CD012977-tbl-0017">Table 17</a>). Comparisons ranged from 22 participants in a single RCT to 1389 participants in ten RCTs. </p> <section id="CD012977-sec-0133"> <h5 class="title">Inhaled treatment</h5> <p>The addition of anticholinergic agents to inhaled beta<sub>2</sub>‐agonists yielded low‐certainty evidence suggesting an unclear effect on the risk of relapse (RR 1.07, 95% CI 0.68 to 1.68; 1389 participants; 10 trials) (<a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a>). </p> <p>The review on anticholinergic agents for children admitted to hospital was unable to estimate the risk of relapse within 72 hours of discharge from hospital because no events occurred in either treatment group (80 participants; 1 trial) (<a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>). </p> </section> <section id="CD012977-sec-0134"> <h5 class="title">Parenteral treatment</h5> <p>The review on intravenous magnesium sulfate demonstrated low‐certainty evidence suggesting an unclear effect on risk of return to the ED within 48 hours (RR 0.41, 95% CI 0.02 to 9.71; 85 participants; 2 trials) (<a href="./references#CD012977-bbs2-0003" title="GriffithsB , KewKM . Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD011050. [DOI: 10.1002/14651858.CD011050.pub2]">Griffiths 2016</a>) . </p> </section> <section id="CD012977-sec-0135"> <h5 class="title">Interventions to reduce the work of breathing</h5> <p>No reviews reported relapse/return to ED as an outcome.</p> </section> <section id="CD012977-sec-0136"> <h5 class="title">Other intervention</h5> <p>A review on the use of LTRAs presented low‐certainty evidence suggesting an unclear effect on relapse within seven days (RR 0.39, 95% CI 0.02 to 8.73; 22 participants; 1 trial) when oral LTRAs were compared to control (<a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a>). </p> </section> </section> <section id="CD012977-sec-0137"> <h4 class="title">Secondary outcome: withdrawals</h4> <p>Four reviews presented a total of 1 comparisons related to treatment withdrawals (<a href="#CD012977-tbl-0018">Table 18</a>). Comparisons ranged from 143 participants in two RCTs to 371 participants in seven RCTs. No data were presented for interventions to reduce the work of breathing. </p> <section id="CD012977-sec-0138"> <h5 class="title">Inhaled treatment</h5> <p>The review on anticholinergic agents in children admitted to hospital presented low‐certainty evidence suggesting an unclear effect on overall withdrawals (RR 0.62, 95% CI 0.31 to 1.26; 294 participants; 2 trials) and very low‐certainty evidence suggesting an unclear effect on withdrawals due to deterioration (RR 2.04, 95% CI 0.38 to 10.89; 210 participants; 1 trial) (<a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>). </p> </section> <section id="CD012977-sec-0139"> <h5 class="title">Parenteral treatment</h5> <p>The review assessing effectiveness of intravenous aminophylline presented seven comparisons related to withdrawals (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>). Moderate‐certainty evidence showed an unclear effect on withdrawals due to any cause (RR 1.65, 95% CI 0.67 to 4.07; 371 participants; 7 trials). Very low‐certainty evidence was provided for all other comparisons, including withdrawals due to adverse health effects and withdrawals due to poor asthma control (both overall and subgrouped by mean theophylline levels). </p> </section> <section id="CD012977-sec-0140"> <h5 class="title">Interventions to reduce the work of breathing</h5> <p>No reviews reported withdrawals as an outcome.</p> </section> <section id="CD012977-sec-0141"> <h5 class="title">Other intervention</h5> <p>The review on the use of LTRAs presented low‐certainty evidence suggesting an unclear effect on withdrawals for both oral LTRA and control (RR 1.00, 95% CI 0.16 to 6.34; 143 participants; 2 trials) and intravenous LTRA versus control (RR 1.13, 95% CI 0.31 to 4.12; 276 participants; 1 trial) (<a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a>). </p> </section> </section> <section id="CD012977-sec-0142"> <h4 class="title">Secondary outcome: other measures of treatment effect</h4> <p>Six reviews presented a total of eight comparisons related to other diverse measures of treatment effect, including three with continuous outcomes (<a href="#CD012977-tbl-0019">Table 19</a>) and five with dichotomous outcomes (<a href="#CD012977-tbl-0020">Table 20</a>). Comparisons ranged from 27 participants in a single RCT to 1074 participants in nine RCTs. </p> <section id="CD012977-sec-0143"> <h5 class="title">Inhaled treatment</h5> <p>The review on anticholinergic agents added to SABAs for initial treatment of asthma identified nine studies showing moderate‐certainty evidence for a small benefit of the addition of anticholinergic agents in terms of the need for repeat bronchodilator treatment after standard protocol prior to disposition (RR 0.87, 95% CI 0.79 to 0.97; 1074 participants; 9 trials) and an unclear effect on the need for corticosteroids in the ED prior to disposition (RR 0.89, 95% CI 0.73 to 1.08; 378 participants; 2 trials) (<a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a>). </p> <p>The review on anticholinergic agents for children admitted to hospital presented low‐certainty evidence suggesting an unclear effect on the need for supplemental asthma therapy (RR 0.77, 95% CI 0.41 to 1.42; 465 participants; 4 trials) and an unclear effect on the time to SABA spaced at four hours or longer (MD ‐2.17, 95% CI ‐7.01 to 2.66; 290 participants; 2 trials) (<a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>). </p> <p>The review on continuous nebulisation of SABA compared to intermittent nebulisation of SABA demonstrated moderate‐certainty evidence showing a reduction in respiratory therapist time (MD ‐22.00, 95% CI ‐26.82 to ‐17.18; 70 participants; 1 trial) favouring continuous nebulisation (<a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a>). </p> </section> <section id="CD012977-sec-0144"> <h5 class="title">Parenteral treatment</h5> <p>The addition of intravenous aminophylline to inhaled SABA and systemic corticosteroids demonstrated moderate‐certainty evidence showing an unclear effect on the number of nebulisers required in 24 hours (MD 0.15, 95% CI ‐0.52 to 0.83; 69 participants; 1 trial) (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>). </p> <p>The review on intravenous ketamine yielded low‐certainty evidence suggesting an unclear effect on the rate of participants worsening and requiring other adjuvant therapy (RR 2.12, 95% CI 0.2 to 22.31; 68 participants; 1 trial) (<a href="./references#CD012977-bbs2-0004" title="JatKR , ChawlaD . Ketamine for management of acute exacerbations of asthma in children. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD009293. [DOI: 10.1002/14651858.CD009293.pub2]">Jat 2012</a>). </p> </section> <section id="CD012977-sec-0145"> <h5 class="title">Interventions to reduce the work of breathing</h5> <p>No reviews reported other measures of treatment effect as an outcome.</p> </section> <section id="CD012977-sec-0146"> <h5 class="title">Other interventions</h5> <p>The review on the use of LTRAs presented low‐certainty evidence suggesting an unclear effect on the requirement for additional care at the end of the RCT for oral LTRA versus control (RR 0.54, 95% CI 0.05 to 5.60; 50 participants; 1 trial) (<a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012977-sec-0147" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012977-sec-0147"></div> <section id="CD012977-sec-0148"> <h3 class="title" id="CD012977-sec-0148">Summary of main results</h3> <p>In this overview, we examined evidence from published Cochrane Reviews on interventions for escalation of therapy for acute exacerbations of asthma in children. We synthesised the results of published Cochrane Reviews, and we identified significant gaps in a number of clinically important questions. We identified further randomised controlled trials (RCTs) that may be eligible for inclusion in review updates. </p> <p>The primary outcomes of our review were length of stay, emergency department (ED) disposition, and adverse events. </p> <p>Eight of the 13 included reviews provided data on ED or hospital length of stay; the only intervention shown to have a beneficial effect was intravenous magnesium sulfate (reduced hospital length of stay). Neither continuous versus intermittent nebulised short‐acting beta<sub>2</sub>‐agonists (SABAs) nor the addition of intravenous magnesium sulfate was shown to reduce ED treatment time. Moderate‐certainty evidence showed an unclear effect on hospital length of stay with the addition of intravenous beta‐agonists. All other comparisons yielded evidence of low or very low certainty, and fewer than 100 participants were included in all but one comparison; none demonstrated a clear difference in hospital length of stay. </p> <p>Less than half of the included reviews had hospital admission as an included outcome; only three reviews provided information on intensive care unit admission, and none demonstrated a reduction in the risk of intensive care unit admission for any therapy. </p> <p>The risk of hospital admission was reduced by the addition of inhaled anticholinergic agents (particularly in a multiple fixed‐dose protocol) to inhaled beta<sub>2</sub>‐agonists and by the use of intravenous magnesium sulfate. We found low‐certainty evidence for a small beneficial effect on the rate of hospital admission for inhaled heliox and no demonstrable effect on hospital admission for intravenous ketamine or leukotriene receptor antagonists (LTRAs). </p> <p>Only 4 of the 13 included reviews provided information on overall adverse events. Apart from evidence of moderate certainty showing a reduction in overall serious adverse events during hospital admission when inhaled magnesium sulfate was added to usual bronchodilator therapy, there was low‐ or very low‐certainty evidence suggesting an unclear effect on adverse events between treatment groups. </p> <p>Nausea and vomiting were more frequent with aminophylline. The addition of anticholinergic therapy to SABAs appeared to reduce the risk of nausea and tremor but not vomiting. Continuous nebulised SABAs were not associated with higher risk of tremor than intermittent dosing. </p> <p>Secondary outcomes were variably reported in trials included in the reviews. Studies assessing spirometry and symptom scores used different measures, often applied at different times after initiation of study treatment. </p> <p>Inhaled anticholinergics appeared to have a beneficial effect on symptom scores in ED treatment, but not after children had been admitted to hospital. Continuous nebulised SABAs, heliox, non‐invasive positive‐pressure ventilation, and oral LTRAs appeared to slightly improve respiratory scores, and inhaled magnesium and intravenous ketamine did not alter asthma scores. Aminophylline reduced symptom scores at six to eight hours, but this effect was not sustained. </p> <p>Spirometric measures varied between studies, including peak expiratory flow rate (PEFR), forced expiratory volume in one second (FEV1), and changes in respiratory resistance. These measures were recorded at different times in different studies and were presented in various ways including percentage of predicted values and/or change from baseline. Effects of specific therapies appeared to be conflicting and inconclusive, or effects were no different from controls. </p> <p>Many other comparisons reporting no significant evidence of benefit were based on single small trials or unpooled combinations of small trials. Due to lack of clear guidelines on minimal clinically significant differences, the clinical impact of statistically significant differences between comparison groups was unclear for many outcomes. </p> </section> <section id="CD012977-sec-0149"> <h3 class="title" id="CD012977-sec-0149">Overall completeness and applicability of evidence</h3> <p>This overview summarises published Cochrane Reviews of all RCTs examining interventions for escalation of therapy for acute exacerbations of asthma in children. </p> <p>Key findings include the need to update a number of reviews, clinical heterogeneity between RCTs and reviews, and lack of consistent outcome measures between reviews. Clinical heterogeneity was evident with regard to study setting (inpatient units, emergency departments, and intensive care units), definition and assessment of asthma severity at the point of study entry, and inclusion criteria. The difference in response to treatment for young children with viral induced wheeze and asthma is a topic of increasing interest – future RCTs and reviews should specifically address this. </p> <p>Outcome measures were inconsistent, and different measures were used at different times between RCTs and between reviews. </p> <p>Given the wide range of treatment options, the heterogeneity of existing evidence, and gaps in the current literature, it is not surprising that practice varies between clinicians. In the absence of a robust evidence base, guidelines and clinical treatment will continue to be based upon other considerations including clinician experience, cost, adverse effects, and established local practices. </p> <p>A further limitation of the included reviews is that only 3 of the 13 reviews had a date of last search in 2017 or later. </p> </section> <section id="CD012977-sec-0150"> <h3 class="title" id="CD012977-sec-0150">Quality of the evidence</h3> <p>Overall, 4 of the 13 included reviews were considered to be at high risk of bias. In all cases, this was due to concerns regarding identification and selection of studies. </p> <p>The reviews used various tools to assess the risk of bias of included trials. Most assessments included a combination of low and unclear risk of bias. </p> <p>Our assessment of the certainty of evidence varied widely (by review and also by outcome) and ranged from very low to high. </p> </section> <section id="CD012977-sec-0151"> <h3 class="title" id="CD012977-sec-0151">Potential biases in the overview process</h3> <p>We conducted the overview according to the published protocol, and we have highlighted any differences between our published protocol and the overview. </p> <p>We identified potentially eligible reviews by applying the published search terms for each review, screening all titles and abstracts, and adding them to the evidence map (<a href="#CD012977-tbl-0006">Table 6</a>). It is possible that this list is incomplete, and that further comprehensive searches for each systematic review or update would identify additional eligible RCTs. </p> <p>We included only Cochrane Reviews; there may be other systematic reviews on interventions for escalation of therapy for acute exacerbations of asthma in children published outside of the Cochrane Library, but we are unable to comment on that. Results and outcomes reported in non‐Cochrane Reviews may have showed different results. </p> <p>Of greatest concern, the overview results are limited to the internal and external validity of the included reviews and trials. For example, there was a degree of heterogeneity between the various review authors in their application of assessment of the certainty of evidence using the GRADE classification, with similar appearing results rated differently by various review groups. </p> </section> <section id="CD012977-sec-0152"> <h3 class="title" id="CD012977-sec-0152">Agreements and disagreements with other studies or reviews</h3> <p>A 2015 overview of systematic reviews of acute asthma treatment in childhood included 28 systematic reviews on all aspects of acute asthma treatment in children (<a href="./references#CD012977-bbs2-0031" title="Castro-RodriguezJA , RodrigoJG , Rodríguez-MartínezCE . Principal findings of systematic reviews of acute asthma treatment in childhood. Journal of Asthma2015;52(10):1038-45.">Castro‐Rodriguez 2015</a>). The paper included reviews that we excluded, in particular, those related to established treatments such as use of short‐acting bronchodilators and systemic or inhaled corticosteroids. In addition, reviews were included if they included children or a mixed population (adults and children); our review extracted only data for children alone. </p> <p><a href="./references#CD012977-bbs2-0031" title="Castro-RodriguezJA , RodrigoJG , Rodríguez-MartínezCE . Principal findings of systematic reviews of acute asthma treatment in childhood. Journal of Asthma2015;52(10):1038-45.">Castro‐Rodriguez 2015</a> reached similar conclusions compared to our overview: (1) the addition of ipratropium in children with moderate to severe exacerbations reduced hospital admission and improved clinical asthma score; (2) heliox‐driven nebulisers reduced exacerbation severity compared to oxygen‐driven nebulisers; and (3) intravenous magnesium sulfate reduced hospital admissions and improved lung function (<a href="./references#CD012977-bbs2-0031" title="Castro-RodriguezJA , RodrigoJG , Rodríguez-MartínezCE . Principal findings of systematic reviews of acute asthma treatment in childhood. Journal of Asthma2015;52(10):1038-45.">Castro‐Rodriguez 2015</a>). </p> <p>Given the inclusion of systematic reviews addressing both mixed populations and children alone, it is unclear how readily results of the <a href="./references#CD012977-bbs2-0031" title="Castro-RodriguezJA , RodrigoJG , Rodríguez-MartínezCE . Principal findings of systematic reviews of acute asthma treatment in childhood. Journal of Asthma2015;52(10):1038-45.">Castro‐Rodriguez 2015</a> overview may be extrapolated to a paediatric population (i.e. problem with indirectness). </p> <p>A recently published review on the efficacy of macrolide antibiotics for children with an acute exacerbation of asthma/wheeze found no difference in hospitalisation between those given macrolides and those who received placebo (<a href="./references#CD012977-bbs2-0076" title="PincheiraMA , BacharierLB , Castro-RodriguezJA . Efficacy of macrolides on acute asthma or wheezing exacerbations in children with recurrent wheezing: a systematic review and meta-analysis. Pediatric Drugs2020;22:217-28.">Pincheira 2020</a>). The review (3 studies; 334 children) found more rapid resolution of symptoms in two of the three included studies, but review authors were unable to perform a meta‐analysis. Single studies reported reductions in symptom severity, reduced use of salbutamol, and improved lung function. Our overview includes a Cochrane Review on various antibiotics for the treatment of acute asthma (<a href="./references#CD012977-bbs2-0008" title="NormansellR , SayerB , WatersonS , DennettEJ , Del FornoM , DunleavyA . Antibiotics for exacerbations of asthma. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD002741. [DOI: 10.1002/14651858.CD002741.pub2]">Normansell 2018</a>); however, the more recent review differs from this by choice of outcome measure and choice of antibiotics. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012977-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/media/CDSR/CD012977/urn:x-wiley:14651858:media:CD012977:CD012977-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Flow diagram." data-id="CD012977-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012977.pub2/media/CDSR/CD012977/image_n/nCD012977-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/media/CDSR/CD012977/image_t/tCD012977-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/full#CD012977-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/media/CDSR/CD012977/image_n/nCD012977-FIG-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD012977-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Excluded reviews</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Reference</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Title</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Reason for exclusion</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0016" title="RoweBH , BretzlaffJA , BourdonC , BotaGW , Camargo CAJr. Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. Cochrane Database of Systematic Reviews2000, Issue 1. Art. No: CD001490. [DOI: 10.1002/14651858.CD001490]">Rowe 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Magnesium sulfate for treating exacerbations of acute asthma in the emergency department</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Replaced by separate reviews in adults and children, <a href="./references#CD012977-bbs2-0003" title="GriffithsB , KewKM . Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD011050. [DOI: 10.1002/14651858.CD011050.pub2]">Griffiths 2016</a> contains all relevant paediatric trials </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0017" title="TraversA , JonesAP , KellyK , BarkerSJ , CamargoCA , RoweBH . Intravenous beta2-agonists for acute asthma in the emergency department. Cochrane Database of Systematic Reviews2001, Issue 2. Art. No: CD002988. [DOI: 10.1002/14651858.CD002988]">Travers 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intravenous beta2‐agonists for acute asthma in the emergency department</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Replaced by 2 new reviews: "Intravenous beta2‐agonists versus intravenous aminophylline for acute asthma" (<a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a>), and "Addition of intravenous beta2‐agonists for acute asthma" (<a href="./references#CD012977-bbs2-0010" title="TraversAH , MilanSJ , JonesAP , Camargo CA Jr, RoweBH . Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010179. [DOI: 10.1002/14651858.CD010179]">Travers 2012a</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0015" title="ManserR , ReidD , AbramsonM . Corticosteroids for acute severe asthma in hospitalised patients. Cochrane Database of Systematic Reviews2001, Issue 1. Art. No: CD001740. [DOI: 10.1002/14651858.CD001740]">Manser 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Corticosteroids for acute severe asthma in hospitalised patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies where the results for children could be separated from the results for adults </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0014" title="JonesA , RoweB , PetersJ , CamargoC , HammarquistC , RoweB . Inhaled beta-agonists for asthma in mechanically ventilated patients. Cochrane Database of Systematic Reviews2001, Issue 4. Art. No: CD001493. [DOI: 10.1002/14651858.CD001493]">Jones 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled beta2‐agonists for asthma in mechanically ventilated patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trials were included in the review</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Excluded reviews</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/full#CD012977-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012977-tbl-0002"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Review characteristics</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Review ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Date of last search</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Total number of studies (total number of participants)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of studies involving children (number of children in review)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Population</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comparison interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes for which data were reported</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Review limitations</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="9" rowspan="1" scope="col" valign="top"> <p><b>Inhaled treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a> </p> <p>Continuous vs intermittent beta‐agonists for acute asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 March 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (644)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants presenting to an ED (or its equivalent) with acute asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous (defined as 1 nebulisation every 15 minutes or &gt; 4 nebulisations per hour) inhaled beta‐agonist therapy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermittent inhaled beta‐agonist therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ PEFR</p> <p>‐ Admission to hospital</p> <p>‐ ED treatment time</p> <p>‐ Respiratory therapist time</p> <p>‐ Symptom scores</p> <p>‐ Tremor</p> <p>‐ Nausea/vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited paediatric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a> </p> <p>Combined inhaled anticholinergics and short‐acting beta‐agonists for initial treatment of acute asthma in children </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 April 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (2632)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (2632)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged 18 months to 18 years presenting to an ED with an acute exacerbation of asthma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single or repeated doses of nebulised or inhaled short‐acting anticholinergics plus SABAs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single or repeated doses of nebulised or inhaled placebo plus SABAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Hospital admission</p> <p>‐ FEV1</p> <p>‐ PEFR</p> <p>‐ Respiratory resistance</p> <p>‐ Clinical asthma score</p> <p>‐ Need for repeat bronchodilator treatment</p> <p>‐ Oxygen saturation measurements</p> <p>‐ Need for corticosteroids in the ED prior to disposition</p> <p>‐ Tremor</p> <p>‐ Vomiting</p> <p>‐ Nausea</p> <p>‐ Relapse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a> </p> <p>Inhaled anticholinergic and short‐acting beta2‐agonists vs short‐acting beta2‐agonists alone for children with acute asthma in hospital </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>November 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (472)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (472)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children 1 to 18 years of age who were hospitalised for an acute asthma exacerbation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nebulised or inhaled anticholinergics with SABA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nebulised or inhaled SABA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Duration of hospital stay</p> <p>‐ Admission to ICU</p> <p>‐ Need for supplemental asthma therapy</p> <p>‐ Time to SABA spaced at 4 hours or longer</p> <p>‐ Asthma clinical scores</p> <p>‐ Relapse within 72 hours of discharge from hospital</p> <p>‐ Predicted PEFR</p> <p>‐ Adverse health effects</p> <p>‐ Overall withdrawals</p> <p>‐ Withdrawals due to deterioration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a> </p> <p>Inhaled magnesium sulfate in the treatment of acute asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 September 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (3301)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (1247)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients with acute asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Inhaled MgSO4</p> <p>‐ Inhaled MgSO4 and inhaled beta2‐agonist</p> <p>‐ Inhaled MgSO4 and inhaled beta2‐agonist and ipratropium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Inhaled beta2‐agonist</p> <p>‐ Inhaled beta2‐agonist and placebo</p> <p>‐ Inhaled beta2‐agonist and ipratropium and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Clinical severity scores</p> <p>‐ Admission at first presentation</p> <p>‐ Admission to PICU/HDU or intubation</p> <p>‐ Serious adverse events</p> <p>‐ Any adverse event (during admission)</p> <p>‐ Hypotension</p> <p>‐ Flushing</p> <p>‐ Pulmonary function (% predicted FEV1)</p> <p>‐ PEF</p> <p>‐ Admission to hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="" class="headercell" colspan="9" rowspan="1" scope="col" valign="top"> <p><b>Parenteral treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a> </p> <p>Intravenous aminophylline for acute severe asthma in children over 2 years of age receiving inhaled bronchodilators </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>February 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (380)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (380)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged between 2 and 17 years with acute severe asthma or status asthmaticus (acute, severe, refractory exacerbations) attending EDs, or in hospital wards or ICUs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loading dose of IV aminophylline followed by maintenance infusion, intravenous aminophylline boluses, or oral theophylline </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ FEV1</p> <p>‐ Peak flow</p> <p>‐ Oxygenation (SaO2 or PaO2)</p> <p>‐ Supplemental oxygen reduction</p> <p>‐ Change in symptom scores</p> <p>‐ Number of nebulisers required in 24 hours</p> <p>‐ ICU admission rates</p> <p>‐ Rates of patients mechanically ventilated in ICU</p> <p>‐ Length of hospital stay</p> <p>‐ Vomiting</p> <p>‐ Headache</p> <p>‐ Tremor</p> <p>‐ Seizures</p> <p>‐ Hypokalaemia</p> <p>‐ Arrhythmias</p> <p>‐ Blood pressure</p> <p>‐ Magnitude of diuresis</p> <p>‐ Death</p> <p>‐ Withdrawal due to adverse health effects</p> <p>‐ Withdrawal due to poor asthma control</p> <p>‐ Withdrawal (any cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0010" title="TraversAH , MilanSJ , JonesAP , Camargo CA Jr, RoweBH . Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010179. [DOI: 10.1002/14651858.CD010179]">Travers 2012a</a> </p> <p>Addition of intravenous beta2‐agonists to inhaled beta2‐agonists for acute asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>September 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (102)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adult or paediatric patients with severe acute asthma presenting to an emergency department (or its equivalent) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV selective or non‐selective beta1‐ and beta2‐agonists in addition to inhaled beta2‐agonists and existing standards of care </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled beta2‐agonists and standard care alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Length of stay</p> <p>‐ Pulse rate</p> <p>‐ Clinical failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited paediatric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a> </p> <p>Intravenous beta2‐agonists vs intravenous aminophylline for acute asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>September 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (371)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (168)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults and children with severe acute asthma presenting to an ED (or its equivalent) and patients admitted to hospital with acute severe asthma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV beta2‐agonists and standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intravenous aminophylline and standard asthma care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Length of stay</p> <p>‐ Clinical failure</p> <p>‐ CPK elevation</p> <p>‐ CPK‐MB elevation</p> <p>‐ Dysrhythmia</p> <p>‐ Headache</p> <p>‐ Hyperglycaemia</p> <p>‐ Hypokalaemia</p> <p>‐ Palpitations</p> <p>‐ Tremor</p> <p>‐ Nausea/vomiting</p> <p>‐ Nausea</p> <p>‐ Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited paediatric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0003" title="GriffithsB , KewKM . Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD011050. [DOI: 10.1002/14651858.CD011050.pub2]">Griffiths 2016</a> </p> <p>Intravenous magnesium sulfate for treating children with acute asthma in the emergency department </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 February 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (182)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (182)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (18 months to 18 years) treated in the ED for acute asthma (all severities)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any dose of IV MgSO4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Hospital admissions</p> <p>‐ ED treatment time</p> <p>‐ Return to ED within 48 hours</p> <p>‐ Hospital length of stay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited paediatric data, small studies</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0004" title="JatKR , ChawlaD . Ketamine for management of acute exacerbations of asthma in children. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD009293. [DOI: 10.1002/14651858.CD009293.pub2]">Jat 2012</a> </p> <p>Ketamine for management of acute exacerbations of asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 September 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (&lt; 18 years) presenting with an acute asthma exacerbation who had not responded to standard therapy with aerosolised beta2‐agonist, with or without aerosolised anticholinergic drugs and oral or parenteral corticosteroid, for at least 1 hour </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketamine (IM or IV)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Reduction in pulmonary index score</p> <p>‐ Disposition for enrolled patients after study enrolment</p> <p>‐ Side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited paediatric data</p> </td> </tr> <tr> <th align="" class="headercell" colspan="9" rowspan="1" scope="col" valign="top"> <p><b>Interventions to reduce the work of breathing</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0009" title="RodrigoG , PollackC , RodrigoC , RoweBH . Heliox for nonintubated acute asthma patients. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD002884. [DOI: 10.1002/14651858.CD002884.pub2]">Rodrigo 2006</a> </p> <p>Heliox for non‐intubated acute asthma patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 August 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (529)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children or adult patients presenting to an ED or equivalent care settings for treatment of acute asthma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled heliox</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control (oxygen or air)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Pulmonary function</p> <p>‐ Heart rate</p> <p>‐ Oxygen saturations</p> <p>‐ Dyspnoea or pulmonary index</p> <p>‐ Hospital admissions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited paediatric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0006" title="KorangSK , FeinbergJ , WetterslevJ , JakobsenJC . Non-invasive positive pressure ventilation for acute asthma in children. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012067. [DOI: 10.1002/14651858.CD012067.pub2]">Korang 2016</a> </p> <p>Non‐invasive positive‐pressure ventilation for acute asthma in children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>February 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children (aged &lt; 18 years) hospitalised for an asthma attack (as defined by the trialists)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any type of NPPV (including CPAP and BiPAP) as add‐on therapy to usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Mortality</p> <p>‐ Serious adverse events</p> <p>‐ Asthma symptom score</p> <p>‐ Pneumonia</p> <p>‐ Non‐serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited paediatric data</p> </td> </tr> <tr> <th align="" class="headercell" colspan="9" rowspan="1" scope="col" valign="top"> <p><b>Other interventions</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0008" title="NormansellR , SayerB , WatersonS , DennettEJ , Del FornoM , DunleavyA . Antibiotics for exacerbations of asthma. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD002741. [DOI: 10.1002/14651858.CD002741.pub2]">Normansell 2018</a> </p> <p>Antibiotics for exacerbations of asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 October 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (670)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (133)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children and adults who presented to an ED, primary care, outpatient clinics, or inpatient wards with an asthma exacerbation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intravenous or oral antibiotics, given at any dose and for any duration of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo or standard care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Adverse events</p> <p>‐ Serious adverse events</p> <p>‐ Length of hospital stay</p> <p>‐ Peak expiratory flow</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited paediatric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a> </p> <p>Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>February 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (1940)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (470)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children and adults with acute asthma presenting for acute medical care to an ED or equivalent setting </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTRA (oral or IV) and standard care (inhaled beta2‐agonists, systemic corticosteroids ± oxygen, ipratropium bromide) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo and standard care (inhaled beta2‐agonists, systemic corticosteroids ± oxygen, ipratropium bromide) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ Hospital admission</p> <p>‐ Requirement for additional care at end of study</p> <p>‐ Change in FEV1</p> <p>‐ Change in pulmonary index score</p> <p>‐ Change in respiratory rate</p> <p>‐ Withdrawals</p> <p>‐ Relapse (within 7 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>ED: emergency department; PEFR: peak expiratory flow rate; FEV1: forced expiratory volume in one second; SABA: short‐acting beta‐agonist; ICU: intensive care unit; LTRA: leukotriene receptor antagonist; MgSO4: magnesium sulfate; PICU: paediatric intensive care unit; HDU: high‐dependency unit; PEF: peak expiratory flow; IV: intravenous; SaO2: saturation of oxygen; PaO2: arterial pressure of oxygen; CPK: creatine phosphokinase; CPK‐MB: creatine phosphokinase myocardial band; IM: intramuscular; NPPV: non‐invasive positive‐pressure ventilation; CPAP: continuous positive airway pressure; BiPAP: bilevel positive airway pressure. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Review characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/full#CD012977-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012977-tbl-0003"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Evidence map</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Cochrane Review</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of included studies involving children (number of participants)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Potential new studies based on review search strategy</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Overview team recommendations for new Cochrane Reviews, or changes to existing reviews</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Overview team suggested research priorities based on evidence presented in this evidence map</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>Inhaled treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous vs intermittent beta‐agonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0082" title="RoseJ , CancelliereS , MatyeP , O'RiordanM . Comparing a breath-actuated vs a conventional continuous-output nebulizer in treating acute asthma in a pediatric emergency department: an ongoing randomized controlled trial. Academic Emergency Medicine2011;18(5):S83-4.">Rose 2011</a>; <a href="./references#CD012977-bbs2-0083" title="SabatoK , WardP , HawkW , GildengorinV , AsselinJM . Randomized controlled trial of a breath-actuated nebulizer in pediatric asthma patients in the emergency department. Respiratory Care2011;56(6):761-70.">Sabato 2011</a>; <a href="./references#CD012977-bbs2-0094" title="WilkinsonM , KingB , IyerS , HigginbothamE , WallaceA , HovingaC , et al. Comparison of a rapid albuterol pathway with a standard pathway for the treatment of children with a moderate to severe asthma exacerbation in the emergency department. Journal of Asthma2018;55(3):244-51.">Wilkinson 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Update review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compare effectiveness in preschool and older children</p> <p>Develop and use core outcome measures, consistent assessment of asthma severity at study entry, and consistent inclusion criteria in future trials </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Combined inhaled anticholinergics and short‐acting beta‐agonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Emergency department setting</p> <p><a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (2632)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0089" title="SupriyatnoB , HarumdiniM , IndawatiW . The efficacy of adding ipratropium bromide to salbutamol nebulization for mild acute asthma attack in children. Paediatric Respiratory Reviews2012;13:S78.">Supriyatno 2012</a>; <a href="./references#CD012977-bbs2-0086" title="Sengul GokalpA , BicerS , SiraneciR . Efficiacy of nebulized ipratropium bromide in the treatment of acute asthma in children: randomised, double blind, placebo-controlled trial. Nobel Medicus2013;9(1):67-75.">Sengul Gokalp 2013</a>; <a href="./references#CD012977-bbs2-0060" title="MemonBN , ParkashAT , AhmedKKM , Gowa MurtazaA , BaiC . Response to nebulized salbutamol versus combination with ipratropium bromide in children with acute severe asthma. Journal of Pakiston Medical Association2016;66(3):243-6.">Memon 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Update review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compare effectiveness in preschool and older children</p> <p>Develop and use core outcome measures, consistent assessment of asthma severity at study entry, and consistent inclusion criteria in future trials </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient setting</p> <p><a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (472)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0095" title="WyattEL , BorlandML , DoyleSK , GeelhoedGC . Metered-dose inhaler ipratropium bromide in moderate acute asthma in children: a single-blinded randomised controlled trial. Journal of Paediatrics and Child Health2015;51(2):192-8.">Wyatt 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Update review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compare effectiveness in preschool and older children</p> <p>Develop and use core outcome measures, consistent assessment of asthma severity at study entry, and consistent inclusion criteria in future trials </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled magnesium sulfate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (1247)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0063" title="MotamedH , VerkiMM , PooladzadeM , MajidiA . Efficacy evaluation of nebulized magnesium, as an additional complementary treatment, in clinical and peak flow metric improvements of acute asthma attack: a randomized double-blinded clinical trial. Jundishapur Journal of Natural Pharmaceutical Products2017;12:4.">Motamed 2017</a>; <a href="./references#CD012977-bbs2-0064" title="MustafaJ , IqbalSMJ , AzharIA , SultanMA . Nebulized magnesium sulphate as an adjunct therapy in the management of children presenting with acute exacerbation of asthma. Pakistan Journal of Medical and Health Sciences2018;12(2):554‐5.">Mustafa 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Update review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compare effectiveness in preschool and older children</p> <p>Develop and use core outcome measures, consistent assessment of asthma severity at study entry, and consistent inclusion criteria in future trials </p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>Parenteral bronchodilators</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intravenous aminophylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (380)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0065" title="NaaoM , KatsunumaT , KimKC , FujisawaT . Efficacy and safety of intravenous aminophylline in children with acute exacerbation of asthma: a multicenter randomized trial. Journal of Allergy and Clinical Immunology2007;119(1 Suppl 2):8.">Naao 2007</a>; <a href="./references#CD012977-bbs2-0035" title="Chen Z-G, LiM , ChenH , Chen Y-F, Chen F-H, Ji J-Zhi. Efficacy of pulmicort suspension plus salbutamol and ipratropium bromide for management of acute asthma exacerbation in children: a comparative study. Journal of Southern Medical University2008;28(3):470-2.">Chen 2008</a>; <a href="./references#CD012977-bbs2-0038" title="D'AvilaRS , PivaJP , MarosticaPJ , AmanteaSL . Early administration of two intravenous bolus of aminophylline added to the standard treatment of children with acute asthma. Respiratory Medicine2008;102(1):156-61.">D'Avila 2008</a>; <a href="./references#CD012977-bbs2-0088" title="SinghiS , GroverS , BansalA , ChopraK . Randomised comparison of intravenous magnesium sulphate, terbutaline and aminophylline for children with acute severe asthma. Acta Paediatrica2014;103(12):1301-6.">Singhi 2014</a>; <a href="./references#CD012977-bbs2-0090" title="TiwariA , GuglaniV , JatKR . Ketamine versus aminophylline for acute asthma in children: a randomized, controlled trial. Annals of Thoracic Medicine2016;11(4):283-8.">Tiwari 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Update review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compare effectiveness in preschool and older children</p> <p>Develop and use core outcome measures, consistent assessment of asthma severity at study entry, and consistent inclusion criteria in future trials </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Addition of intravenous beta2‐agonists to inhaled beta2‐agonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0010" title="TraversAH , MilanSJ , JonesAP , Camargo CA Jr, RoweBH . Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010179. [DOI: 10.1002/14651858.CD010179]">Travers 2012a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0022" title="AubuchonK , MatsudaK , HouseL , FergusonI , SchneiderJ , LewisL . Increased serum albuterol concentrations may be associated with elevations of serum lactate in subjects with acute asthma exacerbations. Academic Emergency Medicine2012;19:S312‐3.">Aubuchon 2012</a>; <a href="./references#CD012977-bbs2-0084" title="SchneiderJ , MatsudaK , HouseSL , FergusonI , AubuchonK , LewisL . Dyspnea scores may be a better predictor of hospital admissions than FEV1 for patients with acute asthma exacerbations. Academic Emergency Medicine2012;19(s1):S312.">Schneider 2012</a>; <a href="./references#CD012977-bbs2-0048" title="HouseSL , MatsudaK , O'BrienG , MakhayM , IwakiY , FergusonI , et al. Efficacy of a new intravenous β2-adrenergic agonist (bedoradrine, MN-221) for patients with an acute exacerbation of asthma. Respiratory Medicine2015;109(10):1268-73.">House 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Update review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compare effectiveness in preschool and older children</p> <p>Develop and use core outcome measures, consistent assessment of asthma severity at study entry, and consistent inclusion criteria in future trials </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intravenous beta2‐agonists vs intravenous aminophylline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (168)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0088" title="SinghiS , GroverS , BansalA , ChopraK . Randomised comparison of intravenous magnesium sulphate, terbutaline and aminophylline for children with acute severe asthma. Acta Paediatrica2014;103(12):1301-6.">Singhi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Update review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compare effectiveness in preschool and older children</p> <p>Develop and use core outcome measures, consistent assessment of asthma severity at study entry, and consistent inclusion criteria in future trials </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intravenous magnesium sulfate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0003" title="GriffithsB , KewKM . Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD011050. [DOI: 10.1002/14651858.CD011050.pub2]">Griffiths 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (182)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compare effectiveness in preschool and older children</p> <p>Develop and use core outcome measures, consistent assessment of asthma severity at study entry, and consistent inclusion criteria in future trials </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0004" title="JatKR , ChawlaD . Ketamine for management of acute exacerbations of asthma in children. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD009293. [DOI: 10.1002/14651858.CD009293.pub2]">Jat 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compare effectiveness in preschool and older children</p> <p>Develop and use core outcome measures, consistent assessment of asthma severity at study entry, and consistent inclusion criteria in future trials </p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>Interventions to reduce the work of breathing</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heliox</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0009" title="RodrigoG , PollackC , RodrigoC , RoweBH . Heliox for nonintubated acute asthma patients. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD002884. [DOI: 10.1002/14651858.CD002884.pub2]">Rodrigo 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0028" title="BighamMT , JacobsBR , MonacoMA , BrilliRJ , WellsD , ConwayEM , et al. Helium/oxygen-driven albuterol nebulization in the management of children with status asthmaticus: a randomized, placebo-controlled trial. Pediatric Critical Care Medicine2010;11(3):356-61.">Bigham 2010</a>; <a href="./references#CD012977-bbs2-0029" title="BrandãoDC , BrittoMC , PessoaMF , deSá RafaelaB , AlcoforadoL , MatosLO , et al. Heliox and forward-leaning posture improve the efficacy of nebulized bronchodilator in acute asthma: a randomized trial. Respiratory Care2011;56(7):947-52.">Brandão 2011</a>; <a href="./references#CD012977-bbs2-0073" title="OrtizJA , FonsecaJS , Salas-SeguraDA . Use of heliox in moderate and severe asthma attacks in the emergency service Rafael Angel Calderon Guardia Hospital. A prospective study. Revista del Instituto Nacional de Enfermedades Respiratorias2012;71(1):21-8.">Ortiz 2012</a>; <a href="./references#CD012977-bbs2-0061" title="MorimotoK , ShimizuN , SaitoO , KodaniT , IkiY , NagaiY , et al. The impact of heliox on obstructive airway diseases with mechanical ventilation. A pilot study. Pediatric Critical Care Medicine2018;19(6 Suppl 1):46.">Morimoto 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Update review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compare effectiveness in preschool and older children</p> <p>Develop and use core outcome measures, consistent assessment of asthma severity at study entry, and consistent inclusion criteria in future trials </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐invasive positive‐pressure ventilation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0006" title="KorangSK , FeinbergJ , WetterslevJ , JakobsenJC . Non-invasive positive pressure ventilation for acute asthma in children. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012067. [DOI: 10.1002/14651858.CD012067.pub2]">Korang 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0069" title="Navanandan Ni, FedericoM , MistryRD . Positive expiratory pressure for the treatment of acute asthma exacerbations: a randomized controlled trial. Journal of Pediatrics2017;185:149-54.e2.">Navanandan 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Update review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compare effectiveness in preschool and older children</p> <p>Develop and use core outcome measures, consistent assessment of asthma severity at study entry, and consistent inclusion criteria in future trials </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐flow nasal oxygen therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>New review needed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compare effectiveness in preschool and older children</p> <p>Develop and use core outcome measures, consistent assessment of asthma severity at study entry, and consistent inclusion criteria in future trials </p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>Other interventions</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0008" title="NormansellR , SayerB , WatersonS , DennettEJ , Del FornoM , DunleavyA . Antibiotics for exacerbations of asthma. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD002741. [DOI: 10.1002/14651858.CD002741.pub2]">Normansell 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (133)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0057" title="MandhanePJ , Paredes Zambrano de SilbernagelP , AungYN , WilliamsonJ , Lee BonitaE , SpierS , et al. Treatment of preschool children presenting to the emergency department with wheeze with azithromycin: a placebo-controlled randomized trial. PloS One2017;12(8):e0182411.">Mandhane 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Update review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compare effectiveness in preschool and older children</p> <p>Develop and use core outcome measures, consistent assessment of asthma severity at study entry, and consistent inclusion criteria in future trials </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Leukotriene receptor antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (470)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0019" title="AdachiM , TaniguchiH , TohdaY , SanoY , IshineT , SmugarSS , et al. The efficacy and tolerability of intravenous montelukast in acute asthma exacerbations in Japanese patients. Journal of Asthma2012;49(6):649-56.">Adachi 2012</a>; <a href="./references#CD012977-bbs2-0059" title="MatsuseH , FukahoriS , TsuchidaT , KawanoT , TomariS , MatsuoN , et al. Effects of a short course of pranlukast combined with systemic corticosteroid on acute asthma exacerbation induced by upper respiratory tract infection. Journal of Asthma2012;49(6):637-41.">Matsuse 2012</a>; <a href="./references#CD012977-bbs2-0096" title="Zubairi AB, SalahuddinN , KhawajaA , AwanS , ShahAA , HaqueAS , et al. A randomized, double-blind, placebo-controlled trial of oral montelukast in acute asthma exacerbation. BMC Pulmonary Medicine2013;13:20.">Zubairi 2013</a>; <a href="./references#CD012977-bbs2-0050" title="KanchanateeraphongS , PhongsamartG , DangsuwanT , VangveeravongM . Study of montelukast for the treatment of acute and post viral-induced wheezing. Journal of Allergy and Clinical Immunology2014;133(2 Suppl 1):AB190.">Kanchanateeraphong 2014</a>; <a href="./references#CD012977-bbs2-0055" title="MagazineR , ShahulHA , ChogtuB , KamathA . Comparison of oral montelukast with oral zileuton in acute asthma: a randomized, double-blind, placebo-controlled study. Lung India2016;33(3):281-6.">Magazine 2016</a>; <a href="./references#CD012977-bbs2-0034" title="ChaudhuryA , GaudeGS , HattiholiJ . Effects of oral montelukast on airway function in acute asthma: a randomized trial. Lung India2017;34(4):349-54.">Chaudhury 2017</a>; <a href="./references#CD012977-bbs2-0056" title="MagazineR , SurendraVU , ChogtuB . Comparison of oral montelukast with oral ozagrel in acute asthma: a randomized, double-blind, placebo-controlled study. Lung India2018;35(1):16-20.">Magazine 2018</a>; <a href="./references#CD012977-bbs2-0091" title="WangX , ZhouJ , ZhaoX , YiX . Montelukast treatment of acute asthma exacerbations in children aged 2 to 5 years: a randomized, double-blind, placebo-controlled trial. Pediatric Emergency Care2018;34(3):160-4.">Wang 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Update review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compare effectiveness in preschool and older children</p> <p>Develop and use core outcome measures, consistent assessment of asthma severity at study entry, and consistent inclusion criteria in future trials </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Evidence map</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/full#CD012977-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012977-tbl-0004"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Details of asthma diagnosis and asthma severity in included reviews</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Review</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Asthma diagnosis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Asthma severity</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Inhaled treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients presenting to an ED or its equivalent</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute exacerbation of asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients presenting to an ED</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute asthma exacerbation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalised for an acute asthma exacerbation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute asthma (excluded chronic or “stable” asthma). “We accepted any reasonable diagnosis of asthma, namely clinical and guideline‐based criteria” </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information provided</p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Parenteral treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute severe asthma or status asthmaticus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No definition provided for severe</p> <p>Status asthmaticus defined as “acute, severe, refractory exacerbations”</p> <p>Patients were attending ED, hospital wards, or intensive care</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0010" title="TraversAH , MilanSJ , JonesAP , Camargo CA Jr, RoweBH . Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010179. [DOI: 10.1002/14651858.CD010179]">Travers 2012a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe acute asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No definition provided for “severe”. Included patients presenting to an ED (or its equivalent) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe acute asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No definition provided for “severe”. Included patients presenting to an ED or admitted to hospital </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0003" title="GriffithsB , KewKM . Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD011050. [DOI: 10.1002/14651858.CD011050.pub2]">Griffiths 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients treated in the ED with acute asthma (all severities)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0004" title="JatKR , ChawlaD . Ketamine for management of acute exacerbations of asthma in children. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD009293. [DOI: 10.1002/14651858.CD009293.pub2]">Jat 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute asthma exacerbation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not responded to standard therapy with aerosolised beta2‐agonist, with or without aerosolised anticholinergic drugs and oral or parenteral corticosteroid, for at least 1 hour </p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Other interventions to reduce the work of breathing</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0009" title="RodrigoG , PollackC , RodrigoC , RoweBH . Heliox for nonintubated acute asthma patients. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD002884. [DOI: 10.1002/14651858.CD002884.pub2]">Rodrigo 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical diagnosis asthma exacerbation (according to accepted criteria such as those published by the American Thoracic Society). Excluded patients with COPD </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presenting to an ED or equivalent care setting. Excluded patients requiring mechanical ventilation at presentation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0006" title="KorangSK , FeinbergJ , WetterslevJ , JakobsenJC . Non-invasive positive pressure ventilation for acute asthma in children. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012067. [DOI: 10.1002/14651858.CD012067.pub2]">Korang 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asthma attack (as defined by the trialists). Excluded children with pneumonia, aspiration, bronchiolitis, cystic fibrosis, or any ciliary dyskinetic syndrome </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children hospitalised for an asthma attack</p> </td> </tr> <tr> <th align="" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>Other interventions</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0008" title="NormansellR , SayerB , WatersonS , DennettEJ , Del FornoM , DunleavyA . Antibiotics for exacerbations of asthma. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD002741. [DOI: 10.1002/14651858.CD002741.pub2]">Normansell 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asthma exacerbation. Excluded pneumonia, COPD, and bronchiectasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presented to the ED, primary care, outpatient clinics, or inpatient wards. Included both inpatients and outpatients </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presenting for acute medical care to an ED or equivalent setting</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>COPD: chronic obstructive pulmonary disease; ED: emergency department.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Details of asthma diagnosis and asthma severity in included reviews</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/full#CD012977-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012977-tbl-0005"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">ROBIS assessment of included reviews</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Review</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Domain 1: study eligibility criteria</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Domain 2: identification and selection of studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Domain 3: data collection and study appraisal</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Domain 4: synthesis and findings</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk of bias in the review</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>Inhaled treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>Parenteral treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0010" title="TraversAH , MilanSJ , JonesAP , Camargo CA Jr, RoweBH . Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010179. [DOI: 10.1002/14651858.CD010179]">Travers 2012a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0003" title="GriffithsB , KewKM . Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD011050. [DOI: 10.1002/14651858.CD011050.pub2]">Griffiths 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0004" title="JatKR , ChawlaD . Ketamine for management of acute exacerbations of asthma in children. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD009293. [DOI: 10.1002/14651858.CD009293.pub2]">Jat 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>Other interventions to reduce the work of breathing</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0009" title="RodrigoG , PollackC , RodrigoC , RoweBH . Heliox for nonintubated acute asthma patients. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD002884. [DOI: 10.1002/14651858.CD002884.pub2]">Rodrigo 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0006" title="KorangSK , FeinbergJ , WetterslevJ , JakobsenJC . Non-invasive positive pressure ventilation for acute asthma in children. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012067. [DOI: 10.1002/14651858.CD012067.pub2]">Korang 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>Other interventions</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0008" title="NormansellR , SayerB , WatersonS , DennettEJ , Del FornoM , DunleavyA . Antibiotics for exacerbations of asthma. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD002741. [DOI: 10.1002/14651858.CD002741.pub2]">Normansell 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Complete details of all components of the ROBIS assessment are presented in <a href="./appendices#CD012977-sec-0171">Appendix 4</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">ROBIS assessment of included reviews</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/full#CD012977-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012977-tbl-0006"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Certainty of evidence in the included reviews</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Review</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of studies where results for children are available and included in this overview</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Summary of findings</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Methodological quality assessment tool</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk of bias assessment (from review authors)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Inhaled treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jadad score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jadad score: 2/5</p> <p>Unclear sequence generation; no allocation concealment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes. High‐certainty evidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assessed according to recommendations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random sequence generation: low risk in 17/27</p> <p>Allocation concealment: low risk in 21/27</p> <p>Blinding: low risk in 23/27</p> <p>Incomplete outcome data: low risk in 23/27</p> <p>Selective reporting: low risk in 20/27</p> <p>Other bias: low risk in 23/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes. Moderate‐certainty evidence for all comparisons</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cochrane ‘Risk of bias’ tool</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random sequence generation: low risk in 2/4</p> <p>Allocation concealment: low risk in 2/4</p> <p>Blinding of participants and personnel: Low risk in 4/4</p> <p>Blinding of outcome assessment: low risk in 4/4</p> <p>Incomplete outcome data: low risk in 4/4</p> <p>Selective reporting: low risk in 2/4</p> <p>Other bias: low risk in 4/4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes. Certainty ranges from very low to low to moderate to high</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cochrane ‘Risk of bias’ tool</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random sequence generation: low risk in 4/8</p> <p>Allocation concealment: low risk in 4/8</p> <p>Blinding of participants and personnel: low risk in 5/8</p> <p>Blinding of outcome assessment: low risk in 5/8</p> <p>Incomplete outcome data: low risk in 5/8</p> <p>Selective reporting: low risk in 5/8; high risk in 2/8</p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Parenteral treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jadad score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jadad score: 4/5 (3 studies); 5/5 (4 studies)</p> <p>Adequate sequence generation: low risk in 2/7</p> <p>Allocation concealment: low risk in 3/7; high risk in 2/7</p> <p>Blinding: low risk in 7/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0010" title="TraversAH , MilanSJ , JonesAP , Camargo CA Jr, RoweBH . Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010179. [DOI: 10.1002/14651858.CD010179]">Travers 2012a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes. Moderate‐ and low‐certainty evidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assessed according to recommendations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random sequence generation: low risk in 2/2</p> <p>Allocation concealment: low risk in 2/2</p> <p>Blinding of participants and personnel: low risk in 2/2</p> <p>Blinding of outcome assessment: low risk in 2/2</p> <p>Incomplete outcome data: low risk in 2/2</p> <p>Selective reporting: unclear risk in 2/2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes. Most scores of moderate certainty. Low certainty for heart rate at 60 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cochrane ‘Risk of bias’ tool</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random sequence generation: low risk in 2/4</p> <p>Allocation concealment: low risk in 2/4</p> <p>Blinding of participants and personnel: low risk in 3/4</p> <p>Blinding of outcome assessment: low risk in 3/4</p> <p>Incomplete outcome data: unclear risk in 4/4</p> <p>Selective reporting: unclear risk in 4/4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0003" title="GriffithsB , KewKM . Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD011050. [DOI: 10.1002/14651858.CD011050.pub2]">Griffiths 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes. Low certainty for all outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cochrane ‘Risk of bias’ tool</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random sequence generation: low risk in 2/5</p> <p>Allocation concealment: low risk in 2/5</p> <p>Blinding of participants and personnel: low risk in 5/5</p> <p>Blinding of outcome assessment: low risk in 4/5</p> <p>Incomplete outcome data: low risk in 2/5</p> <p>Selective reporting: low risk in 3/5</p> <p>Other bias: low risk in 4/5; high risk in 1/5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0004" title="JatKR , ChawlaD . Ketamine for management of acute exacerbations of asthma in children. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD009293. [DOI: 10.1002/14651858.CD009293.pub2]">Jat 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cochrane ‘Risk of bias’ tool</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random sequence generation: low risk</p> <p>Allocation concealment: low risk</p> <p>Blinding of participants and personnel: unclear risk</p> <p>Blinding of outcome assessment: low risk</p> <p>Incomplete outcome data: low risk</p> <p>Selective reporting: unclear risk</p> <p>Other bias: unclear risk</p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Other interventions to reduce the work of breathing</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0009" title="RodrigoG , PollackC , RodrigoC , RoweBH . Heliox for nonintubated acute asthma patients. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD002884. [DOI: 10.1002/14651858.CD002884.pub2]">Rodrigo 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jadad score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jadad score: 4/5 (1 study); 3/5 (2 studies)</p> <p>Allocation concealment: unclear risk in 3/3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0006" title="KorangSK , FeinbergJ , WetterslevJ , JakobsenJC . Non-invasive positive pressure ventilation for acute asthma in children. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012067. [DOI: 10.1002/14651858.CD012067.pub2]">Korang 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes. Very low certainty for all outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cochrane ‘Risk of bias’ tool</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random sequence generation: unclear risk in 2/2</p> <p>Allocation concealment: unclear risk in 2/2</p> <p>Blinding of participants and personnel: low risk in 2/2</p> <p>Blinding of outcome assessment: unclear risk in 2/2</p> <p>Incomplete outcome data: high risk in 1/21/2; low risk in 1/2</p> <p>Selective reporting: low risk in 1/2</p> <p>Other bias: low risk in 2/2</p> </td> </tr> <tr> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="top"> <p><b>Other interventions</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0008" title="NormansellR , SayerB , WatersonS , DennettEJ , Del FornoM , DunleavyA . Antibiotics for exacerbations of asthma. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD002741. [DOI: 10.1002/14651858.CD002741.pub2]">Normansell 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes. Moderate, low, and very low certainty.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assessed according to recommendations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random sequence generation: low risk in 1/3</p> <p>Allocation concealment: low risk in 1/3</p> <p>Blinding of participants and personnel: high risk in 1/3; low risk in 2/3</p> <p>Blinding of outcome assessment: high risk in 1/3</p> <p>Incomplete outcome data: high risk in 2/3; low risk in 1/3</p> <p>Selective reporting: high risk in 2/3</p> <p>Other bias: low risk in 2/3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assessed according to recommendations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random sequence generation: low risk in 3/4</p> <p>Allocation concealment: low risk in 3/4</p> <p>Blinding of participants and personnel: low risk in 3/4</p> <p>Blinding of outcome assessment: low risk in 1/4</p> <p>Incomplete outcome data: low risk in 4/4</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Certainty of evidence in the included reviews</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/full#CD012977-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012977-tbl-0007"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Length of stay measures</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention/Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Results: treatment effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments: overview authors' assessment of the certainty of evidence</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>ED treatment time</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous vs intermittent nebulisation: moderate to severe (<a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ED treatment time (units not specified)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐1.00 (‐13.50 to 11.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and serious risk of bias of the single study: unclear sequence generation, no allocation concealment (single‐blind study) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV magnesium sulfate (<a href="./references#CD012977-bbs2-0003" title="GriffithsB , KewKM . Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD011050. [DOI: 10.1002/14651858.CD011050.pub2]">Griffiths 2016</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ED treatment time (minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 5.00 (‐24.40 to 34.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision</p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>Hospital length of stay</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotics vs placebo (<a href="./references#CD012977-bbs2-0008" title="NormansellR , SayerB , WatersonS , DennettEJ , Del FornoM , DunleavyA . Antibiotics for exacerbations of asthma. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD002741. [DOI: 10.1002/14651858.CD002741.pub2]">Normansell 2018</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay (days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.10 (‐0.53 to 0.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision, risk of bias in single study (before good reporting standards introduced: 6 participants excluded but unclear from which arm they were excluded), indirectness (all children with status asthmaticus and study conducted before current asthma management had been introduced (e.g. they all received IV adrenaline) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Addition of IV SABA to inhaled SABA (<a href="./references#CD012977-bbs2-0010" title="TraversAH , MilanSJ , JonesAP , Camargo CA Jr, RoweBH . Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010179. [DOI: 10.1002/14651858.CD010179]">Travers 2012a</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PICU length of stay (hours)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐12.95 (‐38.74 to 12.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled anticholinergics + SABA vs SABA alone for children hospitalised with asthma (<a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of hospital stay (hours)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.28 (‐5.07 to 4.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>327 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>IV aminophylline + SABA + systemic steroids vs placebo + SABA + systemic steroids (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay (hours): all patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐2.1 (‐9.45 to 5.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay (hours): submaximal inhaled beta2‐agonists <br/>(&lt; 45 mg/kg/h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 6.00 (‐20.49 to 32.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract) and very serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay (hours): maximised inhaled beta2‐agonists (≥ 45 mg/kg/h)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 4.10 (‐13.73 to 21.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay (hours): maximised inhaled beta2‐agonists (≥ 45 mg/kg/h) and anticholinergics </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐4.32 (‐12.79 to 4.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>IV SABA vs intravenous aminophylline for acute asthma (<a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of stay (hours): all patients <i>(positive values favour aminophylline)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 23.19 (‐2.40 to 48.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of stay (hours): paediatric (non‐PICU) patients <i>(positive values favour aminophylline)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 28.10 (‐2.60 to 58.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of stay (hours): PICU patients</p> <p><i>(positive values favour aminophylline)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 12.00 (‐34.31 to 58.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV magnesium sulfate (<a href="./references#CD012977-bbs2-0003" title="GriffithsB , KewKM . Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD011050. [DOI: 10.1002/14651858.CD011050.pub2]">Griffiths 2016</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital length of stay (hours)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐5.30 (‐9.46 to ‐1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; ED: emergency department; IV: intravenous; MD: mean difference; PICU: paediatric intensive care unit: SABA: short‐acting beta2‐agonist; SMD: standardised mean difference. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Length of stay measures</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/full#CD012977-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012977-tbl-0008"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Hospital admission</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Intervention/Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Population</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect: risk ratio (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments: overview authors' assessment of the certainty of evidence</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With intervention</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Inhaled treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Continuous vs intermittent nebulisation: moderate to severe (<a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>667 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>460 per 1000 (220 to 974)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.69 (0.33 to 1.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision; serious risk of bias of single study; unclear sequence generation; no allocation concealment (single‐blind study) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Less severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 per 1000 (11 to 322)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67 (0.12 to 3.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision; serious risk of bias of single study; unclear sequence generation; no allocation concealment (single‐blind study) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="16" valign="top"> <p>Anticholinergic and SABA vs SABA alone (<a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169 per 1000 (146 to 197)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73 (0.63 to 0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2497 (19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single‐dose protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>176 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148 per 1000 (98 to 222)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.84 (0.56 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>419 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple fixed‐dose protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>252 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>181 per 1000 (154 to 212)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (0.61 – 0.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1998 (15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple flexible‐dose protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (not estimable)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and single study with high risk of bias (consecutive assignment rather than randomised) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>298 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217 per 1000 (182 to 259)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73 (0.61 to 0.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1188 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>269 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>161 per 1000 (110 to 239)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.60 (0.41 to 0.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>371 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112 per 1000 (71 to 177)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.77 (0.49 to 1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>463 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122 per 1000 (73 to 206)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.87 (0.52 to 1.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>358 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 per 1000 (29 to 336)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.43 (0.42 to 4.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and very serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Highest tertile control group event rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>487 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>331 per 1000 (273 to 399)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.68 (0.56 to 0.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>669 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Middle tertile control group event rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>241 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>181 per 1000 (137 to 239)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 (0.57 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>780 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lowest tertile control group event rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 per 1000 (47 to 114)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91 (0.59 to 1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>968 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Background corticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>317 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225 per 1000 (187 to 273)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71 (0.59 to 0.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1043 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No background corticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>297 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>199 per 1000 (140 to 279)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67 (0.47 to 0.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>353 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Corticosteroids administered variably (at physician discretion)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>214 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>165 per 1000 (116 to 235)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.77 (0.54 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>511 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Background corticosteroids not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77 per 1000 (44 to 139)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.85 (0.48 to 1.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and very serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Inhaled magnesium sulfate</p> <p>(<a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MgSO4 + SABA + Ipratropium/Placebo + SABA + Ipratropium (Admission at first presentation)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>957 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>919 per 1000 (880 to 967)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96 (0.92 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>508 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author decided on trial inclusion) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MgSO4 + SABA vs Placebo + SABA</p> <p>(<a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98 per 1000 (38 to 257)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.14 (0.44 to 2.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author decided on trial inclusion), and because a majority of patients were from a study judged to be at risk of reporting bias </p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Parenteral treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intravenous magnesium sulfate (<a href="./references#CD012977-bbs2-0003" title="GriffithsB , KewKM . Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD011050. [DOI: 10.1002/14651858.CD011050.pub2]">Griffiths 2016</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intravenous MgSO4/Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>767 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>537 per 1000 (414 to 698)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70 (0.54 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intravenous ketamine vs placebo (<a href="./references#CD012977-bbs2-0004" title="JatKR , ChawlaD . Ketamine for management of acute exacerbations of asthma in children. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD009293. [DOI: 10.1002/14651858.CD009293.pub2]">Jat 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ketamine/Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>829 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>788 per 1000 (622 to 995)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95 (0.75 to 1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to single small study – risk of serious imprecision</p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Other interventions to reduce the work of breathing</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heliox vs placebo for non‐intubated asthma patients (<a href="./references#CD012977-bbs2-0009" title="RodrigoG , PollackC , RodrigoC , RoweBH . Heliox for nonintubated acute asthma patients. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD002884. [DOI: 10.1002/14651858.CD002884.pub2]">Rodrigo 2006</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heliox vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>750 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>517 per 1000 (360 to 742)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.69 (0.48 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of serious imprecision. SR shows asymmetrical funnel plot, suggesting publication bias </p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Other interventions</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Leukotriene receptor antagonists in addition to usual care (<a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral LTRA/Control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 per 1000 (13 to 218)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.86 (0.12 to 3.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intravenous LTRA/Control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>252 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>199 per 1000 (129 to 310)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 (0.51 to 1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>276 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; LTRA: leukotriene receptor antagonist; MgSO4: magnesium sulfate; SABA: short‐acting beta2‐agonist. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Hospital admission</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/full#CD012977-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012977-tbl-0009"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Intensive care unit admission</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Intervention/Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect: risk ratio (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments: overview authors' assessment of the certainty of evidence</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With intervention</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled anticholinergics + SABA vs SABA alone for children hospitalised with asthma (<a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Admission to the ICU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (not estimable)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MgSO4 + SABA + Ipratropium/Placebo + SABA + Ipratropium (<a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HDU/ICU admission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87 per 1000 (47 to 165)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.48 (0.79 to 2.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>505 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author decided on trial inclusion) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intravenous aminophylline + beta2‐agonists + systemic steroids vs placebo + beta2‐agonists + systemic steroids (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ICU admission rates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>370 per 1000 (260 to 530)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.74 (0.52 to 1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; HDU: high‐dependency unit; ICU: intensive care unit; LTRA: leukotriene receptor antagonist; MgSO4: magnesium sulfate; SABA: short‐acting beta2‐agonist. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Intensive care unit admission</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/full#CD012977-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012977-tbl-0010"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Adverse effects</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Intervention/Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect: risk ratio (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments: overview authors' assessment of the certainty of evidence</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With intervention</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>All adverse events</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotics vs placebo (<a href="./references#CD012977-bbs2-0008" title="NormansellR , SayerB , WatersonS , DennettEJ , Del FornoM , DunleavyA . Antibiotics for exacerbations of asthma. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD002741. [DOI: 10.1002/14651858.CD002741.pub2]">Normansell 2018</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 per 1000 (19 to 541)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80 (0.15 to 4.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in single study (possible attrition bias and reporting bias) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled anticholinergics + SABA vs SABA alone for children hospitalised with asthma (<a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse health effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (not estimable)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>290 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and very serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MgSO4 + SABA + Ipratropium vs Placebo + SABA + Ipratropium (<a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse event (during admission)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>204 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>186 per 1000 (131 to 265)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91 (0.64 to 1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>507 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and risk of bias in review (single author decided on trial inclusion) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MgSO4 + SABA vs Placebo + SABA (<a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 per 1000 (0 to 57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.46 (0.04 to 4.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>365 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author decided on trial inclusion) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Serious adverse events</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotics vs placebo (<a href="./references#CD012977-bbs2-0008" title="NormansellR , SayerB , WatersonS , DennettEJ , Del FornoM , DunleavyA . Antibiotics for exacerbations of asthma. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD002741. [DOI: 10.1002/14651858.CD002741.pub2]">Normansell 2018</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (not estimable)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in single study (possible performance bias and detection bias) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MgSO4 + SABA + Ipratropium vs Placebo + SABA + Ipratropium (<a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events (during admission)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 per 1000 (3 to 42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25 (0.07 to 0.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>507 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author decided on trial inclusion) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MgSO4 + SABA vs Placebo + SABA (<a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (not estimable)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author decided on trial inclusion) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐invasive positive‐pressure ventilation (<a href="./references#CD012977-bbs2-0006" title="KorangSK , FeinbergJ , WetterslevJ , JakobsenJC . Non-invasive positive pressure ventilation for acute asthma in children. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012067. [DOI: 10.1002/14651858.CD012067.pub2]">Korang 2016</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (not estimable)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias and very serious imprecision</p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Death</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV aminophylline + SABA + systemic steroids vs placebo + SABA + systemic steroids (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (not estimable)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>326 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐invasive positive‐pressure ventilation (<a href="./references#CD012977-bbs2-0006" title="KorangSK , FeinbergJ , WetterslevJ , JakobsenJC . Non-invasive positive pressure ventilation for acute asthma in children. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012067. [DOI: 10.1002/14651858.CD012067.pub2]">Korang 2016</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (not estimable)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in included study and very serious imprecision</p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Tremor</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous vs intermittent nebulisation: moderate to severe (<a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>257 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144 per 1000 (54 to 383)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.56 (0.21 to 1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and serious risk of bias of the single study; unclear sequence generation; no allocation concealment (single‐blind study) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergic and SABA vs SABA alone (<a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139 per 1000 (103 to 188)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.69 (0.51 to 0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>524 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>IV aminophylline + SABA + systemic steroids vs placebo + SABA + systemic steroids (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tremor: all patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>263 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>355 per 1000 (231 to 545)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.35 (0.88 to 2.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tremor: mean theophylline levels &lt; 15 mg/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>385 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 per 1000 (216 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.30 (0.56 to 3.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tremor: mean theophylline levels ≥ 15 mg/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>244 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>334 per 1000 (205 to 544)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.37 (0.84 to 2.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV SABA vs IV aminophylline for acute asthma (<a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>375 per 1000 w<i>ith SABA</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>694 (334 to 1000) <i>with aminophylline</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.85 (0.89 to 3.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Nausea and/or vomiting</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous vs intermittent nebulisation: moderate to severe (<a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea/Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 per 1000 (0 to 230)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.20 (0.01 to 4.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and serious risk of bias of the single study; unclear sequence generation; no allocation concealment (single‐blind study) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Anticholinergic and SABA vs SABA alone (<a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 per 1000 (18 to 56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.88 (0.49 to 1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1230 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 per 1000 (41 to 102)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.60 (0.38 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>757 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>IV aminophylline + SABA + systemic steroids vs placebo + SABA + systemic steroids (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vomiting: all patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>311 per 1000 (181 to 534)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.69 (2.15 to 6.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>305 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vomiting: mean theophylline levels &lt; 15 mg/L (mcg/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189 per 1000 (81 to 443)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.73 (1.17 to 6.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vomiting: mean theophylline levels ≥ 15 mg/L (mcg/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>433 per 1000 (214 to 874)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.43 (2.19 to 8.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>IV SABA vs IV aminophylline for acute asthma (<a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea/Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000 <i>with</i> <br/><i>SABA</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable due to rate of 0 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.00 (1.15 to 313.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>313 per 1000 w<i>ith SABA</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>694 per 1000 (307 to 1000) <i>with aminophylline</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.22 (0.98 to 4.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>438 per 1000 w<i>ith SABA</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>692 (359 to 1000) <i>with aminophylline</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.58 (0.82 to 3.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Cardiovascular adverse effects</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MgSO4 + SABA + Ipratropium /[SD2] Placebo + SABA + Ipratropium (<a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000 (1 to 44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.51 (0.05 to 5.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>507 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and risk of bias in review (single author decided on trial inclusion) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 per 1000 (2 to 27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67 (0.11 to 4.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>507 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and risk of bias in review (single author decided on trial inclusion) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV aminophylline + SABA + systemic steroids vs placebo + SABA + systemic steroids (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arrhythmias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 per 1000 (1 to 234)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.40 (0.02 to 9.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>IV SABA vs IV aminophylline for acute asthma (<a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dysrhythmia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188 per 1000 w<i>ith SABA</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 per 1000 (2 to 578) wi<i>th aminophylline</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.17 (0.01 to 3.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Palpitations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (not estimable)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Neurological adverse effects</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>IV aminophylline + SABA + systemic steroids vs placebo + SABA + systemic steroids (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache: all patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159 per 1000 (87 to 289)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.28 (0.70 to 2.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>238 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache: mean theophylline levels &lt; 15 mg/L (mcg/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable due to rate of 0 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.48 (0.67 to 44.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache: mean theophylline levels ≥ 15 mg/L (mcg/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>185 per 1000 (97 to 353)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.01 (0.53 to 1.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV SABA vs IV aminophylline for acute asthma (<a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188 per 1000 <i>with SABA</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231 per 1000 (57 to 959) <i>with aminophylline</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.23 (0.30 to 5.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>IV aminophylline + SABA + systemic steroids vs placebo + SABA + systemic steroids (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seizures: all patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 per 1000 (0 to 116)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.01 (0.06 to 15.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>274 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seizures: mean theophylline levels &lt; 15 mg/L (mcg/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (not estimable)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seizures: mean theophylline levels ≥ 15 mg/L (mcg/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 per 1000 (1 to 171)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.01 (0.06 to 15.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>186 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Pneumonia</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐invasive positive‐pressure ventilation (<a href="./references#CD012977-bbs2-0006" title="KorangSK , FeinbergJ , WetterslevJ , JakobsenJC . Non-invasive positive pressure ventilation for acute asthma in children. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012067. [DOI: 10.1002/14651858.CD012067.pub2]">Korang 2016</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pneumonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (not estimable)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Laboratory results</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>IV SABA vs IV aminophylline for acute asthma (<a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CPK elevation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250 per 1000 w<i>ith SABA</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>385 (130 to 1000) <i>with aminophylline</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.54 (0.52 to 4.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CPK‐MB elevation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 per 1000 w<i>ith SABA</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>154 per 1000 (110 to 1000) <i>with aminophylline</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.46 (0.25 to 24.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyperglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000 <i>with SABA</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>920 per 1000 (750 to 1000) <i>with aminophylline</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92 (0.75 to 1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypokalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163 per 1000 w<i>ith SABA</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169 per 1000 (90 to 353) <i>with aminophylline</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.04 (0.48 to 2.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>CI: confidence interval; CPK: creatine phosphokinase; CPK‐MB: creatine phosphokinase myocardial band; GRADE: Grading of Recommendations Assessment, Development and Evaluation; MgSO4: magnesium sulfate; SABA: short acting beta2‐agonist. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Adverse effects</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/full#CD012977-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012977-tbl-0011"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Symptom scores</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention/Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Results: treatment effect (95% CI) unless otherwise stated</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments: overview authors' assessment of the certainty of evidence</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous vs intermittent nebulisation (<a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.66 (0.18 to 1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and serious risk of bias of the single study; unclear sequence generation; no allocation concealment (single‐blind study) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergic and SABA vs SABA alone (<a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in clinical score at 120 minutes (± 30 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.23 (‐0.42 to ‐0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>934 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral LTRA vs control (<a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in pulmonary index score (final assessment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐1.20 (‐1.37 to ‐1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heliox vs placebo for non‐intubated asthma patients (<a href="./references#CD012977-bbs2-0009" title="RodrigoG , PollackC , RodrigoC , RoweBH . Heliox for nonintubated acute asthma patients. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD002884. [DOI: 10.1002/14651858.CD002884.pub2]">Rodrigo 2006</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dyspnoea or pulmonary index</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.51 (‐1.14 to 0.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of serious imprecision. SR shows asymmetrical funnel plot, suggesting publication bias </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled anticholinergics + SABA vs SABA alone for children hospitalised with asthma (<a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asthma clinical scores 8 to 36 hours after initial treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.02 (‐0.34 to 0.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled magnesium sulfate (<a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yung asthma severity score at 60 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.23 (‐0.48 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>472 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author decided on trial inclusion) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign="top"> <p>IV aminophylline + SABA + systemic steroids vs placebo + SABA + systemic steroids</p> <p>(<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in symptom scores 6 to 8 hours after enrolment (all patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.42 (‐0.70 to ‐0.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in symptom scores 6 to 8 hours after enrolment: submaximal inhaled beta‐2 agonists (&lt; 45 mg/kg/h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.31 (‐0.94 to 0.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in symptom scores 6 to 8 hours after enrolment: maximised inhaled beta‐2 agonists (≥ 45 mg/kg/h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in symptom scores 6 to 8 hours after enrolment: maximised inhaled beta‐2 agonists (≥ 45 mg/kg/h) and anticholinergics </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.45 (‐0.77 to ‐0.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in symptom scores 12 to 18 hours after enrolment: submaximal inhaled beta‐2 agonists (&lt; 45 mg/kg/h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.45 (‐1.09 to 0.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in symptom scores 12 to 18 hours after enrolment: maximised inhaled beta‐2 agonists (≥ 45 mg/kg/h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in symptom scores 24 hours after enrolment (all patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.13 (‐0.52 to 0.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in symptom scores 24 hours after enrolment: submaximal inhaled beta‐2 agonists (&lt; 45 mg/kg/h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in symptom scores 24 hours after enrolment: maximised inhaled beta‐2 agonists (≥ 45 mg/kg/h) and anticholinergics </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.13 (‐0.52 to 0.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV ketamine vs placebo (<a href="./references#CD012977-bbs2-0004" title="JatKR , ChawlaD . Ketamine for management of acute exacerbations of asthma in children. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD009293. [DOI: 10.1002/14651858.CD009293.pub2]">Jat 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary Index Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.40 (‐1.21 to 0.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐invasive positive‐pressure ventilation (<a href="./references#CD012977-bbs2-0006" title="KorangSK , FeinbergJ , WetterslevJ , JakobsenJC . Non-invasive positive pressure ventilation for acute asthma in children. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012067. [DOI: 10.1002/14651858.CD012067.pub2]">Korang 2016</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asthma symptom score in the acute phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐2.50 (‐4.70 to ‐0.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in included study</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; LTRA: leukotriene receptor antagonist; MD: mean difference; mg/kg: milligram per kilogram; SABA: short‐acting beta2‐agonist; SMD: standardised mean difference; SR: systematic review. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Symptom scores</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/full#CD012977-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012977-tbl-0012"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Lung function</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention/Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Results: treatment effect (95% CI) unless otherwise stated</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments: overview authors' assessment of the certainty of evidence</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous vs intermittent nebulisation: moderate to severe (<a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PEFR values (end of study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.25 (‐0.22 to 0.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and serious risk of bias of the single study; unclear sequence generation; no allocation concealment (single‐blind study) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="10" valign="top"> <p>Anticholinergic and SABA vs SABA alone: variable corticosteroids (at physicians’ discretion) (<a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change from baseline in %predicted FEV1, 60 minutes after last dose of inhaled bronchodilator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 10.08 (6.24 to 13.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>402 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change from baseline in %predicted FEV1, 120 minutes after last dose of inhaled bronchodilator</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 6.87 (1.17 to 12.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% Change in FEV1 or PEFR at 60 minutes after last inhaled bronchodilator (± 15 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.57 (0.25 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% Change in FEV1 or PEFR at 120 minutes after last inhaled bronchodilator (± 30 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.12 (‐0.15 to 0.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% Change in respiratory resistance at 60 minutes after inhaled bronchodilator (± 15 minutes) – all studies </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.02 (‐0.02 to 0.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>294 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% Change in respiratory resistance at 60 minutes after inhaled bronchodilator (± 15 minutes) – with corticosteroids given within previous 60 minutes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.02 (‐0.13 to 0.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% Change in respiratory resistance at 60 minutes after inhaled bronchodilator (± 15 minutes) – no corticosteroids </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.03 (‐0.02 to 0.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>224 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% Change in respiratory resistance at 120 minutes after inhaled bronchodilator (± 30 minutes) – all studies </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.01 (‐0.09 to 0.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% Change in respiratory resistance at 120 minutes after inhaled bronchodilator (± 30 minutes) – with corticosteroids given within previous 120 minutes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.02 (‐0.12 to 0.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% Change in respiratory resistance at 120 minutes after inhaled bronchodilator (± 30 minutes) – no corticosteroids </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐0.02 (‐0.12 to 0.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antibiotics vs placebo (<a href="./references#CD012977-bbs2-0008" title="NormansellR , SayerB , WatersonS , DennettEJ , Del FornoM , DunleavyA . Antibiotics for exacerbations of asthma. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD002741. [DOI: 10.1002/14651858.CD002741.pub2]">Normansell 2018</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PEFR (L/min)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 38.80 (‐11.19 to 88.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and risk of bias in single study (possible performance bias and detection bias) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral LTRA vs control (<a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in FEV1 (predicted)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐3.10 (‐12.70 to 6.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV LTRA vs control (<a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in FEV1 (litres)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.01 (‐0.06 to 0.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>276 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heliox vs placebo for non‐intubated asthma patients (<a href="./references#CD012977-bbs2-0009" title="RodrigoG , PollackC , RodrigoC , RoweBH . Heliox for nonintubated acute asthma patients. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD002884. [DOI: 10.1002/14651858.CD002884.pub2]">Rodrigo 2006</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.32 (‐0.52 to 1.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of serious imprecision. SR shows asymmetrical funnel plot, suggesting publication bias </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled anticholinergics + SABA vs SABA alone for children hospitalised with asthma (<a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percentages of predicted PEFR at 8 to 36 hours after initial treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐1.60 (‐17.20 to 14.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>MgSO4 + SABA vs Placebo + SABA</p> <p>(<a href="./references#CD012977-bbs2-0005" title="KnightlyR , MilanSJ , HughesR , Knopp-SihotaJA , RoweBH , NormansellR , et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD003898. [DOI: 10.1002/14651858.CD003898.pub6]">Knightly 2017</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary function %predicted FEV1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 8.10 (‐3.03 to 19.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision (single small study) and risk of bias in review (single author decided on trial inclusion) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary function PEF L/min</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 11.90 (‐6.86 to 30.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision (single small study) and risk of bias in review (single author decided on trial inclusion) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="23" valign="top"> <p>IV aminophylline + SABA + systemic steroids vs placebo + SABA + systemic steroids (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in % predicted FEV1 within 4 hours of enrolment: submaximal inhaled SABA (&lt; 45 mg/kg/h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in % predicted FEV1 within 4 hours of enrolment: maximised inhaled SABA (≥ 45 mg/kg/h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.08 (‐9.04 to 13.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision (single small study) and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in % predicted FEV1 6 to 8 hours after enrolment (all patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 8.37 (0.82 to 15.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in % predicted FEV1 6 to 8 hours after enrolment: submaximal inhaled SABA (&lt; 45 mg/kg/h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision (single small study) and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in % predicted FEV1 6 to 8 hours after enrolment: maximised inhaled SABA (≥ 45 mg/kg/h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 5.45 (‐6.33 to 17.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in % predicted FEV1 6 to 8 hours after enrolment: maximised inhaled SABA (≥ 45 mg/kg/h) and anticholinergics </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 10.4 (0.57 to 20.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in % predicted FEV1 12 to 18 hours after enrolment (all patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 8.15 (1.04 to 15.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in % predicted FEV1 12 to 18 hours after enrolment: submaximal inhaled SABA (&lt; 45 mg/kg/h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in % predicted FEV1 12 to 18 hours after enrolment: maximised inhaled SABA (≥ 45 mg/kg/h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 5.74 (‐6.14 to 17.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in % predicted FEV1 12 to 18 hours after enrolment: maximised inhaled SABA (≥ 45 mg/kg/h) and anticholinergics </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 9.50 (0.62 to 18.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in % predicted FEV1 24 hours after enrolment (all patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 8.87 (1.25 to 16.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in % predicted FEV1 24 hours after enrolment: submaximal inhaled SABA (&lt; 45 mg/kg/h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in % predicted FEV1 24 hours after enrolment: maximised inhaled SABA (≥ 45 mg/kg/h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 7.36 (‐7.61 to 22.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in % predicted FEV1 24 hours after enrolment: maximised inhaled SABA (≥ 45 mg/kg/h) and anticholinergics </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 9.40 (0.54 to 18.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in PEF at 6 to 8 hours after enrolment (all patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.92 (0.32 to 1.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in PEF at 6 to 8 hours after enrolment: submaximal inhaled SABA (&lt; 45 mg/kg/h)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.51 (‐0.96 to 1.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract) and very serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in PEF at 6 to 8 hours after enrolment: maximised inhaled SABA (≥ 45 mg/kg/h) and anticholinergics </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 1.00 (0.35 to 1.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in PEF at 12 to 18 hours after enrolment (all patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.75 (0.25 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in PEF at 12 to 18 hours after enrolment: submaximal inhaled SABA (&lt; 45 mg/kg/h)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.71 (‐0.01 to 1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in PEF at 12 to 18 hours after enrolment: maximised inhaled SABA (≥ 45 mg/kg/h) and anticholinergics </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.77 (0.08 to 1.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in PEF at 24 hours after enrolment (all patients)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.39 (‐0.51 to 1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in PEF at 24 hours after enrolment: submaximal inhaled SABA (&lt; 45 mg/kg/h)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.33 (‐1.39 to 2.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in PEF at 24 hours after enrolment: maximised inhaled SABA (≥ 45 mg/kg/h) and anticholinergics </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.66 (0.01 to 1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract) and serious imprecision </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; FEV1: forced expiratory volume in one second; LTRA: leukotriene receptor antagonist; MD: mean difference; mg/kg: milligram per kilogram; PEF: peak expiratory flow; PEFR: peak expiratory flow rate; SABA: short‐acting beta2<sub>-</sub>agonist; SMD: standardised mean difference. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Lung function</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/full#CD012977-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012977-tbl-0013"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Vital signs: dichotomous outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Intervention/Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect: risk ratio (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments: overview authors' assessment of the certainty of evidence</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With intervention</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Anticholinergic and SABA vs SABA alone (<a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxygen saturations &lt; 95% at 60 minutes (± 15 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>365 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>267 per 1000 (210 to 354)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73 (0.55 to 0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>416 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxygen saturations &lt; 95% at 120 minutes (± 30 minutes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>367 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>404 per 1000 (279 to 583)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.10 (0.76 to 1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>185 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious inconsistency, serious imprecision, and serious risk of bias in review (single author selected possible citations) </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; SABA: short‐acting beta2‐agonist. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Vital signs: dichotomous outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/full#CD012977-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012977-tbl-0014"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Vital signs: continuous outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention/Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Results: treatment effect (95% CI) unless otherwise stated</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments: overview authors' assessment of the certainty of evidence</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Addition of IV SABA to inhaled SABA (<a href="./references#CD012977-bbs2-0010" title="TraversAH , MilanSJ , JonesAP , Camargo CA Jr, RoweBH . Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010179. [DOI: 10.1002/14651858.CD010179]">Travers 2012a</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulse rate (beats/min) at 2 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 10.00 (‐1.07 to 21.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral LTRA vs control (<a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in respiratory rate (breaths/min) (final assessment)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐4.60 (‐6.84 to ‐2.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Heliox vs placebo for non‐intubated asthma patients (<a href="./references#CD012977-bbs2-0009" title="RodrigoG , PollackC , RodrigoC , RoweBH . Heliox for nonintubated acute asthma patients. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD002884. [DOI: 10.1002/14651858.CD002884.pub2]">Rodrigo 2006</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heart rate (beats/min)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.0 (‐13.80 to 13.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious imprecision. SR shows asymmetrical funnel plot, suggesting publication bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SaO2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.0 (‐2.51 to 2.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious imprecision. SR shows asymmetrical funnel plot, suggesting publication bias</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV aminophylline + SABA + systemic steroids vs. placebo + SABA + systemic steroids</p> <p>(<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blood pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; LTRA: leukotriene receptor antagonist; MD: mean difference; SABA: short‐acting beta2‐agonist; SaO2: oxygen saturation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Vital signs: continuous outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/full#CD012977-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012977-tbl-0015"> <div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Rates of mechanical ventilation in the intensive care unit</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Intervention/Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect: risk ratio (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments: overview authors' assessment of the certainty of evidence</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With intervention</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV aminophylline + SABA + systemic steroids vs Placebo + SABA + systemic steroids (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rates of patients mechanically ventilated in ICU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 per 1000 (1 to 100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.09 (0.01 to 1.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision and risk of bias in review (single author reviewed each abstract) </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; ICU: intensive care unit; SABA: short‐acting beta2‐agonist. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Rates of mechanical ventilation in the intensive care unit</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/full#CD012977-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012977-tbl-0016"> <div class="table-heading"><span class="table-label">Table 16.</span> <span class="table-title">Clinical failure</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Intervention/Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect: risk ratio (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments: overview authors' assessment of the certainty of evidence</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With intervention</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Addition of IV SABA to inhaled SABA (<a href="./references#CD012977-bbs2-0010" title="TraversAH , MilanSJ , JonesAP , Camargo CA Jr, RoweBH . Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010179. [DOI: 10.1002/14651858.CD010179]">Travers 2012a</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>933 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>354 per 1000 (177 to 728)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.38 (0.19 to 0.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One point deducted as data contributed by only 1 study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV SABA vs IV aminophylline for acute asthma (<a href="./references#CD012977-bbs2-0011" title="TraversAH , JonesAP , Camargo CA Jr, MilanSJ , RoweBH . Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD010256. [DOI: 10.1002/14651858.CD010256]">Travers 2012b</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>303 per 1000 <i>with SABA</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>303 per 1000 (145 to 630) <i>with aminophylline</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 (0.48 to 2.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; IV: Intravenous; SABA: short‐acting beta2‐agonist. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 16.</span> <span class="table-title">Clinical failure</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/full#CD012977-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012977-tbl-0017"> <div class="table-heading"><span class="table-label">Table 17.</span> <span class="table-title">Relapse/Return to the emergency department</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Intervention/Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect: risk ratio (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certaintyof the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments: overview authors' assessment of the certainty of evidence</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With intervention</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anticholinergic and SABA vs SABA alone (<a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 per 1000 (31 to 76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.07 (0.68 to 1.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1389 (10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious imprecision and risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral LTRA vs control (<a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse within 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 per 1000 (1 to 727)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.39 (0.02 to 8.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled anticholinergics + SABA vs SABA alone for children hospitalised with asthma (<a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse within 72 hours of discharge from hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (not estimable)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV magnesium sulfate (<a href="./references#CD012977-bbs2-0003" title="GriffithsB , KewKM . Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD011050. [DOI: 10.1002/14651858.CD011050.pub2]">Griffiths 2016</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Return to ED within 48 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 per 1000 (1 to 211)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.41 (0.02 to 9.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>CI: confidence interval; ED: emergency department; GRADE: Grading of Recommendations Assessment, Development and Evaluation; LTRA: leukotriene receptor antagonist; SABA: short acting beta2‐agonist. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 17.</span> <span class="table-title">Relapse/Return to the emergency department</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/full#CD012977-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012977-tbl-0018"> <div class="table-heading"><span class="table-label">Table 18.</span> <span class="table-title">Withdrawals</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Intervention/Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect: risk ratio (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments: overview authors' assessment of the certainty of evidence</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With intervention</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral LTRA vs control (<a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 per 1000 (4 to 178)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 (0.16 to 6.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded due to very serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV LTRA vs control (<a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 per 1000 (10 to 126)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.13 (0.31 to 4.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>276 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded due to very serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Inhaled anticholinergics + SABA vs SABA alone for children hospitalised with asthma (<a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall withdrawals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 per 1000 (38 to 154)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.62 (0.31 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>294 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to deterioration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 per 1000 (7 to 206)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.04 (0.38 to 10.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and very serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>IV aminophylline + SABA + systemic steroids vs placebo + SABA + systemic steroids (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse health effects: all patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 per 1000 (9 to 75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.48 (0.32 to 6.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>370 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and very serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse health effects: mean theophylline levels &lt; 15 mg/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 per 1000 (7 to 148)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.48 (0.32 to 6.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>186 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and very serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse health effects: mean theophylline levels ≥ 15 mg/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (not estimable)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>184 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and very serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to poor asthma control: all patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 per 1000 (2 to 63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70 (0.13 to 3.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>370 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and very serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to poor asthma control: mean theophylline levels &lt; 15 mg/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 per 1000 (4 to 126)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70 (0.13 to 3.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>186 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and very serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to poor asthma control: mean theophylline levels ≥ 15 mg/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (not estimable)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>184 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and very serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to any cause</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 per 1000 (26 to 154)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.65 (0.67 to 4.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>371 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; LTRA: leukotriene receptor antagonist; mg/L: milligrams per litre; SABA: short acting beta2‐agonist. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 18.</span> <span class="table-title">Withdrawals</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/full#CD012977-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012977-tbl-0019"> <div class="table-heading"><span class="table-label">Table 19.</span> <span class="table-title">Other measures: continuous outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention/Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Results: treatment effect (95% CI) unless otherwise stated</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments: overview authors' assessment of the certainty of evidence</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Continuous vs intermittent nebulisation: moderate to severe (<a href="./references#CD012977-bbs2-0001" title="Camargo CA Jr, SpoonerCH , RoweBH . Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews2003, Issue 4. Art. No: CD001115. [DOI: 10.1002/14651858.CD001115]">Camargo 2003</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Respiratory therapist time</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐22.00 (‐26.82 to ‐17.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to serious risk of bias of the single study; unclear sequence generation; no allocation concealment (single‐blind study) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled anticholinergics + SABA vs SABA alone for children hospitalised with asthma (<a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to SABA spaced at 4 hours or longer (hours)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐2.17 (‐7.01 to 2.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>290 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV aminophylline + SABA + systemic steroids vs Placebo + SABA + systemic steroids (<a href="./references#CD012977-bbs2-0007" title="MitraA , BasslerD , GoodmanK , LassersonTJ , DucharmeFM . Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD001276. [DOI: 10.1002/14651858.CD001276.pub2]">Mitra 2005</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of nebulisers required in 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.15 (‐0.52 to 0.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author reviewed each abstract)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; MD: mean difference; SABA: short‐acting beta2‐agonist. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 19.</span> <span class="table-title">Other measures: continuous outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/full#CD012977-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012977-tbl-0020"> <div class="table-heading"><span class="table-label">Table 20.</span> <span class="table-title">Other measures: dichotomous outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Intervention/Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect: risk ratio (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments: overview authors' assessment of the certainty of evidence</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With intervention</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Anticholinergic and SABA vs SABA alone (<a href="./references#CD012977-bbs2-0002" title="GriffithsB , DucharmeFM . Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD000060. [DOI: 10.1002/14651858.CD000060.pub2]">Griffiths 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Need for repeat bronchodilator treatment after standard protocol prior to disposition</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>539 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>469 per 1000 (426 to 523)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.87 (0.79 to 0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1074 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Need for corticosteroids in<br/>ED prior to disposition </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>516 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>459 per 1000 (377 to 557)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.89 (0.73 to 1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>378 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral LTRA vs control (<a href="./references#CD012977-bbs2-0013" title="WattsK , ChavasseRJPG . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD006100. [DOI: 10.1002/14651858.CD006100.pub2]">Watts 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Requirement for additional care at end of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 per 1000 (4 to 431)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.54 (0.05 to 5.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled anticholinergics + SABA vs SABA alone for children hospitalised with asthma (<a href="./references#CD012977-bbs2-0012" title="VezinaK , ChauhanBF , DucharmeFM . Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010283. [DOI: 10.1002/14651858.CD010283.pub2]">Vezina 2014</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Need for supplemental asthma therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 per 1000 (35 to 122)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.77 (0.41 to 1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>465 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to risk of bias in review (single author selected possible citations) and serious imprecision </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV ketamine vs placebo (<a href="./references#CD012977-bbs2-0004" title="JatKR , ChawlaD . Ketamine for management of acute exacerbations of asthma in children. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD009293. [DOI: 10.1002/14651858.CD009293.pub2]">Jat 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worsened and required other adjuvant therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 per 1000 (6 to 638)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.12 (0.2 to 22.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certainty downgraded due to very serious imprecision</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; ED: emergency department; LTRA: leukotriene receptor antagonist; SABA: short‐acting beta2‐agonist. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 20.</span> <span class="table-title">Other measures: dichotomous outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012977.pub2/full#CD012977-tbl-0020">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012977.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012977-note-0018">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012977-note-0029">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012977-note-0026">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012977-note-0027">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD012977-note-0025">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD012977-note-0022">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD012977-note-0024">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD012977-note-0028">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD012977-note-0021">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD012977-note-0020">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD012977-note-0023">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012977-note-0019">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"/> </img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012977\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012977\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012977\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012977\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012977\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012977\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012977\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012977\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012977\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012977\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012977\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012977\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012977\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012977\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012977\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012977\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012977\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012977\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ytRBD0EW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012977.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012977.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012977.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012977.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012977.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729559409"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012977.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729559413"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012977.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918edfd86a02bd65',t:'MTc0MDcyOTU1OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 